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1. Abstract 
Respiratory infections represent a major health problem worldwide. Among them 
infections caused by the influenza virus causes annual epidemics leading to 250,000 to 
500,000 deaths worldwide.Vaccination has proven to be an effective tool in controlling 
and eradicating many infectious diseases including viral infections. However, 
inadequate protection elicited by current vaccines foster the search for improved or new 
immune interventions. Implementation of adjuvants represents a key approach to 
improve immunogenicity and efficacy of mucosal vaccines. One of the striking features 
of mucosal vaccines is the induction of IL-17 response. The role of IL-17 secreting cells 
in the fight against mucosa associated bacterial and fungal infections have been 
emphasized. However, their role in combating viral infections and their significance for 
mucosal vaccine design remains elusive. Bis-(3’,5’)-cyclic dimeric adenosine 
monophosphate (c-di-AMP), a potent IL-17 inducer, was investigated for its potential to 
induce IL-17-mediated antigen-specific immune responses. In vitro blocking 
experiments illustrated that IL-6 but not IL-23 secreted by c-di-AMP primed bone 
marrow derived dendritic cells seems to be the crucial mediator for c-di-AMP-induced 
Th17 differentiation. Furthermore, intranasal immunization with Ovalbumin or NIBRG-14 
(inactivated, mouse-adapted H5N1 strain) adjuvanted with c-di-AMP resulted in 
impaired T helper 2 cell response and IgA concentrations but enhanced Th1 response 
in mice lacking IL-17. Differences in microbiota composition impacted c-di-AMP-induced 
IL-17 mediated antigen-specific Th1 and IgG responses, but had no significant influence 
on IgA responses.This demonstrates the importance of IL-17 responses for the efficient 
establishment of mucosal immunity. Collectively,the presented data reveals that c-di-
AMP-induced IL-17 response contribute to IgA secretion by favoring plasma cell 
generation in the germinal center (GC) by co-localizing follicular helper T cells and GC B 
cells and by regulating polymeric-immunoglobulin receptor expression on airway 
epithelial cells favoring secretory IgA transport into the lumen. In addition, upon 
challenge, vaccinated mice revealed negligible weight loss, thereby demonstrating that 
vaccination conferred protection against sublethal influenza challenge. The knowledge 
emerging from this thesis clearly shows the beneficial influence of c-di-AMP-induced IL-
17 responsesin regulating mucosal IgA responses. This paves the road towards the 
establishment of a rational design for novel intranasal vaccines. 
 
 
   Abstract 
  
2 
 
Abstract 
Respiratorische Infektionen stellen weltweit ein Gesundheitsproblem dar. Unter ihnen 
das Influenza Virus, wessen jährlich wiederkehrende Epidemien zu 250.000 bis 500.000 
toten weltweit führen. Impfungen haben sich in der Vergangenheit als effektives Mittel in 
der Kontrolle und Ausrottung von Infektionskrankheiten erwiesen. Dies schließt auch 
virale Erreger mit ein. Nichtsdestotrotz, der inadäquate Schutz der derzeit verfügbaren 
Impfungen fördert die Suche nach verbesserten bzw. neuen Immuninterventionen. Die 
Implementierung von Adjuvantien repräsentiert einen Hauptansatz in der Verbesserung 
von Immunogenität und Wirksamkeit von Schleimhaut-Impfstoffen. Eine der 
auffallenden Eigenschaften von Schleimhaut-Impfstoffen ist die Induktion der IL-17 
Immunantwort. Die Rolle von IL-17 sekretierenden Zellen im Kampf gegen Schleimhaut 
assoziierten bakteriellen und fugalen Infektionen wurde hervorgehoben. Ihre Rolle im 
Kampf gegen virale Infektionen eröffnet jedoch noch Fragen. Bis-(3’, 5’)-cyclic dimeric 
adenosine monophosphate (c-di-AMP), ein potentieller IL-17 Induktor, wurde 
Untersucht um dessen Potenzial in der Induktion einer IL-17 meditierten 
Antigenspezifischen Immunantwort zu eruieren. In vitro Blockierungsexperimente 
zeigten, das IL-6 jedoch nicht IL-23 sekretiert von c-di-AMP induzierten, Knochenmark 
abgeleiteten dendritischen Zellen, ein wichtiger Mediator für c-di-AMP induzierte Th17 
Differenzierung ist. Zudem resultierte die intranasale Immunisierung mit c-di-AMP 
adjuvantiertem Ovalbumin oder NIBRG-14 (inaktivierter, Maus adaptierte H5N1 Stamm) 
in der Beeinträchtigung der T helper 2 Immunantwort und der IgA Konzentrationen. Die 
Th1 Immunantwort in IL-17 Defizienten Mäusen wurde jedoch erhöht. Unterschiede in 
der Mikrobiota Zusammensetzung beeinträchtigten c-di-AMP induzierte, IL-17 
meditierte, Antigenspezifische Th1 und IgG Immunantworten. Dies hatte jedoch keinen 
signifikanten Einfluss auf die IgA Immunantwort. Dies demonstriert die Wichtigkeit der 
IL-17 Immunantwort für die effiziente Etablierung einer Schleimhaut basierten 
Immunität. Zusammen zeigen die präsentierten Daten, das eine c-di-AMP induzierte IL-
17 Antwort die IgA Sekretion beiträgt, indem sie die Generation von Plasma Zellen im 
germinalen Zentrum (GC) favorisiert. Dies geschieht durch die co-lokalisierung von TFH 
Zellen und GC B Zellen als wohl durch die Regulierung der polymeric-immunoglobulin 
Rezeptor Expression auf Epithel Zellen der Lunge welche den sekretorischen Transport 
von IgA in das Lumen favorisieren. Zudem verloren immunisierte Mäuse nach einer 
Immunherausforderung kaum an Gewicht. Dies demonstriert den erfolgreichen 
Impfschutz gegen die sublethale Immunherausforderung mit Influenza. Die 
Erkenntnisse aus dieser Arbeit zeigen klar den vorteilhaften Einfluss der c-di-AMP 
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induzierten IL-17 Antwort in der Regulierung der Schleimhaut basierenden IgA 
Immunntwort. Dies eröffnet den Weg zu dem Design einer neuen intranasalen Impfung.
   
  
4 
 
   Introduction 
  
5 
 
2. Introduction 
2.1. The immune system 
The immune system is a host defense system comprised of several structures, cells and 
mediators, which exert different effector functions that protect the host against disease. 
The major function of the immune system is to defend the host from dangerous entities, 
such as infectious pathogens, toxic substances, and transformed cells, as well as to 
distinguish them from host’s healthy self-tissue, thereby preserving the integrity of the 
body [1]. The detection and elimination of pathogens require the critical interaction 
between the innate and adaptive immune mechanisms to induce protective immunity. 
The innate immune system is considered to act in a rapid and unspecific manner, and 
thereby represents the first line of defense. In contrast, the adaptive immune response 
takes several days to become activated and results in antigen-specific responses which 
consist of humoral and cellular components. Another crucial feature of the adaptive 
immunity is the generation of immune memory, which leads to a more vigorous, rapid 
and highly specific immune response upon a second encounter with a pathogen [2, 3]. 
The different innate and adaptive immune mechanisms protect the host from 
colonization and/or invasion by pathogens, as well as subsequent progression of 
infections (Figure 1).  
 
Figure 1: Components of the immune system: The innate and the adaptive immune system comprise 
specific cell populations which differ in their phenotype and effector functions (adapted from [4]). 
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2.1.1. The innate immune system 
The hallmark of innate immunity is its rapid and unspecific response to pathogens. The 
innate immune system is an evolutionarily conserved system which is comprised of 
hematopoietic cells including macrophages, dendritic cells (DCs), mast cells, 
eosinophils, neutrophils, natural killer (NK) cells, natural killer T (NKT) cells and Ȗδ T 
cells. Once the pathogen has crossed the physical barrier, different effector 
mechanisms are activated. Innate immune responses include the secretion of cytokines 
and chemokines, the induction of antimicrobial peptides, the initiation of cell death and 
the recruitment of phagocytic cells to the site of infection [4, 5]. Upon sensing of the 
potentially harmful motifs, a signaling cascade is initiated which leads to the activation 
of appropriate innate immune cells which results in the clearance of invading pathogens 
and the stimulation of the adaptive immunity [1]. 
Most of the innate cells have the ability to take up pathogens via phagocytosis or 
micropinocytosis [6-8]. Amongst others, macrophages and DCs are antigen-presenting 
cells (APCs) which are able to capture the encountered antigens, process them and 
present them either via major histocompatibility complex class II (MHC class II) or MHC 
l molecules. MHC molecules loaded with pathogen-derived peptides are transported to 
the cell surface where they present the processed peptide to T lymphocytes thereby 
inducing a primary immune response. In addition, DCs play a role in the maintenance of 
B cell function by acting as a delivery vehicle of intact antigens to naive B cells [9, 10]. 
APCs express pattern recognition receptors (PRR) which are able to recognize highly 
conserved and specific pathogen-associated molecular patterns (PAMPs) present on 
pathogens such as viruses, bacteria, parasites and fungi [11, 12]. PRRs are a large 
group of receptor molecules, including toll like receptors (TLRs), complement receptors, 
C-type lectin receptors (CLRs), RIG-1-like receptors (RLRS) cytosolic sensors and 
nucleotide-binding oligomerization domain (NOD) receptors which detect a wide range 
of non-mammalian structural motifs found in and on pathogens [13, 14]. Upon activation 
via PAMPs APCs up-regulate the expression of MHC molecules and co-stimulatory 
molecules like CD80 (B7-1) and CD86 (B7-2). Once activated, APCs further initiate pro-
inflammatory responses by the secretion of cytokines and chemokines and migrate to 
draining lymph nodes to activate antigen-specific T or B cells [13, 15]. The ability of DCs 
to activate a large variety of different immune cells is the key to bridge innate and 
adaptive immune responses [16]. 
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2.1.2. The adaptive immune system 
The adaptive immune response is characterized by its high specificity and consists of 
highly specialized cells that participate in the elimination or containment of harmful 
pathogens, thereby preventing the establishment of infections. The adaptive immune 
system is composed of T lymphocytes mediating cellular immunity and B lymphocytes 
mediating humoral immunity. The effector functions of adaptive immune responses are 
based on the secretion of antibodies, targeting and neutralizing the antigen outside the 
host cell, cell-mediated killing of the infected cell and the formation of memory cells 
ensuring long-term protection. 
2.1.2.1. T cell-mediated immunity 
T cells undergo developmental selection and maturation in the thymus. T lymphocytes 
consist of two main subsets, T helper lymphocytes (Th) and cytotoxic T lymphocytes 
(CTL). They are characterized by the surface expression of T cell receptors (TCR) and 
the variability of the TCR repertoire, which enables the detection of a multiplicity of 
pathogens, results from the recombination in germline genes during their 
development [17]. Exposure of antigenic peptides, presented by APCs to naïve T cells 
residing in secondary lymphoid organs, results in T cells activation. T cell-mediated 
immunity includes the priming of naïve T cells, the initiation of their effector function and 
the establishment of long-term persisting memory T cells [18]. 
Priming of naïve T cells 
Naïve T cells are activated by two specific signals provided upon activation of APCs by 
PAMPs [19]. The first signal is represented by antigen presentation via MHC class I or 
MHC class II to a corresponding TCR. The second signal is initiated by the interaction of 
co-stimulatory molecules such as CD80 or CD86 expressed on the surface of activated 
APCs with their corresponding co-receptor CD28 expressed on the surface of T 
cells [20] (Figure 2). 
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Figure 2: T cell activation by APCs: APCs, such as DCs, efficiently activate T cells via signal 1 (MHC - 
TCR) and signal 2 (CD80/CD86 – CD28) (adapted from [21]). 
The engagement of these signals results in cytokine production including an enhanced 
IL-2 secretion by T cells leading to T cell proliferation and activation. In addition, the 
activation of naïve antigen-specific T cells is supported by the surrounding cytokine 
milieu that promotes the differentiation into different CD4+ effector T cell phenotypes 
such as Th1, Th2, Th17, regulatory T cells (Treg) and follicular helper T cells (TFH). 
Presence of IL-12 drives differentiation of naïve T cells into Th1 phenotype and 
presence of IL-4 differentiates into Th2 phenotype. Naïve T cells differentiate into Th17 
cells in presence of IL-6 and TGFȕ. Treg differentiation is mediated in presence of TGFȕ 
and IL-10, and IL-6 and IL-21 drives differentiation of naïve T cells into TFH cell 
phenotype [22] (Figure 3). 
 
Figure 3: CD4 T cell subset differentiation: CD4
+
 T cells are able to differentiate into different subsets 
based on the cytokines secreted during priming of the naïve CD4 cells by APCs (adapted from [23]). 
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Effector functions of activated T helper cells and CTL 
CD4+ T cells, which recognize antigens presented via MHC class II molecules, 
differentiate into different effector phenotypes. Th1 cells mainly secrete IFNȖ, but also 
IL-2 and TNF-α and thus promote pro-inflammatory cell-mediated immunity. 
Furthermore, Th1 cells also induce the production of IgG2c antibody secreted by B 
cells. In contrast, Th2 cells, which primarily secrete IL-4, IL-5, IL-6, IL-10 and IL-13, 
support non-inflammatory immune responses and provide B cell help thus inducing the 
production of IgG, IgA, and IgE antibodies [24]. Th17 cells secrete IL-17A, IL-17F and 
IL-22, and thereby promote pro-inflammatory immune responses [25, 26]. Tregs are 
essential to keep the balance of the immune system and to prevent an excessive 
immune reaction. They secrete immunesuppressive cytokines such as TGF-ȕ and IL-10 
that attenuate immune responses and mediate the maintenance of self thus preventing 
autoimmune diseases [27]. TFH cells secreting IL-21 are required for the formation of 
germinal centers (GCs), as well as regulating GC B cell differentiation into plasma B 
cells and memory B cells [28, 29]. In contrast to CD4+ T cells, CD8+ T cells are activated 
by antigenic peptides presented via MHC class I and develop into effector CTLs, which 
mainly secrete IFNȖ and the contents of lytic granules, and express death ligands, such 
as TNF-related apoptosis-inducing ligand (TRAIL) and Fasligand (FasL), thereby 
promoting the killing of target cells [30-32]. 
Long-term persistence of memory T cells 
Upon encounter with a pathogen a small population of antigen-specific T cells 
differentiates into memory T cells. CD4+ and CD8+ memory T cells reside in lymphoid 
organs for a prolonged period of time. Upon a second encounter with a pathogen these 
memory populations rapidly mediate effector functions, thereby preventing the 
establishment of an infection [33]. The main memory T cell populations are central 
memory T cells (TCM), effector memory T cells (TEM) and tissue-resident memory T cell 
(TRM) [34]. Upon encounter with antigen TEM cells execute effector functions, whereas 
TCM cells rapidly proliferate, expand and acquire effector functions. On the other hand, 
TRM cells demonstrate non-migratory phenotype and promote local antigen-independent 
responses in tissues such as, skin, lungs, gut and vagina. 
2.1.2.2. B cell-mediated immunity 
B cells are bone marrow-derived lymphocytes that express clonally diverse cell surface 
immunoglobulin (Ig) receptors that recognize specific antigenic epitopes. The B cell 
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development involves the combinatorial rearrangement of V, D and J gene segments in 
the heavy (H) chain locus and the V and J gene segments in the light (L) chain locus 
thus resulting in the different repertoire of functional VDJH and VJL rearrangements 
encoding the B-cell receptor (BCR) [35]. 
Based on the Fc-part of the heavy chain, antibodies are classified into five different 
classes namely IgD, IgM, IgA, IgG and IgE [36]. Upon a first antigen encounter with a 
pathogen, mature naïve B cells expressing either IgD or IgM become activated. The 
subsequent interaction with Th2 cells via CD40-CD40L engagement and the effect of T 
cell derived cytokines leads to sequential clonal expansion, isotype-switching, affinity 
maturation and memory B cell generation. Isotype switching leads to the production of 
high-affinity IgG, IgA and IgE antibodies [37]. Systemic humoral responses are 
characterized by IgG and IgE antibodies. Antigen-specific IgG is crucial for the 
elimination of viral or bacterial pathogens, whereas IgE provides immunity against 
parasites such as helminths. However, IgE can also mediate allergic response by 
binding to Fc receptors expressed on mast cells and basophils [38, 39]. In contrast to 
IgG, which acts on the systemic level, IgA secretion forms the hallmark of mucosal 
antibody-mediated protection. IgA exists in a dimeric form which is composed of two IgA 
molecules linked through a short J-chain polypeptide [40, 41]. Dimeric IgA covalently 
binds to the secretory component (SC) and is transported to the mucosal lumen as 
secretory IgA (sIgA) mediated by the polymeric-Ig receptor (pIgR) expressed by 
epithelial cells on the basolateral membrane. Various cytokines such as IL-4, IFNȖ, 
TNFα, IL-6, IL-10 and TGF-ȕ stimulate this process [42]. The sIgA acts as the first line 
of defense for protecting the mucosa from various pathogenic micro-organisms and it is 
essential for the maintenance of the mucosal homeostasis. In addition to their essential 
role in mediating humoral immunity, B cells also contribute to the activation of other 
immune cells. Thus, they prime CD4 T cells by presenting processed antigens and 
influence T cell differentiation by producing different cytokines [43]. 
Germinal center reaction 
The induction of T cell-dependent antibody responses including the affinity maturation 
and generation of memory B cells takes place in GCs which represent transient 
structures that are formed within the peripheral lymphoid organs - spleen and lymph 
nodes. The lymph nodes are characterized by follicles mainly comprised of naïve B cells 
segregated by an inter-follicular region which is surrounded by a T cell-rich zone [44]. 
GCs form within the center of these follicles, which includes a follicular dendritic cells 
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(FDCs) network. The GC reaction is initiated by the activation of naïve B cells and pre-
TFH cells within the follicle or the T cell zone by exogenous antigen. Subsequently, B 
cells and pre-TFH cells migrate to the inter-follicular region where they proliferate and 
interact thus resulting in activated GC B cells (Figure 4). Subsequently, B cells either 
migrate to the medullary chords termed as extra-follicular B cells where they 
differentiate into short-lived plasmablasts or they enter the GC pathway resulting in the 
formation of the early germinal center which consists of B cell blasts surrounded by the 
mantle zone. The GC rapidly expands due to proliferating B cell blasts and differentiates 
into dark zones and light zones marking the establishment of mature GCs [45, 46]. The 
GC B cells subsequently develop into high-affinity long-lived antibody secreting plasma 
cells as well as memory B cells that migrate and reside in the bone marrow.  
 
Figure 4: Formation of the germinal center reaction: (1) FDCs present antigen and activate naïve CD4 
T cells to differentiate into TFH cells. (2) The migration of pre-TFH cells toward the T–B cell border is 
facilitated by CXCR5 expression. B cells undergo signals thereby instructing their maturation pathway 
either to extra-follicular activated B cells or GC B cells. (3) Extra-follicular activated B cells convert to 
short-lived plasma cells and secrete antibody. (4) In the GC, interactions between GC TFH cell and GC 
B cells results in GC maintenance and the formation of memory cell and long-lived plasma cells (adapted 
from [47]). 
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2.2. Viral infections 
Viruses are infectious and obligate intracellular pathogens which depend on the host 
machinery for replication. The viral genome is either comprised of DNA or RNA. Within 
an appropriate host cell, the viral genome is replicated and the virions, new infectious 
virus particles, are the vehicle for transmission of the viral genome to the neighboring 
cells leading to the beginning of the next infectious cycle. Viral infections have been 
responsible for quite a few pandemics e.g. the 1918 “Spanish flu” pandemic that killed 
approximately 50 million people worldwide [48] and the ongoing HIV/AIDS pandemic 
that have killed an estimated 39 million people worldwide [49]. Infectious diseases are 
still the second leading cause of death worldwide hence preventive measures and an in-
depth understanding of the immunological mechanisms essential for pathogen 
elimination are required to combat infectious diseases. 
2.2.1. Influenza A virus 
Influenza A virus belongs to the family of Orthomyxoviruses. It is roughly spherical in 
shape and is 80-120 µm in diameter. The viral envelope contains 3 viral transmembrane 
proteins namely hemagglutinin (HA), neuraminidase (NA) and matrix 2 – ion channel. 
The central core is surrounded by the M1 protein and contains 7-8 pieces of 
segmented, single stranded, negative sense viral RNA genome. Influenza A contains 11 
genes on 8 pieces of RNA encoding for 11 proteins - HA, NA, M2, M1, NP, NS1, NS2, 
PA, PB1, PB1-F2 and PB2 [50] (Figure 5). The influenza A virus is classified based on 
the viral surface proteins HA and NA. Currently, 18 HA and 11 NA serotypes of 
Influenza A virus have been identified. 
 
Figure 5: Structure of Influenza A virus (adapted from [51]). 
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The influenza A virus causes a zoonotic infection and is able to adapt to a wide range of 
hosts thereby resulting in occasional pandemics causing millions of deaths worldwide. 
Pandemics and seasonal epidemics are caused due to the emergence of new influenza 
subtypes caused by “antigen-shift” or “antigen-drift”. Antigen-shift is the process by 
which two different strains of the virus from two different species combine to form a new 
subtype. Antigen-drift is the natural mutation occurring over-time of the known influenza 
strain. In humans, the influenza A virus causes yearly seasonal epidemics resulting in 
high morbidity (3 to 5 million) and mortality (250,000 to 500,000) worldwide [52]. 
Generally, the H1, H2 and H3 subtypes are known to commonly infect humans. A new 
subtype of influenza, H5N1, known as “avian influenza” or “bird flu”, usually does not 
infect humans but poultry. Rare cases of human infections with the avian virus occurred 
due toa close contact causing severe pneumonia leading to mortality in 50% of infected 
individuals [53, 54]. Furthermore, the 2009 outbreak of “swine flu” alarmed the world for 
a new pandemic threat. 
Immune responses initiated upon influenza infection: 
The influenza virus enters the host through the oral or nasal cavities and is first 
countered by the mucus that covers the respiratory epithelium. Upon surpassing the 
mucus the virus attaches to and invades the respiratory epithelial cells from where it 
spreads to the immune cells such as DCs and macrophages in the respiratory tract. The 
viral RNA present within the infected cells is recognized as foreign by various PRRs - 
TLR3 and TLR7 thus leading to the secretion of type I interferons (IFNs), as well a 
further proinflammatory cytokines and chemokines. IFNs secreted by macrophages, 
DCs and plasmacytoid DCs (pDCs) stimulate the expression of IFN-stimulated genes 
(ISGs) in neighboring cells, which induces an antiviral response. Furthermore, the 
proinflammatory cytokines cause local and systemic inflammation and initiate the 
adaptive immune response. Chemokines secreted at the site of infection mediate the 
recruitment of additional immune cells, including neutrophils, monocytes and NK cells, 
which contribute to viral clearance and elimination of infected dead cells [55, 56]. 
However, an excessive production of inflammatory cytokines as well as the infiltration of 
neutrophilsis a key factor contributing to immunopathology resulting in the acute lung 
injury observed during influenza infection [57, 58]. In addition to viral clearance by 
innate cells, the elimination of the virus also requires adaptive immunity mediated by 
CD4 T cells and CD8 T cells, as well as B cells secreting neutralizing antibodies [59]. 
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Vaccination – a critical tool to prevent influenza infection 
Vaccination is the most effective and cost-efficient approaches to prevent influenza 
infections. Three classes of licensed seasonal vaccines, including inactivated, live 
attenuated and recombinant HA vaccines, are currently available against influenza 
infection [60]. The inactivated influenza vaccines (IIV) consist of a split virion or a 
subunit vaccine that is administered intramuscularly or intradermal, respectively. The 
trivalent inactivated vaccine (TIV) contains H1N1 and H3N2 subtypes of influenza A 
along with a dominant influenza B subtype. A recently licensed quadrivalent influenza 
vaccine (QIV) includes an additional influenza B subtype. The IIVs induces strain-
specific systemic IgG antibody response against the viral HA glycoprotein, thus 
inhibiting virus binding and entry into the host cell. Although these strain-specific 
antibodies against HA neutralize the virus and prevents infection, HA is under positive 
selective pressure driving to evolve and thereby circumventing immune recognition. The 
second classes of the licensed vaccine products are the live attenuated influenza 
vaccines (LAIV). They contain the similar influenza strains as the QIV but are 
administered intranasally and thus additionally activate the mucosal components of the 
immune system, such as IgA antibodies which can neutralize viruses at the portal of 
entry. In addition, LAIV induce CTL responses efficiently contributing to protection by 
lysis of infected cells [61]. Despite their great potential to induce protective immunity, 
the use of LAIV is not always recommended for use in groups at risk for severe 
infections, such as small children, elderly or patients affected by chronic infections or 
immunocompromised individuals. The third group of licensed influenza vaccines is 
represented by the first recombinant HA vaccine (FluBlok), which is currently approved 
for adults aged between 18 to 49 years who are allergic to eggs [62]. Although the 
currently licensed influenza vaccines are relatively effective in healthy young individuals, 
several hurdles such as the need for annual vaccination, the emergence of antigenically 
novel viruses, the varying degree of immunogenicity and the missing correlates of 
protection still remain to be addressed [63]. 
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2.3. Mucosal Vaccination 
Pathogens such as influenza enter the body through the mucosal membranes. 
Therefore, vaccines that act already at the entry sites represent an effective tool to 
control disease development and progression. Mucosal vaccines are demonstrated to 
improve the prevention of infectious diseases as they are able to trigger cellular and 
humoral immune protection not only systemically but also at local as well as distal 
mucosal areas, thereby reducing the risk of disease transmission [64, 65]. Mucosal 
vaccines have several advantages over parenteral administrations such as being 
needle-free (i.e. painless), an easy way of administration, and a low risk of cross-
infection and side-effects, therefore resulting in a high acceptance by the public [66]. In 
addition, stimulation of an efficient local response can also reduce colonization of 
pathogens thereby providing protection against both infection and disease. However, to 
date only a few mucosal vaccines have been approved for humans due to safety 
concerns derived from the use of some mucosal vaccines in humans and the poor 
stability and immunogenicity of antigens delivered via mucosal routes [64]. The recent 
technological advances (e.g. the adjuvantation of formulations, use of innovative 
delivery system) might allow the development of efficacious mucosal vaccines that 
display an adequate safety profile. 
2.3.1. Basic principles of the mucosal immune response 
Anatomically, the immune system is divided into functional compartments, of which the 
two most important are the peripheral lymphoid system and the mucosal lymphoid 
system. The mucosa-associated lymphoid tissues (MALT) encompassing the 
nasopharynx-associated lymphoid tissue (NALT), bronchus-associated lymphoid tissue 
(BALT) and gut-associated lymphoid tissue (GALT) are highly vulnerable to infection 
and possess a complex array of specific and unspecific mechanisms to combat 
pathogens [67-69]. 
The unspecific mucosal defense of the respiratory tract is mediated via physical and 
chemical barriers. The physical barrier is composed of an epithelium layer which is lined 
with tiny, hair-like projections called cilia and covered with a layer of mucus which acts 
as the first line of defense by clearing the pathogen via constant mechanical movement. 
The integrity of epithelial cells defines the access of APCs to pathogens, which are 
crucial for initiating a pathogen-specific immune response. Mucosal chemical barriers 
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are composed of mucins, which are secreted by goblet cells and anti-microbial peptides, 
such as defensins, which are secreted by epithelial cells [70-72].  
The mucosal antigen-specific responses mediated by the local production and secretion 
of sIgA, which is resistant to degradation in the protease-rich environment at the 
mucosal surfaces. In humans over 1mg/ml of IgA antibodies are present in the 
secretions that are associated with the mucosal surfaces [73]. The sIgA has multiple 
roles in the mucosal defense system as it entraps pathogens in the mucus, thereby 
preventing the attachment of pathogens to the epithelial layer. It also mediates other 
functions such as antibody-dependent cell mediated cytotoxicity (ADCC) with leads to 
the destruction of local infected cells [74].  
2.3.2. Mucosal vaccines 
The route of vaccination plays an important role in order to evoke immune responses 
against specific pathogens not only at local but also at distant mucosal sites. Mucosal 
vaccines against a specific target pathogen delivered either orally or intranasally induce 
immune response that mimics those observed after natural infections [75]. For example, 
LAIV administered by the intranasal (i.n.) route was proven effective at protecting 
against seasonal influenza infections [76]. Additionally due to the compartmentalization 
within the mucosal immune system oral vaccination usually does not stimulate efficient 
immue responses in genitourinary tract or respiratory tract, whereas i.n. vaccination 
evokes immune responses at local (NALT and respiratory tract) as well as distal 
(vaginal) sites [77]. 
Following intranasal administration, immune responses are initiated at the inductive site 
known as NALT. NALT is a key secondary lymphoid structure of the upper respiratory 
tract which is composed of specialized follicle-associated epithelium which contains 
microfold (M) cells. M cells act as an accessible trans-membranous transporter and 
their basolateral surfaces form intraepithelial pockets which are populated with immune 
cells such as DCs, macrophages, B and T cells. Antigens transcytosed through the M 
cells are processed and presented by APCs including macrophages, DCs and B cells to 
naïve lymphocytes. APCs either stimulate lymphocytes locally or migrate to T and B–
cell regions in the LN [78-80]. GC formation and antibody class switching occur in the B 
cell region. This results in the induction of mucosal and systemic immune response 
characterized by the production of IgA and IgG [81]. Primed immune cells disseminate 
through the common mucosal immune system (CMIS) that connects inductive mucosal 
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sites to effector sites, e.g. the lung (Figure 6). In parallel, activated T cells and B cells 
migrate through the body via the bloodstream and contribute to systemic immune 
response. Mucosal vaccines induce both mucosal and systemic antigen-specific 
immune responses and thereby provide appropriate defensive responses [82]. 
 
Figure 6: Schematic representation of the mucosal immune system indicating inductive and 
effector tissues for antigen-specific immune responses post i.n. vaccine administration: I.n. 
administered antigens are taken up from the lumen of nasal cavities located in the NALT. DCs take up the 
antigen and present it to Th cells in the draining lymph nodes. Consequent interactions between DCs, 
CD4 cells and B cells induce GC center reactions resulting in the generation of IgA producing plasma 
B cells. IgA-committed B cells migrate to the effector site via the peripheral blood and secrete dimeric IgA 
that binds to pIgR and is transported to apical surfaces where they are cleaved into sIgA (adapted 
from [83, 84]). 
2.3.3. Challenges of mucosal vaccines 
Despite the many advantages exhibited by intranasally administered mucosal vaccines 
compared to parental ones, several obstacles such as a poor permeability of the 
administered formulation, degradation of the formulations, release and uptake of the 
vaccine component still needs to be overcome [75, 85]. These obstacles negatively 
impact vaccine stability, and prevent sufficient antigen delivery and presentation by 
resident APCs, which in turn hampers the initiation of proper immune response and 
require higher antigen doses as compared to parental vaccines [86]. The breaching of 
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the mechanical and physiochemical barriers could be facilitated by the use of delivery 
systems [87] and the reduced immunogenicity of the antigen and the insufficient 
induction of systemic humoral and cellular immune responses as compared to parental 
vaccination strategies might be overcome by adjuvantation [88]. In addition to the 
above-mentioned challenges, major concerns exist in terms of their safety profile 
especially in different risk groups, such as immunocompromised individuals, small 
children, elderly and chronically infected patients (e.g. live attenuated vaccines). 
2.3.4. Adjuvants 
Adjuvants are agents which help to increase the immunogenicity of an antigen. This is 
facilitated by different mechanisms including the generation of an antigenic reservoir 
allowing a slow release of antigens. Adjuvants can further improve the delivery of 
antigens to APCs thereby improving antigen presentation and processing. In addition, 
adjuvants can be used to tailor the antigen-mediated immune response in a desired 
direction [89]. An ideal adjuvant should not exhibit antigenic properties by itself but 
promote well-defined immune responses and improve antigen-specific immunity. The 
different classes of adjuvants that are used for the implementation in vaccines are either 
immunostimulators, such as TLR ligands and bacterial toxins, or vehicles such as 
virosomes, liposomes emulsions and mineral salts [90]. Only a few adjuvants have been 
approved for the implementation in human vaccines (Table 1). Only one of these 
adjuvants, CTB, has been approved for mucosal administration. 
Table 1: Adjuvants licensed for use in human vaccines (adapted from [91, 92]). 
Adjuvant Class Components Diseases 
Alum (1924) Mineral salts Aluminium phosphate 
or aluminum 
hydroxide 
Diphtheria toxoid, tetanus 
MF59 (Novartis; 
1997) 
Oil-in-water 
emulsion 
Squalene, polysorbate 
(Tween 80; ICI 
Americas), 
sorbitantrioleate 
(Span 85; Croda 
International) 
Fluad (seasonal 
influenza), Focetria 
(pandemic influenza), 
Aflunov (pre-pandemic 
influenza) 
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2.3.4.1. Mucosal adjuvants 
The need of mucosal vaccines fosters the search for adjuvants applicable for mucosal 
administration. Mucosal vaccines co-formulated with adjuvants represent a beneficial 
tool to overcome obstacles such as the large dosage due to the instability of antigens at 
mucosal surfaces, the poor immunogenicity and the insufficient induction of systemic 
and mucosal immune responses [93]. Adjuvants used in mucosal vaccines have a 
similar mode of action as compared to the parental vaccines. Commonly used mucosal 
adjuvants for pre-clinical studies comprise cholera toxin (CT) and its subunits and 
Escherichia coli heat labile enterotoxin (LT). However, safety concerns in terms of 
toxicity represent one of the major concerns for their application as adjuvant in human 
mucosal vaccines. In this line, Nasalflu (Berna Biotech AG, Switzerland) adjuvanted 
with the active LT was linked to several cases of Bell’s palsy [94]. TLR agonists (TLR2, 
3, 4, 5, 6, 7, 8 and 9) represent another widely studied group of potential mucosal 
adjuvants. TLR agonists mainly target APCs resulting in the activation of adaptive 
immune response, thereby inducing a strong cellular and humoral immune response. 
However, the use of a TLR4 agonist as a mucosal adjuvant has been reported to induce 
detrimental influenza-specific Th17 responses [95]. Furthermore, none of the TLR 
agonist promotes both mucosal and cellular responses. Some of them stimulate 
humoral responses (e.g. TLR2, TLR4), whereas others are more efficient in promoting 
cellular immunity (e.g. TLR9). Other potential mucosal adjuvants being used in pre-
clinical studies are α-galactosylceramide (α-GalCer) and cyclic dinucleotides (CDNs) 
[96-98]. Thus, efforts are needed to identify mucosal vaccine formulations with a 
ASO3 (GSK; 2009) Oil-in-water 
emulsion 
Squalene, Tween 80, 
α-tocopherol 
Pandemrix (pandemic 
influenza), Prepandrix 
(pre-pandemic influenza) 
Virosomes (Berna 
Biotech; 2000) 
Liposomes Lipids, hemagglutinin Inflexal (seasonal 
influenza), Epaxal 
(hepatitis A) 
ASO4 (GSK; 2005) Alum-
absorbed 
TLR4 agonist 
Aluminium hydroxide, 
MPL 
Fendrix (Hepatitis B), 
Cervarix (human 
papilloma virus) 
CTB Bacterial toxin Cholera toxin B 
subunit 
Dukoral (Cholera) 
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negligible risk of side-effects but able to induce efficient immune responses tailored to 
the location and the threat of the invading pathogen. 
Bacterial cyclic di-nucleotides - promising mucosal adjuvants 
The family of cyclic di-nucleotides (CDNs), a group of natural compounds, consists of 
bis-(3’, 5’) –cyclic dimeric guanosine monophosphate (c-di-GMP), bis-(3’, 5’) –cyclic 
dimeric adenosine monophosphate (c-di-AMP) and (3’, 5,)-cyclic adenosine 
monophosphate-guanosine monophosphate (cGAMP). These are well known 
secondary bacterial messenger, involved in biofilm formation, regulation of bacterial 
virulence and motility [99, 100]. In this line, c-di-GMP was demonstrated to decrease the 
pathogenicity of Listeria monocytogenes, Mycobacterium tuberculosis and Vibrio 
cholera [101-103]. c-di-AMP was shown to alter bacterial cell size and regulate cell 
envelope stress and biofilm formation favoring antibiotic resistance and bacterial 
virulence in Staphylococcus aureus and Streptococcus suis [104, 105]. On the other 
hand, the cGAMP produced by prokaryotes are 3′3′-cGAMP. A related compound to 
cGAMP known as 2′3′-cGAMP has been described in eukaryotes [106]. 
The c-di-GMP and c-di-AMP activate the crucial signaling molecule called STING 
(stimulator of interferon genes) that has been identified as an innate cytosolic DNA 
sensor and in turns leads to the activation of the TBK3-IRF3 signaling pathway resulting 
in the production of both type I IFNs and TNFα [107-110]. 
 
Figure 7: Chemical structures of bacterial cyclic di-nucleotides (adapted from [111]). 
CDNs have recently demonstrated to exhibit strong immune modulatory 
properties [112]. In animal models, intranasally delivered c-di-GMP was shown to 
provide protection against Klebsiella or Streptococcus pneumonia challenge by 
stimulating the production of several pro-inflammatory cytokines and chemokines, as 
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well as by recruiting immune effector cells to the site of infection [113]. Interestingly, 
CDNs were shown to be active as adjuvants when administered via mucosal or parental 
routes, thereby inducing a strong humoral response at systemic (IgG) and mucosal 
(IgA) levels. In addition, CDNs were demonstrated to mediate cellular immunity by 
inducing antigen-specific multifunctional CD4+ and cytotoxic T cells [97, 114, 115]. 
Studies comparing the adjuvant properties of c-di-AMP and c-di-GMP provided 
evidence that the immunostimmulatory properties of individual CDN molecules differ. 
The c-di-AMP exhibited improved capacity in stimulating the activation of human DCs 
in vitro as compared to c-di-GMP. Interestingly, in vivo co-administration of c-di-AMP 
with Ovalbumin (OVA) as model antigen resulted in significantly improved stimulation of 
immune responses at mucosal and systemic levels as compared to c-di-GMP [97]. 
Further, in comparison to c-di-GMP and cGAMP, c-di-AMP was shown to be a strong 
inducer of Th17 responses used as mucosal adjuvant [97, 116]. A proof-of-concept 
study showed that mice vaccinated intranasally with recombinant influenza 
nucleoprotein (rNP) co-administered with c-di-AMP generated significant antigen-
specific cellular and humoral immunity in both mucosal and systemic compartments 
which conferred protection against a sublethal influenza challenge [117]. This renders c-
di-AMP a promising candidate adjuvant for the development of mucosal vaccines. 
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2.4. IL-17 ‘a proinflammatory cytokine’ 
IL-17 secreting cells predominantly resides at the mucosal surfaces and are therefore 
one of the features induced by mucosal vaccines. The IL-17 cytokine family consists of 
IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. The biological functions and 
regulation of IL-17A and IL-17F are well studied, whereas much less is known about the 
other members. IL-17 mediates its biological functions via surface receptors which are 
ubiquitously expressed among non-hematopoietic cells, such as fibroblasts and 
epithelial cells, and innate and adaptive immune cell populations. IL-17A and IL-17F 
cytokines are recognized by the heterodimeric form of the receptor complex IL-17RA 
and IL-17RC. Functionally, both IL-17A and IL-17F mediate proinflammatory 
responses [118, 119]. In brief, the activation of IL-17RA-C complex by ligation of IL-17 
initiates innate defense and repair responses that include the induction of chemokines, 
cytokines and anti-bacterial peptides [120]. 
Innate IL-17 producing cells 
Innate IL-17 producing cells are an integral part of IL-17-mediated immune responses 
during stress, injury or in the presence of invading pathogens. Large populations of 
innate cells such as Ȗδ T cells, iNKT cells, lymphoid-tissue inducer (LTi)-like cells, 
neutrophils and paneth cells have been recognized as the early sources of IL-17 
production [121]. Innate IL-17 producing cells predominantly reside at the mucosal 
surfaces such as lung, intestinal mucosa and skin, where they possess a pre-activated 
phenotype and recognize the antigen via an array of sensory receptors expressed on 
their surface. Innate IL-17-secreting cells acts directly on epithelial cells promoting 
secretion of antimicrobial peptides and defensins, which protect the host against 
infections. Innate IL-17-secreting cells also induce epithelial cells to secrete the 
granulocyte colony-stimulating factor (G-CSF) and CCL20. This mediates neutrophil 
recruitment to the site of infection, thereby triggering rapid non-specific immunity against 
infectious agents such as Citrobacter rodentium [122, 123], Klebsiella pneumonia [124-
126], S. aureus and Candida albicans [127-129] (Figure 8). 
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Figure 8: Functions of innate IL-17 secreting cells: Infections or other stress conditions promote APCs 
to produce proinflammatory cytokines. These cytokines are required for the activation of innate IL-17-
secreting cells. Secreted IL-17 induces the secretion of inflammatory cytokines, chemokines and growth 
factors by various cell types of target tissues, thereby resulting in neutrophil recruitment. IL-17 also acts 
directly on epithelial cells to promote therelease of defensins, regenerating (REG) proteins and S100 
proteins, which have antimicrobial activities and protect the host against infections (modified from [121]). 
Adaptive IL-17 producing cells 
A decade ago, the dogma of immune regulation by Th cells was amended. The new 
lineage named Th17 was characterized by their ability to secrete IL-17A, IL-17F and IL-
22. Th17 cells are dependent on STAT3 signaling and can differentiate from other Th 
cells based on the expression of the lineage transcription factor RORȖt [130]. Within the 
adaptive arm, much emphasis has been placed on Th17 cell as the source of IL-17. 
However, some cytotoxic T cells termed Tc17 as well as B cells have been identified to 
contribute to IL-17 secretion. IL-17 secreting B cells have been detected in response to 
Trypanosoma cruzi infection [131]. IL-17+ Tc17 have been described in various 
conditions, such as infections, anti-tumor activities and autoimmune inflammation. 
Irrespective of their potential in providing immunity, Tc17 cells have received only 
marginal attention. Apart from their role in infections and autoimmunity, Th17 cells have 
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received considerable attention in the field of vaccine development due to the observed 
Th17 induction upon administration of vaccines via mucosal routes. 
Differentiation of Th17 cells 
Upon TCR activation, naïve CD4 T cells differentiate into different Th lineages based on 
the cytokine milieu in the surrounding environment. In mice, naïve CD4 T cells 
differentiate into Th17 cells in the presence of IL-6, IL-23, IL-1ȕ and TGF-ȕ. These 
cytokines establish the early commitment to the Th17 lineage by activating STAT3, 
which in turn induces the expression of IL-21 which is required for Th17 expansion. 
Autocrine signaling of IL-21 promotes STAT3-dependent expression of IL-23R, IL-17A 
and the transcription factor RORȖt. Furthermore, IL-23 is required for the maintenance 
and stabilization of Th17 effector functions [132, 133] (Figure 9). 
 
Figure 9: Differentiation of Th17 cells: IL-6 and TGF-ȕ secreted by APCs initiate the differentiation of 
naive CD4
+
 T cells to Th17 cells by activating STAT3. Autocrine signaling of IL-21 promotes expression of 
IL-23R, IL-17A and RORȖt. IL-23 is responsible for Th17 maintenance and expansion (adapted from 
[134]). 
Functions of IL-17 secreting cells – matter of concern 
In addition to their crucial role in the fight against infectious pathogens, such as bacteria 
and fungi, IL-17+ cells can also contribute to chronic inflammation by providing the 
proinflammatory cytokine milieu. In a collagen-induced arthritis model, Ȗδ T cells were 
identified as the early source of IL-17 in response to IL-1ȕ and IL-23 and the cause of 
disease progression [135]. Furthermore, production of IL-17 has been reported to inhibit 
Th1 differentiation thereby inhibiting the production of IFNȖ and IL-2, which are required 
for the induction of CTLs and anti-viral activity [136]. Thus, the inhibition of Th1 cells by 
Th17 cells was shown to lead to viral persistence in a case of Theiler's murine 
encephalomyelitis virus (TMEV) infection [137]. In addition, Th17 cells have been 
   Introduction 
  
25 
 
associated with many autoimmune diseases including multiple sclerosis (MS), 
rheumatoid arthritis (RA), inflammatory bowel disease and psoriasis. Using 
experimental mouse model for autoimmune encephalomyelitis (EAE) which resembles 
human MS, it was revealed the key role played by IL-17 and associated cytokines in 
driving central nervous system inflammation and lesion formation [138-140]. IL-17A was 
also detected in synovial fluid in an RA mouse model where it is associated with 
disease progression [141, 142]. Current clinical studies targeting IL-17 and IL-23 
displayed promising results for the treatment of human autoimmune disorders such as 
psoriasis [143, 144], RA [145, 146] and MS [147, 148]. Therefore, gaining knowledge of 
functional and regulatory mechanisms of IL-17+ cells might benefit the development of 
novel immune therapeutics against infectious agents and in addition reduce the 
inflammatory damage in non communicable diseases. 
IL-17-inducing vaccines 
Despite the bad reputation of IL-17, studies performed in experimental animal models 
have shown that vaccine-induced Th17 responses can mediate protective immunity 
against a wide range of pathogens, such as Bordetella pertusis, M. tuberculosis, 
K. pneumonia and Pseudomonas aeruginosa [149-153]. Vaccines consisting of highly 
conserved outer membrane proteins of K. pneumoniae were shown to induce a strong 
Th17 response and to confer protection against a range of different K. pneumoniae 
strains [149]. Further, a live-attenuated vaccine against P. aeruginosa PA14ΔaroA 
induces Th17 cell-dependent protective immunity against heterologous strains of 
P. aeruginosa [154]. In addition, vaccination with the mycobacterial peptide ESAT-6(1-
20) conferred protection against subsequent challenge with M. tuberculosis by induction 
of IL-17+ CD4 T cells which are required for the recruitment of IFNȖ+ T cells [153]. The 
mechanism of protection initiated by the vaccine-induced Th17-mediated defense 
against pathogens consists of the secretion of antimicrobial peptides by epithelial cells, 
neutrophil recruitment to the site of infection, initiation of humoral immunity and 
augmentation of other T cell effector populations. The role of IL-17 in activating B cells 
as well as in GC and inducible-BALT (iBALT) formation is very well documented [142, 
155, 156]. In addition, Th17 cells have been reported to enhance pIgR expression on 
lung and intestinal epithelial cells, thereby regulating the influx of sIgA into the 
lumen [157, 158]. Irrespectively of these findings, to date there is no direct evidence 
linking IL-17 secretion and vaccine-induced immune responses. 
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The role of IL-17 in the combat against influenza infections is also still under debate, 
with reports supporting its contribution to both protective but also pathogenic roles. A 
study demonstrated that IL-10-deficient mice displayed a strong Th17 response 
resulting in increased survival upon challenge with lethal doses of influenza A/PR8 
(H1N1) virus [159]. In contrast, other studies suggested that the use of Th17 cell-
inducing adjuvants, such as CTB and TLR4 agonists, might result in increased morbidity 
and exacerbated lung injury upon subsequent influenza challenge [95, 160]. Therefore, 
an in-depth understanding of the mechanisms controlling pathogenic versus protective 
Th17 cell responses will facilitate the design of efficient mucosal vaccines. In addition, 
the identification of novel Th17 cell-modulating adjuvants displaying a good safety 
profile will also have a tremendous impact on the design of safe and effective vaccines. 
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3. Aim of the thesis 
In the last years, the crucial role of IL-17 secreting cells in the fight against mucosa 
associated bacterial and fungal infections as well as their important impact in regulating 
immune responses have been emphasized. However, their influence in the fight against 
viral infections and their significance for mucosal vaccine design has not been 
completely elucidated. Mucosal infections like influenza represent a major health 
problem worldwide leading to 250,000 – 500,000 deaths annually. The existing vaccines 
often mediate only inadequate protection which strongly points to the need for the 
establishment of improved or new vaccination approaches. The implementation of 
adjuvants represents one key approach to enhance the immunogenicity and efficacy of 
mucosal vaccines. The c-di-AMP recently demonstrated to elicit potent mucosal 
immunity, and it has also been shown to induce strong Th17 responses following i.n. 
administration. However, the underlying mechanisms resulting in c-di-AMP mediated 
Th17 cell differentiation still remain elusive. Thus, the first specific objective of this 
thesis was to dissect the immunological factors contributing to c-di-AMP induced Th17 
differentiation. To this end, an in vitro co-culture system consisting of CD4+ T cells and 
BMDCs was established to elucidate factors contributing to c-di-AMP-mediated Th17 
differentiation. Flow cytometry analysis and CBA (cytometric bead array) were applied 
to elucidate the immunological factors involved in c-di-AMP-induced Th17 
differentiation. 
Our current knowledge on the impact of Th17 cells in the stimulation of adaptive 
immunity, which encompasses (i) initiation of humoral immunity by regulating GC and 
iBALT formation and (ii) enhancement of other T helper cell responses, highlights the 
potential of Th17 cells as a target for in mucosal vaccination strategies. However, the 
proinflammatory role of IL-17, which is well documented in auto-immune diseases, 
should not be neglected. Therefore, the second objective of this thesis was to elucidate 
the impact of c-di-AMP activated IL-17 secreting cells in the generation of antigen-
specific immune responses. To this end, wild type and IL-17a/f deficient mice were 
immunized with either the model antigen OVA or an inactivated influenza vaccine co-
administered with the Th17-stimulating adjuvant c-di-AMP. An advanced multi-
parametric flow cytometry approach was developed which enabled the multifunctional 
characterization of antigen-specific T and B cells. In addition, ELISA was performed to 
investigate humoral immunity by determining antigen-specific antibody titers (IgG and 
IgA). Further to investigate the underlying mechanisms responsible for c-di-AMP 
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induced Th17-dependent antigen-specific immunity, in vitro co-culture studies, 
immunohistochemistry and RT-PCR were performed to detect colocalization of TFH cells 
and GC B cells in GCs and gene expression. The results derived from this thesis deliver 
crucial insight into the underlying mechanisms by which c-di-AMP-induced Th17 cell 
differentiation as well as their contribution to the generation of antigen-specific 
immunity. The obtained knowledge will pave the way towards the development of novel 
mucosal vaccine. 
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4. Materials and methods 
4.1. Materials 
4.1.1. Technical equipment 
Table 2: Technical equipment 
Equipment  Company 
Centrifuge Biofugepico 
Heraeus, Germany Centrifuge Megafuge R40 
Centrifuge Multifuge 3S-r 
Cell counter, Z2 Coulter counter Beckman Coulter, Germany 
Cell culture plates Greiner, Germany 
Cell strainer 100 µm BD Bioscience, USA 
Cell tric 50 µm  PArtec GmbH, Germany 
ChemiDocTM MP Imaging System Bio-Rad, Germany 
Coverplates Thermo Scientific, Germany 
CTL Immunospotanalyser Cellular Technology, Ltd., Germany 
ELISA Reader Synergy2  BioTek, Germany 
ELISA Washer BioTek, Germany 
Falcon tubes Greiner, Germany 
Flow cytometry tubes 1.2 ml MP Biomedicals, France 
Flow cytometry tubes 5 ml BD Bioscience, USA 
Fortessa BD Bioscience, USA 
Flow cytometry AriaII BD, USA 
Handystep Brand, Germany 
High binding ELISA plates Greiner, Germany 
Heating magnetic stirrer IKA Labortechnik, Germany 
Incubator, Heracell 240i Thermo Scientific, Germany 
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4.1.2. Chemical and reagent 
Table 3: Chemicals and reagents 
Mangomix Bioline, Germany 
pH-meter Hannah Instruments, Germany 
Pipettes (0.2–2µl, 2-20µl, 20-200µl, 100-1000µl) Thermo Scientific, Germany 
Pipettboy Thermo Scientific, Germany 
Plate washer ELx 405 BioTek, Germany 
Precision 2000 automated microplates pipettes BioTek, Germany 
Serological pipets Roth, Germany 
Sterile hood Hera Safe Thermo Scientific, Germany 
Synergy 2 Multi-ModeMicroplate Reader BioTek, Germany 
Thermomixer compact Eppendorf, Germany 
Vortex Genie-2 Omnilab, Germany 
Water bath Köttermann, Germany 
Chemicals Company 
2,2’-azino-bis (3-ethyibenzthiazoline-6 sulfonic acid) 
diammonium salt (ABTS) 
Sigma-Aldrich, Germany 
3-amino-9-ethyl-carbazole (AEC substrate) BD Pharmingen, USA 
Acetic acid (CH3COOH) Merk, Germany 
Acetonitrile (CH3CN) Sigma-Aldrich, Germany 
Ampuwa® Serumwerk, Germany 
Avidin-HRP (horseradish peroxidase) conjugated BD Pharmingen 
Ammonium chloride (NH4Cl) Merk, Germany 
ȕ-mercaptoethanol Merk, Germany 
Blocking solution for immunofluorescence staining Zytomed systems, Germany 
Bovine serum albumin (BSA) Sigma-Chemie, Germany 
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Brefeldin A Sigma-Chemie, Germany 
Citrat acide-1-hydrate (C6H8O7*H2O) Invitrogen, Germany 
Citrate Buffer Sigma-Aldrich, Germany 
Collagenase D Roche, Germany 
Concanavalin A fromcanavaliaensiformis Sigma-Aldrich, Germany 
DEPC-treated water ThermoFisher, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Germany 
Dulbecco's Modified Eagle's Medium (DMEM) (low 
and high glucose) 
Gibco, UK 
Dnase Roche, Germany 
dNTP mix ThermoFisher, Germany 
Ethylenediaminetetraactic acid (EDTA) Fluka, Switzerland 
Ethanol 100% Fluka, Switzerland 
Fetal calf serum, South America (FCS) Greiner Bio-One, USA 
Formaldehyde > 36.5% Riesel-de-Haën, Germany 
GeneRuler DNA ladder mix Thermo Scientific, Germany 
Gentamicine Gibco, UK 
L-Glutamine Gibco, UK 
Granulocyte-macrophage colony stimulating factor 
(GM-CSF) 
eBioscience, USA 
Hepes Gibco, UK 
Hydrogen peroxide (H2O2) Sigma-Aldrich, Germany 
3H-thymidine PerkinElmer, USA 
Ionomycin BD, USA 
Isofluran® Curamed vet inhalation anesthetic Essex Tierarznei, Germany 
Isopropanol  Merk, Germany 
Isoton II (acid-free balanced electrolyte solution) Beckman Coulter, USA 
Kappa master mix Kapa Biosystems, Germany 
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MangoMix Bioline, Germany 
2-Mercaptoethanol (50mM) Gibco, UK 
Midori green advanced green DNA stain Nippon Generics, Germany 
Minimal essential medium (MEM) Gibco, UK 
OVA protein EndoGrade, Hyglos, Germnay 
Oligo (dT)18 primer ROTH, Germany 
Paraformaldehyde (PFA) Merk, Germany 
Penicillin/streptomycin (100 units/ml penicillin G 
sodium; 50µg/ml streptomycin sulfate in 85% saline) 
Gibco, UK 
Phorbol 12-myrisate 13-acetate (PMA) Sigma-Aldrich, Germany 
Peanut agglutinin (PNA) Sigma-Aldrich, Germany 
Potassium chloride (KCl) Fluka, Switzerland 
Potassium hydrogen carbonate (KHCO3) Merk, Germany 
Potassium dihydrogen phosphate (KH2PO4) Carl-Roth, Germany 
Proteinase K Bioline, Germnay 
5x reaction mixture ThermoFisher, Germany 
RevertAidTM H minus Reverse Transcriptase ThermoFisher, Germany 
RPMI 1640 medium (+L-glutamine) Gibco, UK 
Receptor destroying enzyme (RDE) Sigma-Aldrich, Germany 
Sodium acetate (CH3CooNa) Merk, Germany 
Sodium carbonate (Na2CO3) Carl-Roth, Germany 
Sodium chloride (NaCl) Carl-Roth, Germany 
Sodium dihydrogen phosphate (NaH2PO4) Merk, Germany 
Sodium hydrogen carbonate (NaHCO3) Merk, Germany 
Sodium hydroxide (NAOH) Carl-Roth, Germany 
Sulfuric acid Sigma-Aldrich, Germany 
Tris/HCl Sigma-Aldrich, Germany 
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4.1.3. Antibodies for flow cytometry 
Table 4: Antibodies used in flow cytometry analysis 
Trizol Sigma-Aldrich, Germany 
Trypan Blue Sigma-Aldrich, Germany 
Trypsin Sigma-Aldrich, Germany 
Tween 20 Carl-Roth, Germany 
Antigen Flurochrome Clone Dilution Company 
CD3 V500 500A2 1:200 BD Horizon, USA 
CD3 BV785 17A2 1:200 BioLegend, USA 
CD4  PE-Cy7 RM4.5 1:1000 eBioscience, Germany 
CD4 BV605 RM4.5 1:800 BioLegend, USA 
CD4  Alexa700 RM4.5 1:500 BioLegend, USA 
CD4 APC-A750 RM4.5 1:500 eBioscience, Germany 
CD4 BV421 RM4.5 1:500 BioLegend, USA 
CD8 PE-Cy7 53-6.7 1:800 eBioscience, Germany 
CD8 BV650 53-6.7 1:300 BioLegend, USA 
CD11b PE-Cy7 M1/70 1:800 eBioscience, Germany 
CD11b BV605 M1/70 1:300 BioLegend, USA 
Cd11b PB M1/70 1:800 BioLegend, USA 
CD11c FITC N418 1:800 eBioscience, Germany 
CD11c APC N418 1:300 eBioscience, Germany 
CD11c BV785 N418 1:200 BioLegend, USA 
CD19 PB 6D5 1:800 BD Horizon, USA 
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CD19 BV785 6D5 1:800 BioLegend, USA 
CD19 APC-Cy7 6D5 1:600 BD Horizon, USA 
CD25 PE PC61 1:300 BD Horizon, USA 
CD27 PE-Cy7 LG.7F9 1:1200 eBioscience, Germany 
CD44 BV785 1M7 1:150 BioLegend, USA 
CD44 APC 1M7 1:400 eBioscience, Germany 
CD45R APC-Cy7 R.A3-6B2 1:200 BD Horizon, USA 
CD62L FITC MEL-14 1:1000 BD Horizon, USA 
CD62L BV605 MEL-14 1:250 BioLegend, USA 
CD69 BV605 H1.2F3 1:100 BioLegend, USA 
CD86 PE GL1 1:500 BD Horizon, USA 
CD86 BV605 GL1 1:150 BioLegend, USA 
CD138 BV421 281-1 1:400 BioLegend, USA 
CD138 BV711 281-2 1:200 BioLegend, USA 
CXCR5 PE-Cy7 2G8 1:500 BD Horizon, USA 
F4/80 FITC BM8 1:100 eBioscience, Germany 
F4/80 PerCP-Cy5.5 BM8 1:200 BioLegend, USA 
IgA Bio 1-1-44-2 1:200 eBioscience, Germany 
IgG1 PE A85.1 1:200 BD Horizon, USA 
ICOS PE E398.4A 1:400 BioLegend, USA 
IFNȖ BV711 XMG1.2 1:300 BioLegend, USA 
IFNȖ BV650 XMG1.2 1:200 BioLegend, USA 
IL-2 APC-Cy7 JES6-5H4 1:200 BD Horizon, USA 
IL-4 APC 11B11 1:200 eBioscience, Germany 
IL-10 BV421 JES5-16E3 1:150 BioLegend, USA 
IL-12/IL-23p40 Alexa647 C17.8 1:400 eBioscience, Germany 
IL-17 V450 TC11-18H10 1:200 BD Horizon, USA 
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4.1.4. Antibodies for Enzyme-linked immunospot Assay 
(ELISPOT) 
Table 5: Antibodies used in ELISPOT 
IL-17 FITC eBio17B7 1:500 eBioscience, Germany 
IL-17 BV605 TC11-18H10.1 1:300 BD Horizon, USA 
IL-17RA PE PAJ-17R 1:100 eBioscience, Germany 
IL-21 APC Rat IgG2B 1:20 R&D, USA 
Ly6G PE-Cy7 1A8 1:200 BioLegend, USA 
MHCI Alexa AF6-S8.5 1:200 BioLegend, USA 
MHCI PB H-2Kb 1:200 BioLegend, USA 
MHCII FITC AF6-120.1 1:100 BD Horizon, USA 
NK1.1 APC PK136 1:400 eBioscience, Germany 
NK1.1 Bv510 PK136 1:100 BioLegend, USA 
NKp46 A660 29A1.4 1:200 eBioscience, Germany 
RorȖt PE B2D 1:100 eBioscience, Germany 
TNFα PerCPeF710 MPG-XT22 1:200 eBioscience, Germany 
ȖδTCR PE GL3 1:200 BioLegend, USA 
Streptavidin BV605 - 1:400 BioLegend, USA 
Streptavidin BV650 - 1:400 BioLegend, USA 
Antibody Conjugated Dilution Company 
Anti-mouse IFNȖ Purified 1:200 BD Pharmagen, USA 
Anti-mouse IFNȖ Biotinylated 1:250 BD Pharmagen, USA 
Anti-mouse IL-2 Purified 1:200 BD Pharmagen, USA 
Anti-mouse IL-2 Biotinylated 1:250 BD Pharmagen, USA 
Anti-mouse IL-4 Purified 1:200 BD Pharmagen, USA 
Anti-mouse IL-4 Biotinylated 1:250 BD Pharmagen, USA 
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4.1.5. Antibodies for Enzyme-linked immunosorbent Assay 
(ELISA) 
Table 6: Antibodies used in ELISA 
4.1.6. Solutions and buffers 
Table 7: Solutions and buffers 
Anti-mouse IL-17A Purified 1:250 eBioscience, USA 
Anti-mouse IL-17A Biotinylated 1:250 eBioscience, USA 
Streptavidin HRP 1:100 BD Pharmagen, USA 
Antibody Conjugated Dilution Company 
Goat, anti-mouse IgA Purified 1:500 Sigma-Aldrich, Germany 
Goat, anti-mouse IgA Biotinylated 1:5000 Southern Biotech, USA 
Goat, anti-mouse IgG Biotinylated 1:5000 Sigma-Aldrich, Germany 
Goat, anti-mouse IgG1 Biotinylated 1:5000 Southern Biotech, USA 
Goat, anti-mouse IgG2c Biotinylated 1:5000 Southern Biotech, USA 
Goat, anti-mouse pIgR Biotinylated 1:200 R&D, USA 
α-goat IgG HRP 1:5000 Jackson Immuno Research, 
Germany 
Streptavidin HRP 1:1000 BD Pharmagen, USA 
Solution/buffer Composition 
ABTS 0.3 g/L ABTS in 0.1 M citric acid 
ABTS + H2O2 0.03% (v/v) H2O2 in ABTS solution 
Acetate solution (0.1 M) 
148 ml acetic acid, 0.2 mM + 352 ml of 0.2 mM sodium 
acetate; adjust volume to1L with H2O,pH 5.0 
ACK lysis buffer 0.1M mM EDTA, 1mM KHCO3, 155 mM NH4Cl, pH 7.3 
Aminoethylcarbazole 
(AEC) stock solution 
100mg AEC substrate in 10 ml DMF 
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AEC + H2O2 
333.3 µl AEC stock solution in 10 ml 0.1 M acetate 
solution, 5µl H2O2 (30%) 
3% Avicel 15 g Avicel + 500 ml dH20 
1% Avicel-DMEM (100 ml) 33,3 ml 3% Avicel + 66,7 ml DMEM 
Blocking Buffer (ELISA) PBS + 3% BSA 
Blocking Buffer (FOCI 
assay) 
0.5% Tween20 + 1% BSA in PBS 
Carbonate buffer (0.1 M) 4.401 g NaHCO3 + 1 L H2O, pH 8.2 
Calcium saline 1 g CaCl2*2H20 + 9 g NaCl + 1.2 g H3BO3 + 0.052 g 
Na2B4O7*10H20 
Dilution buffer (ELISA) PBS + 0.1% Tween 20 + 1% BSA 
Dilution buffer (ELISPOT) 1x PBS containing 10% FCS 
Fixative (FOCI assay) 4% formalin in PBS 
Fixative (MN assay) 80% acetone + 20% PBS 
Infection medium DMEM + 0.1% BSA + 2.5 µg/ml N-Acetylated Trypsin 
(NAT) 
Lung digestion medium RPMI 1640 containing 5% FCS, 2.5% Hepes, 0.2 mg/ml 
collagenase D, 0.1 mg/ml Dnase 
MACS buffer 0.5% BSA; 0.5% saponin/PBS (w/v) 
Overlay 1% Avicel-DMEM + 10% BSA + 5mg/ml NAT 
2% Paraformaldehyde 
(PFA) 
2% PFA/PBS (w/v), pH 7.0 (fixation) 
1 x PBS (phosphate-
buffered saline) 
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4*7H2O, 0.24 g 
KH2PO4 in 1 L H2O, pH 7.2 
Quencher 0.5% Triton x100 + 20mM Glycine in PBS 
Trypan blue solution 0.1% Trypan blue in PBS (w/v) 
Virus diluents DMEM + 1% PenStrep + 0.1% BSA + 2.5 µg/ml NAT + 
25nM Hepes 
Wash buffer (ELISA) PBS + 0.1% Tween 20 
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4.1.7. Antigen and adjuvants 
Table 8: Antigen and adjuvant 
4.1.8. Cell line used in experiments 
Table 9: Cell line used in the experiments 
 
 
4.1.9. Cell Culture Media 
Table 10: Cell culture media 
Wash buffer (ELISPOT) PBS + 0.05% Tween 20 
Antigen / Adjuvant Company 
Α-galactosylceramide polyethylene glycol 
(αGCMPEG) 
HZI, Germany 
Cyclic-di-adenosine-monophosphate (c-di-AMP) BioLog, Germany 
H5N1 (NIBRG-14; see 4.1.10) NIBSC, UK 
Lipopolysaccharide (LPS) Sigma-Aldrich, Germany 
Ovalbumin (OVA; Grade VII, LPS free) Sigma-Aldrich, Germany 
Cell Type Description 
MDCK Madin-Darby Canine Kidney (MDCK) cells are adherent 
epithelial cells which are suitable transfection host and are 
used in influenza research, provided by Prof. Dr. Klaus 
Schughart (INFG, HZI, Germany) 
Media Supplements 
RPMI 1640 complete 10% v/v FCS heat inactivated (h.i.), 100 U/ml penicillin, 50 
µg/ml streptomycin, 2mM L-glutamine 
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4.1.10. Influenza virus 
Table 11: Influenza virus strains used for challenge studies 
4.1.11. Mice 
Table 12: Mice used in the experiments 
 
 
4.1.12. Primers for genotyping IL-17a/f-/- mice 
Table 13: Primers used in PCR for genotyping (Provided by Eurofins) 
RPMI 1640 for BMDCs 10% v/v FCS heat inactivated (h.i.), 100 U/ml penicillin, 50 
µg/ml streptomycin, 2mM L-glutamine, 2-mercaptoethanol 
50 µM, 50 µg/ml gentamycin 
DMEM 100 U/ml penicillin, 50 µg/ml streptomycin 
MEM 10% v/v FCS h.i., 100 U/ml penicillin, 50 µg/ml 
streptomycin 
Strain Description 
H5N1 (formaldehyde- 
inactivated, mouse-
adapted) 
The influenza reference virus NIBRG-14 is a reassortant 
prepared by reverse genetics from A/Vietnam/1194/2004 
(H5N1) virus and A/PR/8/34(H1N1) virus (NIBSC, UK) 
Mouse Description Provider 
Wild type (WT) C57/BL6 Harlan, Germany 
IL-17a/f
-/-
 Animal lacking functional IL-17a/f, 
developed on C57/BL6 background 
[161] 
Kindly provided by Prof. Dr. ImmoPrinz 
(MHH, Hannover, Germany) 
SFB 
NOD-Scid, mono-colonized mice, 
breed at hygienic conditions 
Kindly provided by Prof. Dr. Andrea 
Bleich (MHH, Hannover, Germany) 
Primer Sequence 
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4.1.13. Primers for assessing gene expression 
Table 14: Primers used in qPCR for gene expression (provided by Eurofins) 
4.1.14. PCR cycle 
Table 15: PCR cycle for the SybrGreen program 
 
 
 
4.1.15. Kits used for cytokine and antibody detection 
Table 16: Kits used for cytokine and antibody detection 
KO IL17 fw Atccaatcccccatcacctt 
KO IL17 rv Gttgggacttgccattctga 
WT IL17 fw Ctttcagggtcgagaagatgctg 
WT IL-17 rv Aagcagtttgggacccctttaca 
Primers Sequence 
pIgRfw Gtgcccgaaactggatcacc 
pIgRrv Tggagacccctgaaaagacagt 
Gapdhfw Aggtcggtgtgaacggatttg 
Gapdhrv Tgtagaccatgtagttgaggtca 
Steps Temperature [°C] Time [sec] Cycles Analysis 
Pre-incubation 95 60 1  
Amplification 95 3 
40 Quantification 
 60 30 
Melting curve 95 continuous 1 Melting curve 
Cooling 37 60 1  
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Kit Manufacturer 
Mouse Th1/Th2/Th17/Th22 13plex Kit FlowCytomix eBioscience, USA 
Mouse GM-CSF, IL-23, IL-1ȕ, TGF-ȕ1 
FlowCytomixsimplex Kit 
eBioscience, USA 
LEGENDplexTMMulti-Analyte Flow Assay Kit BioLegend, USA 
MILLIPLEX® MAP Kit Merck KGaA, Germany 
Live/Dead® Fixable dead cell stain Kit Life technologies, 
Germany 
Mouse IFNȖ, IL-2, IL-4 or IL-17 ELISPOT pair kit BD Bioscience, Germany 
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4.2. Methods 
4.2.1. IL-17a/f-/- genotyping by PCR 
To ensure the appropriate phenotype of the IL-17 a/f-/- mice, a polymerase chain 
reaction (PCR) based genotyping was performed. For this, tail derived DNA samples 
were analyzed by PCR. Briefly, the tails were lysed in lysis buffer containing 
proteinase K overnight at 56˚C under constant shaking at 800 rpm. Proteinase K is a 
serine protease that is used here to degrade native as well as denatured proteins. 
Proteinase K was deactivated by exposing the samples to 95˚C for 10 min after the lysis 
procedure. Then, the samples were cooled down and 3 µl of sample suspensions were 
used for a PCR reaction of a total volume of 20 µl. A single reaction contained 10 μl of 
DNA Mangomix, 5.5 µl H2O, and 1 µl of each primer (Table 13) at a final concentration 
of 10 µM. The protocol of the PCR cycle is displayed in Figure 10. 
 
Figure 10: PCR temperature cycles for IL-17a/f genotyping: Lysed tail samples were mixed with the 
appropriate primers. PCR was performed using the displayed temperature cycle protocol. 
The PCR products were analyzed by agarose gel electrophoresis. To this end 4% (w/v) 
agarose gels were prepared in TAE buffer containing Midori Green (25 µl/l), a nucleic 
acid dye, which upon exposure to ultraviolet (UV) light, emits green fluorescence when 
bound to DNA and therefore allows the visualization of DNA bands. PCR samples were 
loaded onto the gel and the Gene Ruler Ladder Mix was used as a DNA fragment size 
standard. The gel electrophoresis was performed for 1 h at 110 V. Following, the DNA 
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was visualized by exposing the gel to UV light at a wavelength of 530 nm using the 
GelDocXRS system. 
4.2.2. c-di-AMP induced Th17 differentiation 
4.2.2.1. Generation of BMDCs 
To generate BMDCs, bone marrow derived cells were isolated from femur and tibia of 6-
8 weeks old wild type (WT) and IL-17a/f-/- mice. For this, mice were euthanized using 
CO2 and hind legs were dissected. The bones were cleaned of muscle tissue, incubated 
for 1-2 min in 70% (v/v) ethanol, rinsed in fresh RPMI medium and then, the ends of the 
bones were removed. The bone marrow cells were flushed by pressing fresh RPMI 
medium through the medullary cavity of femur and tibia. The cell suspension was 
transferred into 50 ml falcon tubes and centrifuged for 10 min at 1200 rpm at room 
temperature. The supernatant was discarded and the pellet was re-suspended in ACK 
lysis buffer (Table 7) for 1 min to remove the erythrocytes. Next, 10 ml RPMI medium 
was added to stop the reaction, followed by another centrifugation step for 10 min at 
1200 rpm at room temperature. The supernatant was discarded and the cell pellet was 
re-suspended in 10 ml RPMI medium and pressed through a 100 µm filter mesh. The 
cell number was determined as described in section 4.2.7, adjusted to a final 
concentration of 1×106 cells/ml and distributed at a concentration of 5×106 cells in 5 ml 
per well in a 6 well plate. Cell differentiation towards DCs was directed by the presence 
of 5 ng/ml mouse GM-CSF in the growth RPMI medium. The cells were incubated at 
37˚C in a humidified atmosphere containing 5% CO2, with exchanging half of the 
volume per well with fresh medium every second day until day 7. At this time the cells 
were ready to be used for in vitro experiments. 
4.2.2.2. In vitro assessment of Th17 differentiation 
The effect of c-di-AMP induced Th17 differentiation was assessed in vitro by co-
culturing c-di-AMP primed BMDCs together with sorted CD4+ T cells. BMDCs were 
stimulated in GM-CSF free medium. Briefly, the culture medium was gently removed 
and replaced by fresh medium supplemented with 40 µg/ml OVA, 5 µg/ml c-di-AMP 
alone or in combination or with medium asa control. After the treatment BMDCs were 
incubated for 24 h at 37°C in a humidified atmosphere containing 5% CO2, secreted 
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cytokines present in the supernatant as well as surface expression of activation markers 
and intracellular cytokines were analyzed.  
Further, for the in vitro assessment of Th17 differentiation treated BMDCs were co-
cultured together with sorted CD4+ T cells. For this, CD4 T cells were sorted using 
FACS Aria II system (BD, Bioscience, USA) and activated for 2 days with plate bound 
αCD3 and αCD28. For sorting of naïve non-activated CD4+ T cells, single cell 
suspensions from spleen were stained with the following antibodies: anti-CD4, anti-
CD25, anti-CD62L and anti-CD44 and naïve CD4+ T cells were sorted as CD4+CD25-
CD44lowCD62Lhi lymphocytes. After 2 days of activation, 5×105 CD4+ T cells were co-
cultured with 5×104 c-di-AMP primed BMDCs in a ratio 1:10 and incubated for 2 days. 
Following, intranuclear FACS staining as mentioned in 4.2.10 was performed, and IL-17 
and RORȖt expression were evaluated (Figure 11). 
 
Figure 11: Scheme of in vitro experiments to evaluate the mechanism of c-di-AMP-induced Th17 
differentiation: Murine bone marrow cells derived from WT and IL-17a/f
-/-
 mice were cultured for 7 days 
in the presence of GM-CSF to enrich BMDCs. The enriched cells were then treated with OVA (40 µg/ml) 
alone or co-treated with c-di-AMP (5 µg/ml) for 24 h. Untreated cells were used as controls. 
Simultaneously CD4 T cells were sorted and activated for 2 days with plate bound αCD3 and αCD28. 
Subsequently, CD4 T cells were co-cultured with BMDCs and incubated for 2 days. Following, IL-17 
secretion and RORȖt expression were evaluated on CD4+ T cells by FACS. In addition, surface 
expression of the activation markers MHC class I and II, CD86, IL-17RA and IL-12/IL-23p40, and the 
secretion of IL-6, TNFα, IL-1ȕ, TGFȕ, IL-17 and IL-23 by BMDCs were assessed. 
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4.2.3. c-di-AMP induced plasma B cell differentiation 
4.2.3.1. In vitro activation of B cell upon treated with c-di-AMP 
The effect of c-di-AMP on the activation of B cells was assessed in vitro by treating 
sorted B cells with or without c-di-AMP. B cells were sorted using FACS Aria II system 
(BD, Bioscience, USA). For sorting B cells, single cell suspension from spleens was 
stained with anti-CD19 and anti-B220 and B cells were sorted as CD19+B220+ 
lymphocytes. Following, B cells were treated with 40 µg/ml OVA, 5 µg/ml c-di-AMP 
alone or in combination or with the medium as acontrol for 1 h. After 1 h, B cells were 
washed to remove the medium containing c-di-AMP and were further supplemented 
with fresh medium and incubated for 24 h at 37°C in a humidified atmosphere 
containing 5% CO2. Then, the surface expression of B cell activation markers was 
analyzed by using flow cytometry. 
4.2.3.2. In vitro assessment of plasma B cell differentiation 
The effect of c-di-AMP on plasma B cell differentiation was assessed in vitro by co-
culturing sorted TFH cells and GC B cells from WT and IL-17a/f
-/- mice supplemented 
with c-di-AMP. TFH cells and GC B cells were sorted using a FACS Aria II system (BD, 
Bioscience, USA). For sorting of GC B cells and TFH cells, single cell suspension from 
spleen and cervical lymph nodes (cLNs) were stained with the following antibodies: anti-
CD19, anti-PNA, anti-CD4 and anti-CXCR5. GC B cells were sorted as CD19+PNA+ 
lymphocytes and TFH cells were sorted as CD4
+CXCR5+ lymphocytes. The cells were 
plated into a 96 well V-bottom plates at a ratio of 1:1 (5×104 cells/well each) and 
incubated for 6 days at 37˚C. Anti-CD3 and anti-CD28 were added to each well to 
induce TFH cell activation. To address the role of IL-17 in plasma B cell differentiation 
exogenous IL-17A was added into one set of TFH:GC B cells sorted from IL-17a/f
-/- mice 
supplemented with c-di-AMP. Every second day the plate was centrifuged at 300 rpm 
for 1 min and 100 µl of supernatant was collected and stored at -20˚C for further 
analysis of secretory components. The cells were supplemented with 100 µl of fresh 
complete RPMI medium. After incubation, FACS staining for surface markers as 
mentioned in 4.2.10 was performed and the plasma B cell differentiation was evaluated 
based on CD138 expression. 
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Figure 12: Scheme of in vitro experiments to evaluate the mechanism of c-di-AMP induced plasma 
B cell differentiation: Sorted TFH cells and GC B cell from wild type (C57BL/6) and IL-17a/f
-/-
 mice were 
co-cultured for 6 days in the presence of c-di-AMP (5 µg/ml). Then, plasma B cell differentiation was 
evaluated by FACS. 
4.2.4. Mouse immunization experiments 
The influence of c-di-AMP-stimulated Th17-mediated immune responses on adaptive 
immunity was assessed in immunization experiments. WT and IL-17a/f-/- mice were 
vaccinated with 10 µg of OVA antigen or 0.5 µg of NIBRG-14 antigen alone or co-
administered with 5 µg c-di-AMP per dose/mouse. The control groups received PBS 
alone. The mixture of antigen and adjuvant were formulated in PBS 30 min before the 
i.n. administration of 10 µl per nostril. For this, animals were anesthetized with 
isofluorane and 20 µl of the vaccine formulation were administered per mouse. Five to 
six animals per group of 8-14 weeks old mice were immunized on day 0, 14 and 28 as 
shown in Figure 13. Animals were sacrificed 14 days after the 2nd boost and samples 
were collected, as mentioned in 4.2.5. 
 
Figure 13: A schematic overview of mouse immunization experiments. The picture of the mouse is 
adopted from [162]. 
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4.2.5. Sample collection 
To collect the different organs for further in vitro studies or ex vivo analysis, animals 
were anesthetized with isoflurane. To detect serum derived antibodies or cytokines, 
blood samples were collected from the retro-orbital complex, centrifuged for 5 min at 
8000 × g, and sera were stored at -20˚C for further analysis of IgG titers. The mice were 
euthanized by exposure to CO2 and spleen, cLNs, lung as well as nasal and lung lavage 
samples were collected. Briefly, the abdominal area of the mice was sprayed with 
ethanol and the spleens, cLNs and lung were removed, placed in complete RPMI 
medium and processed separately, as described in 4.2.6. The samples for analysis of 
IgA in the nasal cavity and lung were collected in a 1.5 ml tubes which were prefilled 
with 10 µl of 40 mM PMSF. Then, the samples were centrifuged at 8000 × g for 10 min 
and the supernatants were stored at -20˚C. 
4.2.6. Preparation of single cell suspension 
4.2.6.1. Spleen 
To perform ELISPOT and FACS staining single cell suspensions of spleens were 
obtained by mincing the organs through a 100 µm cell mesh using the flat end of a 2 ml 
syringe plunger. Cell suspensions were transferred to a 15 ml Falcon tube and 
centrifuged at 240 × g for 10 min at 4˚C. The supernatant was discarded and 
erythrocytes were lysed by re-suspending the pellets in ACK lysis buffer (Table 7, 
1 ml/spleen). After incubation for 1 min, the lysis was stopped by filling the tubes with 
complete RPMI medium. The cell suspensions were centrifuged at 240 × g for 10 min at 
4˚C, the supernatant was discarded and the pellets were re-suspended in complete 
RPMI (2 ml/spleen). Subsequently, the cells were filtered through a 100 µm mesh to 
remove fat and debris, washed twice with RPMI medium and the cell number was 
determined. The splenocytes were stored on ice until further use. 
4.2.6.2. Cervical Lymph Nodes 
To determine the functionality of immune cells in terms of cytokine secretion by FACS 
single cell suspensions of cLNs were obtained by mincing the organs through a 100 µm 
cell mesh using the flat end of a 2 ml syringe plunger. Cell suspensions were 
transferred to a 15 ml tube and centrifuged at 240 × g for 10 min at 4˚C. The 
supernatant was discarded and the pellets were re-suspended in complete RPMI 
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(2 ml/cLNs). Subsequently, the cells were filtered through a 100 µm mesh to remove fat 
and debris, washed twice with RPMI medium and the cell number was determined. The 
cells were stored on ice until further use. 
4.2.6.3. Lung 
To determine the functionality of immune cells in terms of cytokine secretion by FACS 
single cell suspension of lungs were obtained. For this, the thoracic diaphragm was 
deflated and the ribcage was cut from both sides in order to expose the lungs. Lungs 
were perfused through the heart with 2 ml PBS/mouse and meshed through a 100 µm 
mesh in digestion medium (Table 7, 5 ml/lung) by using the flat end of a 2 ml syringe 
plunger. The suspensions were transferred to a 15 ml tube and subsequently digested 
for 20 min at 37˚C in a water bath. The digestion was stopped by filling up the tube with 
complete RPMI medium (10 ml/lung). The cell suspension was centrifuged at 240 × g 
for 10 min at RT and supernatant was discarded. To separate the lymphocytes, a 
density gradient centrifugation was performed. For this, the pellet re-suspended in 4 ml 
30% Easycol Separating Solution (r = 1.124 g/ml, Biochrom AG, diluted in complete 
RPMI medium) was carefully pipetted onto 4 ml of 70% Easycol Separating Solution. 
The density gradient was centrifuged at 1020 × g for 20 min at RT without abrake. The 
lymphocytes were collected at the interface between the two density solutions and 
transferred to a new 15 ml tube. The cells were re-suspended in 10 ml RPMI and 
centrifuged at 240 × g for 10 min at 4˚C. This step was repeated to ensure complete 
removal of remaining Easycol Separating Solution. To lyse the erythrocytes, the cell 
pellet was re-suspended in ACK lysis buffer (Table 7, 500 µl/lung) and the reaction was 
stopped after 1 min by filling up the tubes with complete RPMI medium. The cells were 
centrifuged at 240 × g for 10 min at 4˚C, washed twice with RPMI medium and the cell 
number was determined. The cells were stored on ice until further use. 
4.2.7. Cell counting 
The cell cytometer was used to determine the number of cells in suspensions. The cells 
were diluted in Isotone II at a ratio 1:1000 and measured using the multi-size analyzer 
and Multi32 Coulter Z2®Acc Comp® software. Cells with a diameter between 5-16 µm 
were counted. A size below 5 µm was considered as debris and excluded. 
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4.2.8. Detection of cytokine production in spleen cells from 
immunized mice by ELISPOT 
ELISPOT was performed to assess the number of IFNȖ, IL-2, IL-4 and IL-17 by 
splenocytes following vaccination according to the ELISPOT kit manufacturer's 
instructions. Briefly, the 96 well HTS filter plates were coated overnight at 4˚C with 
100 μl of anti-mouse IFNȖ, IL-2, IL-4 or IL-17 capture antibodies diluted in PBS 
(Table 5). The following day, the plates were washed with complete RPMI medium two 
times and blocked for 2 h at RT. For cell activation, 100 μl of spleen cells were 
distributed on plates at a concentration of 5×105 cells/well and re-stimulated with OVA 
(5 μg/ml) or NIBRG-14 (0.2 μg/ml). Unstimulated cells served as background control. 
Then, the splenocytes were incubated for either 24 h (IFNȖ) or 48 h (IL-2, IL-4, IL-17) at 
37˚C in a humidified atmosphere containing 5% CO2. For the detection, cell 
suspensions were aspirated and the wells were washed with deionized water and with 
wash buffer (PBS containing 0.05% Tween-20) followed by 2 h incubation with the 
corresponding detection antibody diluted in PBS (Table 5). After washing with wash 
buffer and 1 h incubation with avidin-horseradish peroxidase (HRP) diluted in PBS 
(Table 5), the plates were finally washed with wash buffer and PBS. Spot development 
was monitored 5-60 min after the addition of the substrate solution (AEC + H2O2, 
Table 7). The reaction was stopped by washing the plates with deionized water. The 
plates were scanned using a CTL ELISPOT reader and the spots were quantified using 
the ImmunoSpot image analyzer software v3.2. Spot number values of the cells without 
re-stimulation were subtracted from the spot number values of the antigen-re-stimulated 
cells. Then, the average spot number value of triplicates was calculated for each group. 
4.2.9. Re-stimulation of cells for multifunctional T and B cell 
analysis 
To analyse the functionality of lymphocytes in terms of cytokine secretion, cells were re-
stimulated overnight with the antigen. For this, cells seeded at a concentration of 
1×107 cells/ml into 12 well plates were incubated in complete medium with or without 
OVA (40 μg/ml) or NIBRG-14 (1 μg/ml) for 16 h at 37˚C in a humidified atmosphere 
containing 5% CO2. For additional 6 h, brefeldin A and monensin were added into the 
cell suspension to block the cytokine transport from the endoplsmic reticulum to the 
golgi apparatus. Afterward, cells were collected into 2ml FACS tubes and washed with 
PBS by centrifuging them at 240 × g for 10 min at 4˚C. The pellets were then re-
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suspended in PBS and the phenotypic and functional analysis of the cells was 
performed using FACS analysis, as described in 4.2.10. 
4.2.10. Preparation of samples for flow cytometry analysis 
Surface staining  
Single cell suspensions were transferred to a V-bottom plate and centrifuged at 320 × g 
for 5 min at 4˚C. Then, cells were re-suspended in 100 μl PBS containing FcR-block 
(diluted 1:2000) and incubated for 20 min at 4˚C. Cells were washed with 100 µl 
PBS/well and the plate was centrifuged at 320 × g for 5 min at 4˚C. The supernatants 
were discarded and the wash step was repeated. Antibodies for the surface staining 
were diluted in a volume of 50 μl per sample and added to the cells. After 20 min of 
incubation at 4˚C, cells were washed twice with PBS and in case no intracellular 
staining was carried out, cells were re-suspended in 100 µl 2% PFA, transferred to 
FACS tubes containing 100 µl PBS and stored until acquisition. 
Intracellular staining  
To determine the cytokines secreted by immune cells intracellular staining was 
performed. Cells were re-suspended in 100 µl of cytofix/cytoperm buffer/well (BD 
Bioscience, USA) to fix the cells. Following 20 min incubation at 4˚C, cells were washed 
with 100 µl/well of 1x Perm wash buffer and centrifuged at 320 × g for 5 min at 4˚C. The 
supernatant was discarded and the washing step was repeated. The cells were re-
suspended in 50 µl/well of 1x Perm wash buffer that contained the appropriate diluted 
antibodies (Table 4). After 20 min incubation at 4˚C, cells were washed with 100 µl of 
1x Perm wash buffer and centrifuged at 320 × g for 5 min at 4˚C. The supernatant was 
discarded and the cells were washed once again. Then, cells were re-suspended in 
200 µl PBS, transferred to FACS tubes and stored at 4˚C until acquisition. 
Intranuclear staining  
To determine the transcription factor expression by immune cells, intranuclear staining 
was performed. Cells were re-suspended in 100 µl/well of 1x Fixation/Permeabilization 
buffer (eBioscience, USA) to fix the cells. Following 1 h incubation at 4˚C, cells were 
washed with 100 µl of 1x Permeabilization buffer and centrifuged at 320 × g for 5 min at 
4˚C. The supernatant was discarded and the cells were washed once again. Next, the 
cells were re-suspended in 50 µl/well of Permeabilization buffer that contained the 
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appropriate diluted antibodies (Table 4). After 20 min incubation at RT, cells were 
washed with 100 µl of 1x Permeabilization buffer and centrifuged at 320 × g for 5 min at 
4˚C. The supernatant was removed and the wash step was repeated. Afterward, cells 
were re-suspended in 200 µl PBS, transferred to FACS tubes and stored at 4˚C until the 
analysis. Immune cells, i.e. T cells, were gated as displayed in the gating strategy 
(Figure 14). 
Single stainings and compensation beads were prepared for each used fluorochrome 
for later compensation purposes to prevent false positive signals. The FACS 
measurement was performed by Fortessa (BD Bioscience, USA) and FlowJo was used 
for the analysis (Treestar Inc.). 
 
Figure 14: Gating strategy: Measurement distribution was excluded by gating SSC-W vs Time. Then, T 
cells were identified as the living single lymphocyte population that expresses CD3. Cells within this CD3 
gate were further characterized into CD4 and CD8 phenotype. Further, from the CD4 gate the 
functionality of the cells was characterized based on the cytokine secretion. 
4.2.11. Cell proliferation for cytokine assay 
Splenic cells obtained from immunized mice were re-stimulated with the respective 
antigen to induce cytokine secretion. For this, 100 μl of spleen cells were distributed on 
96-well plates at a concentration of 5×105 cells/well and further re-stimulated with OVA 
(40 µg/ml) or NIBRG-14 (2 µg/ml) at 37˚C in a humidified atmosphere containing 
5% CO2. Unstimulated cells served as the background control. After 72 h of incubation, 
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the plates were centrifuged at 300 rpm for 1 min and 100 µl of the supernatant was 
collected and stored at -20˚C for further analysis of secreted cytokines, described in 
4.2.12. 
4.2.12. Cytometric bead array (CBA) 
The 13-plex FlowcytomixKit (CBA, AffymetrialeBioscience) combined with the analytes 
from the simplex Kits were used to assess changes in cytokine levels induced by re-
stimulation of splenic cells derived from immunized animals. The lyophilized standards 
were centrifuged for a few seconds and reconstituted in sterile H2O, according to the 
volume stated on each standard vial, swirled thoroughly and kept at RT for 
20 min. Then, the standards were diluted 1:20 and filled up to 200 µl volume with assay 
buffer. A serial 1:3 dilution of the standard mix was performed. The vial containing the 
bead mix for each of the analytes was vortexed for 5 seconds and 1/20 of the final 
volume of each bead set was pipetted into a microcentrifuge tube. The tube was filled 
up to the final needed volume with 1x assay buffer. Then, the bead mix was vortexed 
and centrifuged for 5 min at 3000 × g. The supernatant was discarded and the pellet 
was re-suspended in the equal volume of 1x assay buffer that was removed. To prepare 
the biotin-conjugate solution 1/20 of the total needed volume (50 µl/test) of each biotin 
conjugate was pipetted to a new vial and filled up to the needed volume with 1x assay 
buffer. The prepared standard dilutions and the supernatant were plated into individual 
wells at a volume of 25 µl/well. In each well, including blanks that contained 1x assay 
buffer instead of the sample, 25 µl of the bead mix and 50 µl of the biotin conjugate 
were added. The plate was further incubated for 2 h at RT, protected from light. 
Next, the wells were washed with 100 µl 1x assay buffer and centrifuged for 5 min at 
200 × g. The supernatants were discarded and the wash step was 
repeated. Then, 50 µl of a diluted streptavidin-PE solution was added and incubated for 
1 h at RT, protected from light. The plate was washed twice as described above and the 
samples were transferred into FACS tubes in 300 µl 1x assay buffer. The setup beads 
were used to configure the flow cytometer. Samples were measured using the FACS 
Fortessa (BD Bioscience, USA) and analyzed with the FlowCytomixTM Pro 3.0 Software 
(Affymetrix/eBioscience). 
4.2.13. In vivo Cytotoxic T Lymphocyte (CTL) assay 
To assess the functionality of antigen-specific Th1 response, CTL assays were 
performed. For this, splenocytes from naïve mice were collected and single cell 
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suspensions were prepared in complete RPMI medium. The cells were then washed 3x 
with RPMI medium without FCS. Then, the cell concentration was adjusted to 
20×106 cells/ml and the cells were divided into two aliquots of equal cell count. One 
aliquot of cells was labelled with 0.1 µM CFSE and the other with 1 µM CFSE and 
incubated for 7 min in the dark at 37˚ C. The reaction was stopped by filling up the 
falcon tubes with FBS and incubated for 10 min at 37˚ C. Then, the cells were 
centrifuged for 10 min at 240 × g and each pellet was resuspended with 20 ml of 
complete RPMI medium. The aliquot of 1 µm CFSE-labelled cells was pulsed with 
15 µg/ml SINFEKL (OVA-peptide) for 1 h at 37°C whereas the second aliquot of cells 
was not pulsed. Next, cells were washed 2x with complete RPMI medium, the cell 
concentration was adjusted to 1×108 cells/ml in PBS and the two aliquots were pooled 
with the same amount of cells at 1:1 ratio. Subsequently, immunized mice were injected 
i.v. with 200 µl of CFSE-labeled donor cells and after 48 h of adoptive transfer spleen 
and lungs were collected and single cell suspensions were performed. The lysis 
capacity of CTLs in the spleens and lungs was assessed by FACS as a correlate of 
reduced CFSE+ cell frequencies, according to the formula mentioned below. % of lysis = ͳͲͲ − ቆሺ% of peptide pulsed cellsሻ/ሺ% of unpulsed cellsሻ immunizedሺ% of peptide pulsed cellsሻ/ሺ% of unpulsed cellsሻ control ቇ x ͳͲͲ 
4.2.14. ELISA measurement of antigen-specific IgG, IgG1 and 
IgG2c titers 
To assess antigen-specific serum IgG, lgG1 and lgG2c titers ELISA was performed. For 
this, high-affinity binding 96 well plates were coated with 100 µl/well of OVA or NIBRG-
14 at a concentration of 2 µg/ml diluted in coating buffer and incubated overnight at 4˚C. 
Then, plates were washed six times with wash buffer (PBS + 0.1% Tween-20) and 
blocked with 200 µl/well of blocking buffer (PBS + 3% BSA) and incubated for 1 h at 
37˚C. The serum samples were diluted 1:1000 for OVA and 1:10,000 for NIBRG-14 in 
blocking buffer and 200 µl/well were added to the first column. Serial 1:2 dilutions 
(column 1 to11) were performed using the ELISA robot (Precision 2000, BioTek). Wells 
only incubated with blocking buffer served as blank control. The plates were incubated 
for 2 h at 37˚C, and then washed six times with wash buffer. Following addition of 
100 μl/well of detection antibodies (Table 6) diluted in dilution buffer (PBS + 0.1% 
Tween-20 + 1%BSA), plates were incubated for 1 h at 37˚C followed by six times of 
wash procedure, described above. Then, 100 µl/well of streptavidin-HRP diluted at 
1:1000 in dilution buffer were added and the plates were incubated for 30 min at 
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37˚C. Subsequently, the plates were washed again six times and incubated in the dark 
for 15 min at RT with 100 µl/well of ABTS substrate solution. The absorbance of light at 
405 nm wavelength was measured using a synergy 2 Multi-Mode Microplate Reader. 
Titers were determined by subtracting the mean of the black samples as background. 
The results are expressed as endpoint titers, which are determined as the dilution that 
yielded the first OD405 value above the double value of the blank mean. 
4.2.15. ELISA measurement of total IgA and antigen-specific 
IgA 
To investigate humoral mucosal immune responses, antigen-specific IgA titers were 
measured by ELISA. High-affinity binding 96-well plates were coated overnight at 4˚C 
with 100 μl/well of either OVA or NIBRG-14 (2 μg/ml) or with anti-mouse lgA (2 μg/ml) 
dissolved in coating buffer. The lavage samples were diluted in blocking buffer 1:50 for 
the determination of total IgA and 1:10 for assessment of OVA-specific IgA. For 
determining NIBRG-14-specific IgA titers the starting dilution was 1:1000 for total IgA 
and 1:500 for NIBRG-14-specific IgA. The blocking buffer was used as blank control. 
The detection steps were performed as described in 4.2.13 for the measurement of IgG 
titers, but using a biotinylated goat- anti-mouse IgA antibody diluted 1:5000 in dilution 
buffer. Titers were determined by subtracting the mean of the blank samples as 
background. The concentrations shown in the result represent the end point of 
normalized concentration calculated as the amount of antigen-specific lgA concentration 
in 1 µg of total lgA concentration. 
4.2.16. Microbial 16S analyses 
To assess the microbial composition in the feces 16 S analyses were performed. Fecal 
pellets were collected and frozen immediately at -20°C until processing. DNA isolation 
was done using a phenol-chloroform based protocol. The methods used for 16S rRNA 
sequencing analyses are based on the Human Microbiome Project HMP. In brief, we 
employed Illumina Mi-seq 250 bp paired-end sequencing of the hypervariable V4 
region. The obtained reads were assembled; quality controlled and clustered using the 
QIIME v1.8.0 (Quantitative Insights into Microbial Ecology) analysis pipeline. In short, 
quality filtering was set up to -q 30, minimum read length 200 bp and a minimum 
number of sequences per sample = 1000. The operational taxonomic unit (OTU) 
clusters and representative sequences were determined using open-reference OTU 
picking using UCLUST at 97% identity, followed by taxonomy assignment using the 
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RDP Classifier with a bootstrap confidence cutoff of 80%. The OTU absolute 
abundance table and mapping file are used for statistical analyses and data 
visualization in the R statistical programming environment, package PHYLOSEQ. 
4.2.17. Immunofluorescence staining 
Immunofluorescence staining to determine GC formation by evaluating localization of 
GC B cells and TFH cells in draining LNs was performed at mousepathology platform at 
HZI, Braunschweig. For this, mice were immunized (day 0 and 6) with NIBRG-14 co-
administered with c-di-AMP via i.n. route and the animals were sacrificed at day 12 and 
samples (cLNs and spleen) were collected. Samples were fixed in 4% neutrally buffered 
formaldehyde for 24 h and embedded in paraffin. Consecutive sections of 3 µm 
thickness were cut with a Microm HM 340E Microtom. Paraffin-embedded sections were 
subsequently deparaffinized and rehydrated. Heat-induced epitope retrieval was used. 
Tissue sections were cooked in citrate buffer using a pressure cooker. All further steps 
were performed in coverplates. Tissue sections were blocked with blocking solution for 
5 min at RT. Working concentrations of primary antibodies were determined by 
performing titration of the stock solution and testing on a known positive specimen. The 
primary antibodies anti-CXCR5 and anti-PNA were incubated overnight at 4°C, with a 
working concentration of 1 to 50. For CXCR5 staining, tissue sections were incubated 
with primary antibody anti-CXCR5 and the secondary antibody Alexa Fluor 594-
conjugated AffiniPure Goat anti-rabbit IgG for 30 minutes at RT. Background staining 
was performed with DAPI. Slides were covered with Vectashield Mounting Medium 
Hard Set (H -1400). Immunofluorescence stainings were evaluated two times 
randomized and blinded to the experimental groups at a Zeiss fluorescence microscope 
4.2.18. Gene expression assessment by RT PCR 
4.2.18.1. RNA extraction by TRIZOL 
RNA from lung tissue was extracted to generate cDNA for the assessment of pIgR 
expression. For this, mice were immunized (day 0 and 14) with NIBRG-14 co-
administered with c-di-AMP via i.n. route and the animals were sacrificed at day 15, 20 
and 25 post immunization, and lung and lung lavage was collected. Lung tissues with a 
length of 2 cm long were collected and transferred into a microfuge tube containing 
1mm beads and 1 ml of TRIZOL. The tissue was homogenized by placing the tubes in 
the beadbeater for 1 min and then rested on ice for 1 min. The step was repeated 3-4 
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times until the tissue was homogenized. Into each tube, 200 µl of chloroform was 
added, vortexed vigorously for 15 sec and incubated at RT for 3 min. The samples were 
centrifuged at 12,000 × g for 15 min at 4°C and the upper aqueous phase was collected 
without disturbing the interface. Then, 500 µl of isopropyl was added and the samples 
were incubated at -20°C overnight. Next day samples were centrifuged at 12,000 × g for 
30 min at 4°C and the supernatant was discarded. The pellet was washed by re-
suspending it in 1 ml of 75% EtOH. Samples were vortexed and centrifuged at 7,500 × g 
for 5 min at 4°C and the supernatant was discarded. The pellet was air-dried and 
dissolved in 100 µl of ddH2O and stored at -80°C until further use. 
4.2.18.2. cDNA generation and gene expression assessment by qPCR 
To assess the mechanism for IgA response, pIgR expression was determined by 
synthesizing cDNA from RNA extracted from lung tissue. In a nuclease free tube 2 µg of 
RNA, 5 µl Oligo (dT) 18 primer and up to10 µl Diethyl pyrocarbonate (DEPC)-treated 
water were added and briefly centrifuged. The mixture was incubated at 65°C for 5 min, 
cooled on ice and briefly centrifuged. Then, 1x master mix was prepared containing 4 µl 
reaction buffer, 2 µl dNTP mix, 1 µl RevertAidTM H minus Reverse Transcriptase and 3 
µl DEPC-treated water. Next, 10 µl of master mix was added to the tubes containing the 
RNA mix. The tubes were briefly centrifuged and the samples were further incubated at 
42°C for 60 min and then the reaction was terminated by heating at 85°C for 5 min. At 
the end, 180 µl of water was added to 20 µl of cDNA.  
To perform qPCR 1x master mix consisting of 5 µl kappa master mix plus 0.5 µl primers 
(Table 14) was added into qPCR plates containing 4.5 µl cDNA. The plate was spun 
down and covered with the qPCR lid. The plate was loaded into the Real-Time cycler 
and SybrGreen detection program was run. The PCR cycle for SybrGreen protocol is 
mentioned in Table 15. Quantitative gene expression for pIgR was normalized to a 
house-keeping gene (GAPDH) expression. 
4.2.19. Propagation and titration of influenza virus 
4.2.19.1. Virus propagation in embryonated hen ’s eggs 
Stocks of H5N1 virus were prepared by propagating virus in specific pathogen-free 
(SPF) eggs.The SFB eggs were placed in a humidified incubator at 37°C with 70% 
humidity with regular rotation for 10 days. Virus dilutions (10-3 and 10-4) were prepared 
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in 1x PBS and placed on ice. The blunt end of all eggs was disinfected using iodine and 
with a sterile needle, a small hole was pierced in the shell over the air sac of each egg. 
Then, 200 μl of diluted virus solution was injected into the allantoic cavity and the eggs 
were sealed using glue. Further, the eggs were incubated for 48 h at 37°C and 50-70% 
humidity without rotation. Afterward, the eggs were placed overnight at 4°C to ensure 
that the embryo was dead. The virus was harvested by opening the blunt side of the 
eggs with a knife. Carefully the outer membrane was removed and the embryo was 
pressed with a spoon sideways and the allantoic fluid was collected with a pipette and 
placed into a 15 ml falcon tube on ice. The presence of the virus was determined by 
performing hemagglutination (HA) assay. 
4.2.20. Hemagglutination assay 
The HA assay was performed to determine the presence of the virus. From the 
undiluted virus obtained from each egg 100 μl were added to the first column of a 96 
well V-bottom plate. In the remaining columns 50 μl of PBS was added and a serial 1:2 
dilutions (column 1 to 11) was performed. Furthermore, 50 µl of 1% chicken red blood 
cells (RBCs) was added to each well and the plate was incubated at RT for 30 min. 
Wells containing RBCs in suspension were evaluated as positive yields, whereas in 
wells where the RBCs had settled down were evaluated as a negative yield. Falcons 
containing positive yield of the virus were pooled, aliquoted in 500 µl eppis and stored at 
-80°C for further use. 
4.2.21. Microneutralization (MN) assay 
MDCK cells were adjusted to 1.5×105 cells/ml in MEM medium. 200 µl of cells were 
added to each well in a 96 flat-bottom plate and were incubated for 4 h at 37°C, 
5% CO2. In another V-bottom plate, 50 µl of virus diluent was added to each well and 
additionally 40 µl of virus diluent was added into row A. 10 µl of RDE-treated serum 
samples were added into the row A and a serial 1:2 dilution (row B to H) was performed. 
Further 50 µl of virus containing 100 TCID50 diluted in virus diluent was added into each 
well. Cells only incubated with medium or virus served as cell controls (CC) or virus 
controls (VC) respectively. The virus-serum mixtures were gently agitated and 
incubated for 1 h at 37°C, 5% CO2. Virus-serum mixtures were then added to PBS-
washed MDCK cell monolayers and 100 µl of virus diluent was added and the plates 
were incubated for overnight. Next day the medium was removed and cells were 
washed with 200 µl of PBS. 100 µl of cold fixative was added to each well and 
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incubated at RT for 10 min. Fixative was removed and the plates were washed three 
times with wash buffer. The plates were incubated for 2 h at 37˚C, and then washed 
three times with wash buffer. Following addition of 100 µl/well of primary antibody (anti-
influenza A NP) diluted 1:1000 in blocking buffer (PBS + 0.1% Tween-20 + 1%BSA) 
plates were incubated for 1 h at RT followed by three times of wash procedure. Then, 
100 µl/well of secondary antibody (Anti-Goat-HRP) diluted at 1:1000 in blocking buffer 
were added and the plates were incubated for 1 h at RT. Subsequently, the plates were 
washed for five times with wash buffer and 100 µl/well of freshly prepared substrate (o-
phenylenediaminedihydrochloride) was added and incubated at RT for 10-15 min at RT 
and the reaction was stopped using stop solution (1 N H2SO4). The absorbance of light 
at 490 nm wavelength was measured using a synergy 2 Multi-Mode Microplate Reader. 
The virus neutralizing antibody end point titer was determined using the following 
equation.  X = ሺAverage OD of CC wellsሻ + ቆሺAverage OD of VC wellsሻ/ሺAverage OD of CC wellsሻ ʹ ቇ 
4.2.22. Challenge of immunized mice 
Mice immunized with inactivated H5N1 as described in 3.2.6 were challenged with 
2.5×104 foci forming units of the H5N1 virus diluted in 20 µl of PBS by i.n. route on day 
42 post immunization. For the next following 7 days the animals were monitored with 
respect to their weight development and health conditions. Mice that had lost 20% of 
their starting bodyweight or showed abnormal clinical features with respect to 
physiological conditions were sacrificed and considered as killed by the infection. 
4.2.23. Statistical analysis 
Data were analyzed using the GraphPad Prism 6 software (GraphPad Software, USA). 
Statistical differences were assessed using student’s t test for the comparison of 
independent groups. Two-way ANOVA statistical tests were performed for the 
comparison of multiple groups. Values of p  0.05 were considered as statistically 
significant and in the figures * indicates p  0.05, ** indicates p  0.01, *** indicates p  
0.001, **** indicates p  0.0001 and n.s. indicates not significant. 
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5. Results 
5.1. Distribution of immune cells in WT and IL-17a/f deficient 
mice 
The immune cell composition in WT and IL-17a/f-/- mice was analyzed in order to 
exclude possible discrepancies due to differences in the genetic background. This 
assessment represents a prerequisite for the subsequent immunization studies to 
evaluate the impact of c-di-AMP-induced IL-17 response in the generation of antigen-
specific immune responses. For this, cells from spleensand lungs of naïve WT and IL-
17a/f-/- mice were isolated and stained for the expression of surface markers that define 
specific immune cell populations: neutrophils (CD11c- CD11b+ Ly6G+), Ȗδ T cells 
(CD3+ȖδTCR+), Th cells (CD3+ CD4+), DCs (CD11c+), NKT cells (CD3+ NK1.1+) and 
CTLs (CD3+ CD8+). The evaluation of the frequencies of Ȗδ T cells, Th cells, DCs, NKT 
cells and CTL cells showed no significant differences between WT and IL-17a/f-/- mice 
(Figure 15).However, the frequency of neutrophils was significantly reduced in both 
spleen and lung of IL-17a/f-/- mice as compared to WT mice.  
 
Figure 15: Distribution of immune cell populations in WT and IL-17a/f
-/-
 mice: Splenocytes and lung 
lymphocytes were isolated from WT and IL-17a/f
-/-
 mice, stained for specific surface markers of 
neutrophils (CD11c
-
 CD11b
+
 Ly6G
+), Ȗδ T cells (CD3+ Ȗδ TCR+), Th cells (CD3+ CD4+), DCs (CD11c+), 
NKT cells (CD3
+
 NK1.1
+
) and CTLs (CD3
+
 CD8
+
), and further analyzed by flow cytometry. Frequencies of 
the cell populations were compared in naïve WT and IL-17a/f
-/-
 mice. Columns represent the mean ± SEM 
(n=3), one out of two independent representative experiments is shown. Asterisks denotes significant 
values comparing WT and IL-17a/f
-/- 
mice as calculated by unpaired t-test; *** p < 0.0001; * p < 0.05. 
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5.2. Comparison of two different adjuvants for their potential to 
induce IL-17 secreting cells 
To assess whether in vivo administration of the adjuvants c-di-AMP and αGalCerMPEG 
can stimulate innate IL-17 secreting cells, a kinetic experiment was performed. For this, 
WT derived lung lymphocytes and splenocytes isolated 12 h or 72 h after i.n. 
administration of 5 µg of either αGalCerMPEG or c-di-AMP were analyzed for innate IL-
17 secretion. The following innate immune cells known to secrete IL-17 after stimulation 
were investigated: Ȗδ T cells, NKT cells, NK cells and CD3-CD4+LTi cells. 
Administration of αGalCerMPEG resulted in significantly increased MFI of lung IL-
17+Ȗδ T cells and NKT cells at both investigated time points (Figure 16A and B left). 
Splenocytes displayed elevated MFI of IL-17+Ȗδ T cells and NKT cells 72 h, but not 12 h 
after αGalCerMPEG treatment (Figure 16A and B right). A αGalCerMPEG-induced 
secretion of IL-17 by NK cells and CD3-CD4+LTi cells was not detected (Figure 16C 
and D). In contrast, the adjuvant c-di-AMP did not induce any stimulation of innate IL-17 
secretion cells at the different analyzed time points. These data demonstrate that 
αGalCerMPEG but not c-di-AMP induces innate IL-17 secretion. 
Results 
  
61 
 
 
Figure 16: IL-17 secretion by γδ T cells and NKT cells upon adjuvant treatment: Naïve WT mice 
were i.n. administered with a single dose of αGalCerMPEG (5 µg) or c-di-AMP (5 µg). After 12 and 72h 
splenocytes and lung lymphocytes were isolated and subjected to flow cytometry analysis. MFI of IL-17 
secreted by A) Ȗδ T cells (CD3+ȖδTCR+), B) NKT cells (CD3+NK1.1+), C) NK cells (CD3-NK1.1+) and 
D) CD3
-
CD4
+
cells are shown. Columns represent the mean ± SEM of one experiment (n=3). Asterisks 
denote significant values as calculated by Two-way ANOVA as compared to untreated controls; *** p < 
0.001; ** p < 0.01; * p < 0.05; n.s. = not significant. 
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These findings show that although αGalCerMPEG blocks adaptive IL-17 responses as 
recently demonstrated in our group [163], it can induce the activation of certain innate 
IL-17 secreting immune cells. In contrast, c-di-AMP appears not to be able to stimulate 
innate IL-17 responses, whereas it has been shown by ELISPOT analysis to activate 
antigen-specific splenic IL-17 secretion [97]. To address which adaptive immune cells 
secrete IL-17 and whether also lung-derived immune cells can become activated by c-
di-AMP, immunization studies in WT and IL-17a/f-/- mice using OVA as model antigen 
were performed. The antigen-specific immune responses were analyzed by FACS. WT 
mice immunized i.n. with OVA co-administered with c-di-AMP revealed significantly 
enhanced frequencies of splenic and lung IL-17-secreting CD4+ T cells as compared to 
PBS and OVA alone (Figure 15A and B). This illustrates that c-di-AMP used as a 
mucosal adjuvant induces a strong Th17 response locally and systemically. As 
expected, immunization of IL-17a/f-/- mice with OVA co-administered with c-di-AMP did 
not induce any IL-17 secretion, thereby confirming the genetic background of the IL-17 
deficient mouse strain. 
 
Figure 17: c-di-AMP-induced IL-17 secretion by CD4
+
 T cells: WT and IL-17a/f
-/- 
mice were i.n. 
immunized with PBS, OVA alone (10 μg/dose) or OVA co-administered with c-di-AMP (5 μg/dose) on 
days 0, 14 and 28. Splenocytes and lung lymphocytes of immunized mice were re-stimulated with OVA 
(40 µg/ml) overnight. The cells were incubated with brefeldin A (5 μg/ml) and monensin (6 μg/ml) for 
additional 4 h and then they were analyzed for IL-17-producing CD4
+
 T cells (CD3
+
 CD4
+
) by flow 
cytometry. Frequencies of CD3
+
CD4
+
IL-17
+ 
cells in A) spleen and B) lung are shown. Results are 
expressed as subtracted background of unstimulated samples from stimulated samples. Columns 
represent the mean ± SEM of one experiment (n=5). Shown is one representative out of three 
independent experiments. Asterisks denote significant values as calculated by Two-way ANOVA 
comparing WT and IL-17a/f
-/-
 mice;**** p < 0.0001; ** p < 0.01. Plus denote significant values as 
calculated by Two-way ANOVA comparing WT mice immunized with PBS, OVA alone or with OVA co-
administered with c-di-AMP; ++++ p < 0.0001; ++ p < 0.01. 
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5.3. Mechanism of c-di-AMP-induced Th17 differentiation 
As described above, c-di-AMP preferentially induces strong Th17 responses rather than 
innate IL-17 secreting cells following i.n. administration. However, the mechanisms 
contributing to the observed c-di-AMP-induced Th17 differentiation are still elusive. To 
address this point, an in vitro co-culture system consisting of CD4+ T cells and BMDCs 
was established. Recent findings in our lab showed that c-di-AMP has the capacity to 
activate BMDCs as assessed by the up-regulation of co-stimulatory molecules and 
MHC class I and II expression [96, 115]. This model was used to investigate whether 
BMDCs derived from WT and IL-17a/f-/- mice differ in their capacity to differentiate 
CD4+ T cells into Th17 cells upon c-di-AMP stimulation.  
5.3.1. BMDCs derived from IL-17a/f-/-  mice display reduced 
maturation upon treatment with c-di-AMP 
To compare the maturation of BMDCs derived from WT and IL-17a/f-/- mice, BMDCs 
were treated with OVA or c-di-AMP alone or in combination and analyzed for their 
expression of CD86, MHC class I and MHC class II by FACS. Treatment with OVA 
alone did not result in BMDCs maturation as compared to untreated (medium) samples 
independently of the used mouse strain. However, stimulation with c-di-AMP alone or 
co-cultured with antigen induced a significant maturation of BMDCs in both WT and IL-
17a/f-/- mice, as demonstrated by the enhanced surface expression of CD86, MHC 
class I and MHC class II (Figure 18A, B and C). The c-di-AMP induced expression of 
the maturation markers CD86 and MHC class I was more intense in BMDCs derived 
from WT as compared to IL-17a/f-/- mice (Figure 18A and B). No significant differences 
were observed in MHC class II expression comparing WT and IL-17a/f-/- mice upon 
treatment with OVA + c-di-AMP (Figure 18C). Interestingly, c-di-AMP-stimulated 
BMDCs displayed also an enhanced expression of IL-17RA in WT mice (Figure 18D). 
These findings show that BMDCs derived from IL-17a/f-/- mice display a reduced 
maturation after c-di-AMP treatment as compared to cells from WT mice. 
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Figure 18: Expression of maturation markers and IL-17RA by BMDCs upon in vitro stimulation: 
GM-CSF-enriched BMDCs derived from WT and IL-17a/f
-/-
 mice were left untreated or treated with OVA 
(40 µg/ml) or c-di-AMP (5 µg/ml) alone or in combination for 24 h. BMDCs (CD11c
+
) were then stained for 
maturation markers A) CD86, B) MHC I C) MHC II and D) IL-17RA and analyzed by flow cytometry. 
Columns represent the mean ± SEM of one experiment (n=3). Shown is one representative out of three 
independent experiments. Asterisks denote significant values as calculated by Two-way ANOVA when 
comparing WT and IL-17a/f
-/-
 BMDCs; **** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05. Plus denote 
significant values as calculated by Two-way ANOVA when comparing BMDCs derived from WT mice 
treated with OVA alone and in combination with c-di-AMP; ++++ p < 0.0001; ++ p < 0.01. 
5.3.2. BMDCs derived from IL-17a/f-/-  mice are defective in 
driving Th17 differentiation upon c-di-AMP stimulation 
The observed impaired maturation of BMDCs derived from IL-17a/f-/- mice suggested 
that deficient IL-17 production by DCs might affect Th17 differentiation. To address this 
issue the potential of c-di-AMP-stimulated BMDCs derived from WT or IL-17a/f-/- mice to 
mediate the differentiation of WT CD4+ T cells into Th17 cells was evaluated.To this 
end, CD4+ T cells derived from WT mice were activated by plate bound antibodies 
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(αCD3 and αCD28). BMDCs derived from either WT or IL-17a/f-/- mice were stimulated 
for 48 h with either OVA or c-di-AMP alone or OVA+c-di-AMP in combination, and then 
co-cultured with WT CD4+ T cells under different culture conditions (i.e. in presence of 
fresh medium or the supernatant fluids from the re-stimulated BMDCs). WT CD4+ T 
cells co-cultured with medium or supernatant derived from BMDCs supplemented with 
OVA alone, c-di-AMP alone or in-combination did not result in c-di-AMP induced Th17 
generation. However, WT CD4+ T cells co-cultured with WT BMDCs-derived 
supernatant supplemented with OVA and c-di-AMP induced the differentiation of WT 
CD4+ T cells into Th17 cells as assessed by IL-17 secretion and RORȖt expression. In 
contrast, WT CD4+ T cells co-cultured with BMDCs-derived supernatant from IL-17a/f-/- 
mice exhibited impaired effects on promoting Th17 differentiation (Figure 19A and B). 
These data suggest that an intacted IL-17 axis is required in BMDCs for achieving 
optimal maturation and subsequent stimulation of Th17 differentiation. 
 
Figure 19: Th17 differentiation upon in vitro c-di-AMP stimulation: GM-CSF-enriched BMDCs 
derived from WT and IL-17a/f
-/-
 mice were stimulated with either OVA alone (40 μg/ml), or c-di-AMP alone 
(5 μg/ml) or OVA in combination with c-di-AMP, and co-cultured with WT CD4+ T cells for 48 h. The cells 
were incubated with brefeldin A (5 μg/ml) and monensin (6 μg/ml) for additional 4 h, then stained for 
markers for Th17 differentiation (RORȖt and IL-17) and further analyzed by flow cytometry. Columns 
represent the mean ± SEM of one experiment (n=3). Shown is one representative out of two independent 
experiments.Asterisks denote significant values as calculated by Two-way ANOVA when comparing WT 
and IL-17a/f
-/- 
CD4
+
 T cells; * p < 0.05. 
5.3.3. Identification of secreted mediators contributing to c-di-
AMP-induced Th17 differentiation 
BMDCs derived from IL-17a/f-/- mice showed impaired capacity to induce Th17 
differentiation of CD4+ T cells. This suggests differences in the secreted cytokine 
profiles of WT and IL-17a/f-/- derived BMDCs stimulated with c-di-AMP. It has previously 
been reported that IL-1ȕ, TGF-ȕ, IL-6 and IL-23 secreted by DCs are involved in the 
development and maintenance of Th17 cells [164]. Thus, studies were performed to 
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address whether a changed cytokine secretion profile of BMDCs derived from IL-17a/f-/-
mice is responsible for the impaired Th17 differentiation. To this end, the concentration 
of cytokines known to be required for Th17 differentiation was evaluated in the 
supernatant fluids of WT or IL-17a/f-/- derived BMDCs treated with OVA or c-di-AMP 
alone or in combination. The secretion of IL-23 was not detectable under any condition. 
The level of IL-1ȕ and TGFȕ production by WT and IL-17a/f-/- mice was not impacted by 
treatment with OVA alone, c-di-AMP alone or c-di-AMP co-administered with OVA as 
compared to untreated controls (Figure 20). However, IL-1ȕ levels were in general 
higher in IL-17a/f-/- mice as compared to WT mice, regardless of the treatment. On the 
other hand, BMDCs derived from WT or IL-17a/f-/- mice stimulated with OVA +c-di-AMP 
or c-di-AMP alone exhibited enhanced IL-6 secretion as compared to untreated controls 
and OVA alone (Figure 20). No significant difference in the concentration of IL-6 was 
observed when comparing BMDCs derived from WT and IL-17a/f-/- mice (Figure 20). 
 
Figure 20: Cytokine secretion upon in vitro stimulation of BMDCs: GM-CSF-enriched BMDCs 
derived from WT and IL-17a/f
-/-
 mice were stimulated in vitro with OVA alone (40 μg/ml), c-di-AMP alone 
(5 μg/ml) or OVA + c-di-AMP for 24 h. Subsequently, the supernatant was collected and analyzed for the 
concentration of IL-1ȕ, TGFȕ and IL-6 by cytometric bead array. Columns represent the mean ± SEM of 
one independent experiment (n=3). Plus denote significant values as calculated by Two-way ANOVA 
when comparing BMDCs derived from WT mice treated with OVA alone and with OVA in combination 
with c-di-AMP; ++++ p < 0.0001. 
Since IL-23 was not detected in the supernatant of treated BMDCs, the frequency of 
cells expressing IL-12/IL-23p40 was evaluated by FACS. IL-12/IL-23p40 antibody reacts 
with the p40 subunit of IL-12 (p35p40) and IL-23 (p19p40) and is widely used to 
determine the frequency of cells expressing IL-12/IL-23 intracellularly by FACS. To this 
end, BMDCs treated for 24 h with OVA or c-di-AMP alone or in combination were 
incubated with brefeldin A and monensin for additional 4 h and subsequently analyzed. 
The frequency of IL-12/IL-23p40+ CD11c+ BMDCs derived from WT and IL-17a/f-/- mice 
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following stimulation with OVA and c-di-AMP was 20 and 10-fold higher as compared to 
the control and OVA-stimulated samples, respectively (Figure 21A and B). However, 
CD11c+ BMDCs derived from IL-17a/f-/- mice displayed reduced frequencies of IL-12/IL-
23p40 expression on cells as compared to BMDCs derived from WT mice (Figure 21B). 
The MFI of IL-12/IL-23p40+ cells confirms that BMDCs derived from WT mice upon 
treatment with OVA and c-di-AMP have a higher capacity to induce IL-12/IL-23p40 
expression as compared to BMDCs derived from IL-17a/f-/- mice (Figure 21C). These 
findings suggest that the observed defective Th17 differentiation of WT CD4+ T cells co-
incubated with IL-17a/f-/- derived BMDCs is in part due to an impaired IL-23 expression, 
thereby suggesting IL-23 as a crucial factor for c-di-AMP induced Th17 differentiation.  
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Figure 21: IL-12/IL-23p40 expression on BMDCs upon in vitro stimulation: GM-CSF-enriched 
BMDCs derived from WT and IL-17a/f
-/- 
mice were left untreated (medium) or stimulated with either OVA 
alone (40 μg/ml) or OVA co-administered with c-di-AMP (5 µg/ml) for 24 h. Then, cells were incubated 
with brefeldin A (5 μg/ml) and monensin (6 μg/ml) for additional 4 h, further stained for the DC marker 
CD11c and intracellular IL-12/IL-23p40, and subsequently analyzed by flow cytometry. Frequencies of 
CD11c
+
IL-12/IL-23p40
+
 cells derived from A) WT and B) IL-17/f
-/-
 mice are shown. Results are depicted as 
percentage of IL-12/IL-23p40 producing cells within the CD11c
+
 cell subpopulation. C) MFI of IL-12/IL-
23p40 expressed by BMDCs derived from WT and IL-17a/f
-/-
 mice analyzed 24 h post treatment. Columns 
represent the mean ± SEM of one experiment (n=3). One representative out of two independent 
experiments is shown. Asterisks denote significant values as calculated by Two-way ANOVA when 
comparing WT and IL-17a/f
-/- 
BMDCs; ** p < 0.01. 
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5.3.4. IL-6 is required for c-di-AMP-induced Th17 
differentiation 
The differentiation of naïve T cells into Th17 cells and the subsequent stabilization of 
this commitment were shown to be dependent on IL-6 and IL-23 respectively [165-167]. 
In addition, the stimulation of naïve T cells with IL-23 was described to result in the 
generation and expansion of pathogenic Th17 cells [168]. The strong increase in IL-6 
levels and IL-23 expression on BMDCs 24 h after c-di-AMP stimulation hints towards a 
potential role for both cytokines with respect to the observed Th17 differentiation 
(Figure 19, Figure 20 and Figure 21). Therefore, to confirm the role of IL-6 and IL-23 for 
c-di-AMP-induced Th17 differentiation, the in vitro were repeated in the presence of αIL-
6 and αIL-23 blocking antibodies and Th17 differentiation was analyzed by flow 
cytometry. As observed earlier, co-culture of WT CD4+ T cells and BMDCs in the 
presence of c-di-AMP alone or in combination with OVA induced significant Th17 
differentiation as compared to cultures supplemented with OVA alone. BMDCs derived 
from IL-17a/f-/- mice exhibited an impaired effect on Th17 differentiation under all tested 
conditions (Figure 20). The supplementation of αIL-6 blocking antibodies resulted in a 
significant reduction of Th17 (CD4+IL-17+) cells, whereas the addition of αIL-23 blocking 
antibodies had no impact on c-di-AMP-induced Th17 differentiation (Figure 22). These 
obtained results indicate that c-di-AMP-stimulated enhanced IL-6 secretion in WT and 
IL-17a/f-/- mice is required for the c-di-AMP-induced Th17 differentiation, as confirmed 
by an impaired c-di-AMP-induced Th17 differentiation upon blocking of IL-6 signaling. 
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Figure 22: Impact of IL-6 and IL-23 blocking on c-di-AMP-induced Th17 differentiation: GM-CSF-
enriched BMDCs derived from WT and IL-17a/f
-/-
 mice were stimulated with OVA alone (40 μg/ml), c-di-
AMP alone (5 μg/ml) or OVA + c-di-AMP and co-cultured with WT CD4+ T cells in the presence of αIL-6 
or αIL-23 alone or in combination for 48 h. The cells were incubated with brefeldin A (5 μg/ml) and 
monensin (6 μg/ml) for additional 4 h and subsequently stained for the secretion of IL-17 by CD3+CD4+ 
cells as a correlate of Th17 differentiation and analyzed by flow cytometry. Results are expressed as fold 
change respect to untreated controls. Columns represent the mean ± SEM of one experiment (n=3). 
Shown is one representative out of two independent experiments. Asterisks denote significant values as 
calculated by Two-way ANOVA comparing WT and IL-17a/f
-/- 
CD4
+
 T cells; **** p < 0.0001; *** p < 0.001; 
** p < 0.01. Plus denote significant values between different treatment groups of OVA co-administered 
with c-di-AMP as calculated by Two-way ANOVA; +++ p < 0.001; n.s. = not significant.
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5.4. Impact of c-di-AMP-induced IL-17 secretion on the 
elicitation of antigen-specific adaptive immune response 
The role of IL-17 in augmenting antigen-specific T helper cells, cytotoxic CD8+ T cells 
and humoral responses still remains elusive. Therefore, immunization experiments were 
performed to evaluate the immune stimulatory potency of c-di-AMP-induced IL-17 
secretion in the elicitation of antigen-specific immune responses. To this end, WT and 
IL-17a/f-/- mice were immunized by i.n. route with PBS, OVA alone (10 µg) or OVA co-
administered with c-di-AMP (5 µg) on day 0, 14 and 28 (Figure 23). On day 42 serum, 
nasal and lung lavage samples were collected from the animals and analyzed for 
determining humoral (IgG and IgA production) immune responses. Single cell 
suspensions were also prepared from cLN, lung and spleen that were used to analyze 
cellular immune parameters (analysis of T and B cell functionality and cytokine 
production). 
 
Figure 23: Experimental design for the evaluation of antigen-specific immune responses: WT and 
IL-17a/f
-/- 
mice were i.n. immunized with PBS, OVA alone (10 μg/dose) or OVA co-administered with c-di-
AMP (5 μg/dose) on day 0 and received booster doses at day 14 and 28. The sampling was performed on 
day 42 after the initial immunization. Nasal and lung lavages were collected to evaluate the mucosal 
humoral response (IgA production). Serum samples were collected in order to analyze the systemic 
humoral response (IgG production). Spleen and lung cells were re-stimulated with the antigen and 
antigen-specific activation was evaluated by FACS and ELISPOT. The cytokine profile in the supernatant 
of ex vivo re-stimulated splenocytes was evaluated by CBA. 
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5.4.1. c-di-AMP-induced IL-17 secretion enhances OVA-
specific Th2 and humoral responses 
To explore the potency of c-di-AMP-induced IL-17 secretion to enhance antigen-specific 
Th2 responses, the secretion of IL-4 by splenocytes was assessed by ELISPOT 
following re-stimulation with OVA. The number of IL-4-producing cells was significantly 
enhanced in samples derived from WT animals immunized with OVA co-administered 
with c-di-AMP as compared to samples derived from WT and IL-17a/f-/- animals 
immunized with PBS or OVA alone (Figure 24A). Furthermore, a significant reduction in 
the number of IL-4-producing cells was observed in IL-17a/f-/- mice immunized with OVA 
co-administered with c-di-AMP as compared to WT mice. To elucidate which specific 
cell population is responsible for the detected IL-4 secretion, splenic and lung single cell 
suspensions derived from individual animals were re-stimulated with OVA (40 μg/ml) 
and subjected to FACS analysis. In accordance with the data derived from the ELISPOT 
analysis, the absolute number of splenic IL-4 secreting CD4+ T cells was significantly 
reduced in IL-17a/f-/- animals immunized with OVA co-administered with c-di-AMP as 
compared to the WT counterparts (Figure 24B). IL-4 secreting cells were not detected in 
the lungs of WT or IL-17a/f-/- mice (data not shown). These data demonstrate that c-di-
AMP-induced IL-17 secretion drives the stimulation of Th2 responses. 
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Figure 24: Impact of c-di-AMP-induced IL-17 secretion on antigen-specific Th2 responses: WT and 
IL-17a/f
-/- 
mice were i.n. immunized with PBS, OVA alone (10 μg/dose) or OVA co-administered with c-di-
AMP (5 μg/dose). Splenocytes were re-stimulated with OVA (40 µg/ml) overnight. The cells were 
incubated with brefeldin A (5 μg/ml) and monensin (6 μg/ml) for additional 4 h and were analyzed by 
ELISPOT and flow cytometry. A) IL-4-secreting cells identified by ELISPOT assay and B) absolute 
number of IL-4 secreting CD4
+
 T cells identified by flow cytometry. Results are expressed as subtracted 
background of unstimulated samples from stimulated samples. Columns represent the mean ± SEM of 
one experiment (n=5). Shown is one representative out of three independent experiments. Asterisks 
denote significant values as calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/- 
mice;** p 
< 0.01; * p < 0.05. Plus denote significant value as calculated by Two-way ANOVA when comparing WT 
mice immunized with OVA alone or OVA co-administered with c-di-AMP; ++ p < 0.01. 
To understand the impact of c-di-AMP-induced IL-17 secretion on the OVA-specific Th1 
response, splenocytes werere-stimulated with OVA (40 μg/ml) and the number of IFNȖ 
producing splenic cells was evaluated by ELISPOT. In both WT and IL-17a/f-/- mice, the 
number of IFNȖ-secreting splenic cells was significantly enhanced in the groups 
immunized with OVA co-administered with c-di-AMP as compared to OVA and PBS 
alone. Interestingly, IL-17a/f-/- mice immunized with OVA co-administered with c-di-AMP 
displayed a higher number of CD4+IFNȖ-secreting cells as compared to WT mice 
(Figure 25A). These findings were confirmed by FACS analysis of OVA re-stimulated 
(40 μg/ml) splenic and lung single cell suspensions that showed elevated frequencies of 
CD4+IFNȖ-secreting cells in both organs derived from IL-17a/f-/- mice immunized with 
OVA co-administered with c-di-AMP as compared to WT mice (Figure 25B and C). 
These data indicate that immunization with c-di-AMP induces Th1 responses that are 
stronger in the absence of IL-17 signaling. 
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Figure 25: Impact of c-di-AMP-induced IL-17 on antigen-specific Th1 responses: WT and IL-17a/f
-/-
 
mice were i.n. immunized with PBS or OVA alone (10 μg/dose) or OVA co-administered with c-di-AMP 
(5 μg/dose). Splenic and lung lymphocytes were re-stimulated with OVA (40 µg/ml) overnight. The cells 
were incubated with brefeldin A (5 μg/ml) and monensin (6 μg/ml) for additional 4 h and then analyzed for 
A) IFNȖ secreting cells by ELISPOT (splenocytes), and frequencies of B) splenic and C) lung-derived 
CD4
+
 T cells by FACS. Results are expressed as subtracted background of unstimulated samples from 
stimulated samples. Columns represent the mean ± SEM of one experiment (n=5). Shown is one 
representative out of two independent experiments. Asterisks denote significant values as calculated by 
Two-way ANOVA when comparing WT and IL-17a/f
-/-
 mice; **** p < 0.0001; ** p < 0.01. Plus denote 
significant valuesas calculated by Two-way ANOVA when comparing WT mice immunized with OVA 
alone and with OVA co-administered with c-di-AMP; ++++ p < 0.0001; ++ p < 0.01. 
In addition to the Th responses, CTLs represent an important effector mechanism within 
the cellular immune system. Therefore, to address the impact of c-di-AMP-induced IL-
17 secretion on CTLs, the frequency of lung-derived CD8+ IFNȖ-secreting was 
determined by FACS. Consistent with the findings presented for the Th1 response, an 
enhanced IFNȖ secretion by CD8+ cells was detected in samples derived from WT and 
IL-17a/f-/- mice immunized with OVA co-administered with c-di-AMP as compared to the 
PBS and OVA immunized groups. Interestingly, an enhanced number of lung-derived 
IFNȖ-secreting CD8+ cells was observed in IL-17a/f-/- mice immunized with OVA co-
administered with c-di-AMP as compared to corresponding WT group (Figure 26A). 
Furthermore, the functionality of OVA-specific CTLs was evaluated by performing an 
in vivo CTL assay. For this, immunized mice were injected i.v. with CFSE-labeled donor 
cells pulsed with OVA antigen and the lysis capacity of CTLs in the lungs was assessed 
by FACS. The cytotoxic capacity was significantly enhanced in WT and IL-17a/f-/- 
animals immunized with OVA co-administered with c-di-AMP as compared to the PBS 
or OVA alone groups. IL-17a/f-/- mice displayed an enhanced lysis capacity as 
compared to WT mice (Figure 26B). These data demonstrate that c-di-AMP-induced 
CTL responses are further increased in the absence of IL-17 signaling. 
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Figure 26: Impact of c-di-AMP-induced IL-17 secretion on the activation of cytotoxic T 
lymphocytes: WT and IL-17a/f
-/-
 mice were i.n. immunized with PBS or OVA alone (10 μg/dose) or OVA 
co-administered with c-di-AMP (5 μg/dose). Lung lymphocytes were re-stimulated with OVA (40 µg/ml) 
overnight. The cells were incubated with brefeldin A (5 μg/ml) and monensin (6 μg/ml) for additional 4 h 
and then analyzed for A) the frequency of IFNȖ producing CD8+ T cells by FACS, and B) cytolytic activity 
of lung cells from WT and IL-17a/f
-/-
 mice upon immunization. Results are expressed as subtracted 
background of unstimulated samples from stimulated samples. Columns represent the mean ± SEM of 
one independent experiment (n=5). Asterisks denote significant values as calculated by Two-way ANOVA 
when comparing WT and IL-17a/f
-/-
 mice; ** p < 0.01 * p < 0.05. Plus denote significant values as 
calculated by Two-way ANOVA when comparing WT mice immunized with OVA alone and with OVA co-
administered with c-di-AMP; ++++ p < 0.0001. 
Besides the cellular immune response, the humoral immune response plays an 
important role in providing protection against pathogens. Therefore, to understand the 
role of c-di-AMP-induced IL-17 for the generation of systemic humoral immunity, IgG 
titers in sera derived from immunized mice were analyzed by ELISA. Immunization of 
WT and IL-17a/f-/- mice with OVA co-administered with c-di-AMP stimulated enhanced 
IgG titers as compared to PBS and OVA alone (Figure 27A). Furthermore, a 
significantly lower level of IgG was detected in IL-17a/f-/- mice as compared to 
corresponding WT group (Figure 27A). The analysis of the IgG subclasses IgG1 and 
IgG2c in sera derived from mice immunized with OVA co-administered with c-di-AMP 
revealed significantly lower levels of IgG1 in IL-17a/f-/- mice as compared to WT mice. In 
contrast, no significant differences were observed regarding IgG2c titers (Figure 27B). 
These findings suggest that c-di-AMP-induced IL-17 secretion supports systemic 
humoral responses induced by Th2 cells as shown by high IgG1 titers. These results 
are in agreement with the observed T helper responses (see above). 
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Figure 27: Impact of c-di-AMP-induced IL-17 secretion on antigen-specific IgG production: WT and 
IL-17a/f
-/-
 mice were i.n. immunized with PBS, OVA alone (10 μg/dose) or OVA co-administered with c-di-
AMP (5 μg/dose). Sera of individual animals were analyzed for the level of antigen-specific IgG and IgG 
isotype titers by ELISA. OVA-specific titres of A) IgG and B) IgG, IgG1 and IgG2c were determined. 
Boxes represent the interquartile range, horizontal lines show the mean value and whiskers show the 
overall range of the data. Columns represent the mean ± SEM of one experiment (n=5). Shown is one 
representative out of three independent experiments. Asterisks denote significant values as calculated by 
Two-way ANOVA when comparing WT and IL-17a/f
-/-
 mice; ** p < 0.01; n.s. = not significant. Plus denote 
significant value as calculated by Two-way ANOVA when comparing WT mice immunized with OVA alone 
and with OVA co-administered with c-di-AMP; ++++ p < 0.0001. 
To further understand the impact of c-di-AMP-induced IL-17 secretion on mucosal 
immunity, IgA concentrations were analyzed in nasal washes as well as lung lavage 
samples by ELISA. In both, WT and IL-17a/f-/- mice, the IgA concentrations were 
significantly enhanced in mice immunized with OVA co-administered with c-di-AMP as 
compared to PBS and OVA alone (Figure 28). Significantly lower levels of OVA-specific 
IgA were detected in nasal and lung lavage samples derived from IL-17a/f-/- mice as 
compared to WT mice (Figure 28A and B). This indicates that c-di-AMP-induced IL-17 
secretion positively impacts the local mucosal humoral response. 
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Figure 28: Contribution of c-di-AMP-induced IL-17 secretion to the production of antigen-specific 
IgA response: WT and IL-17a/f
-/-
mice were i.n. immunized with PBS, OVA alone (10 μg/dose) or OVA 
co-administered with c-di-AMP (5 μg/dose). Nasal and lung lavage samples of individual animals were 
analyzed for the level of antigen-specific IgA in 1 µg of total IgA by ELISA. IgA concentrations detected in 
A) nasal and B) lung lavage samples. Boxes represent the interquartile range, horizontal lines show the 
mean value and whiskers show the overall range of the data. Columns represent the mean ± SEM of one 
experiment (n=5). Shown is one representative out of three independent experiments. Asterisks denote 
significant values as calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/-
 mice; **** p < 
0.0001; ** p < 0.01. Plus denote significant value as calculated by Two-way ANOVA when comparing WT 
mice immunized with OVA alone and with OVA co-administered with c-di-AMP; ++++ p < 0.0001. 
5.4.1.1. The contribution of c-di-AMP-induced IL-5 secretion to the 
induction of humoral immune responses 
Activated immune cells secrete a variety of cytokines, thereby shaping and activating 
other immune cells. Thus, the c-di-AMP-induced cytokine environment was investigated 
to gain insights into the factors contributing to the induced humoral immune response. 
To this end, splenic cells obtained from immunized mice were stimulated ex vivo with 
OVA protein for 72 h and secreted cytokines (IFNȖ, IL-2, IL-4, IL-5, IL-6, IL-13, IL-17 
and IL-22) into supernatant fluids were analyzed by performing a CBA. Splenic cells 
obtained from WT and IL-17a/f-/- mice immunized with OVA co-administered with c-di-
AMP showed enhanced levels of IFNȖ, IL-2, IL-4, IL-5, IL-6, IL-13, IL-17 and IL-22 as 
compared to samples derived from mice immunized with PBS or OVA alone. The 
comparison of cell obtained from WT and IL-17a/f-/- mice immunized with OVA co-
administered with c-di-AMP confirmed enhanced levels of IFNȖ-secretion in IL-17a/f-/- as 
compared to WT mice. Besides lower levels of secreted IL-17- and IL-22, significantly 
reduced levels of IL-5 were observed in IL-17a/f-/- mice immunized as compared to WT 
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mice (Figure 29). Th2 cell-derived IL-5 is known to play a crucial role in initiating 
humoral immune responses [169]. This indicates IL-5 as one of the potential factors 
contributing to c-di-AMP-induced and IL-17-depentent humoral immune response. 
 
Figure 29: Immunization-induced serum cytokines: Splenic cells derived from WT and IL-17a/f
-/- 
mice 
immunized with PBS, OVA alone or OVA-co-administered with c-di-AMP were re-stimulated ex vivo with 
OVA protein (20 μg/ml) for 72 h, the supernatant was collected and subsequently analyzed to determine 
the cytokine profiles by CBA. Concentrations of A) Th1 (IFNȖ, IL-2), B) Th2 (IL-4, IL-5, IL-6, IL-13) and 
C) Th17 (IL-17, IL-22) cytokines were determined. Columns represent the mean ± SEM of one 
experiment (n=3).Shown is one representative out of two independent experiments. Asterisks denote 
significant values as calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/- 
supernantant; 
**** p < 0.0001; *** p < 0.001; ** p < 0.01. 
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5.4.1.2. TFH cells contributes to the c-di-AMP-induced antibody 
response by supporting plasma B cell differentiation 
In addition to cytokines such as IL-5, TFH cells play a crucial role in inducing humoral 
immune responses, since they are critical for GC reactions [170]. The generation of 
antigen-specific antibody responses requires interactions between B cells and CD4+ T 
helper cells. In this context, TFH cells are fundamentally required for the generation of T 
cell dependent B cell responses by providing cognate help to B cells [171]. Thus, TFH 
cells might play a key role in the c-di-AMP-induced enhanced antibody response by 
supporting the differentiation of B cells into antibody secreting cells. TFH cells are 
characterized by the expression of CD4, the chemokine receptor 5 (CXCR5) and the 
inducible costimulatory molecule receptor (ICOS). GC B cells, characterized by the 
expression of CD19 and PNA are mainly found in GCs and are known to interact with 
TFH cells to differentiate into plasma B cells (CD19
- CD138+). Thus, to explore the role of 
TFH cells for the enhanced humoral response observed upon administration of c-di-AMP, 
the frequency of TFH cells, GC B cells and plasma B cells in cLNs of immunized animals 
were determined. Elevated frequencies of TFH cells were observed in cLNs derived from 
IL-17a/f-/- mice as compared to WT mice immunized with PBS, OVA alone or co-
administered with c-di-AMP (Figure 30A). However, while the frequency of TFH cells in 
IL-17a/f-/- mice was not impacted by the immunization. Immunization of WT mice with 
OVA resulted in significantly increased frequencies of TFH cells as compared to control 
WT mice immunized with PBS. The co-administration of c-di-AMP led to an additional 
significant increase of this cell type in WT mice (Figure 30A). Significantly increased 
frequencies of GC B cells and plasma B cells were also observed in WT and IL-17a/f-/-
mice immunized with OVA co-administered with c-di-AMP as compared to mice 
immunized with PBS or OVA alone (Figure 30B and C). Furthermore, significantly 
reduced frequencies of GC B cells and plasma B cells were observed in IL-17a/f-/- mice 
immunized with OVA co-administered with c-di-AMP as compared to what observed in 
WT mice. These data demonstrate that c-di-AMP-induced IL-17 secretion contributes to 
the generation of GC B cells and plasma B cells and thus seems to contribute to the 
stimulation of antigen-specific humoral immune responses. 
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Figure 30: Frequencies of TFH cells, GC B cells and plasma B cells upon immunization of WT and 
IL-17a/f
-/- 
mice: WT and IL-17a/f
-/- 
mice were i.n. immunized with PBS, OVA alone (10 μg/dose) or OVA 
co-administered with c-di-AMP (5 μg/dose). Cells from cLNs were isolated, stained ex vivo with antibodies 
specific for markers of TFH cells (CD4
+
 CXCR5
+
), GC B cells (CD19
+
 PNA
+
) and plasma B cells (CD19
-
 
CD138
+
) and analyzed by flow cytometry. Frequency of A) TFH cells, B) GC B cells and C) plasma B cells 
were determined. Columns represent the mean ± SEM of one experiment (n=5, pooled samples with 
three replicates). Shown is one representative out of three independent experiments. Asterisks denote 
significant values as calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/-
 mice; **** p < 
0.0001; *** p < 0.001. Plus denote significant value as calculated by Two-way ANOVA when comparing 
WT mice immunized with PBS, OVA alone and with OVA co-administered with c-di-AMP; ++++ p < 
0.0001; ++ p < 0.01; + p < 0.05. 
In previous studies c-di-AMP was shown to activate APCs, such as DCs and 
macrophages [97, 151]. In addition to the secretion of antibodies, B cells might also 
function as APCs, thereby mediating TFH cell direct activation and supporting plasma B 
cell generation. However, the role of c-di-AMP in the direct activation of B cells has not 
been assessed yet. Therefore, to address the role of c-di-AMP in the activation of B 
cells, sorted B cells (CD19+B220+) derived from WT mice were incubated for 24 h in 
presence of OVA alone, c-di-AMP alone or OVA + c-di-AMP. MALP, a known B cell 
stimulus was used as a positive control [172]. Stimulated B cells were stained for the 
expression of the activation marker CD69 and the maturation markers CD86 and MHC 
class II. A significant up-regulation of CD69, CD86 and MHC class II surface expression 
was observed upon treatment with c-di-AMP alone or co-administered with OVA when 
compared to B cells treated with PBS or OVA alone (Figure 31A-C). In this context, 
treatment with c-di-AMP alone or in combination with OVA resulted in an expression 
level of CD86 and MHC class II comparable to the expression induced by MALP. This 
suggests that c-di-AMP directly activates B cells and hence can mediate TFH cell 
activation, thereby supporting plasma B cell generation. 
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Figure 31: B cell activation upon in vitro stimulation: Sorted B cells (CD19
+
B220
+
) derived from WT 
mice were left untreated or stimulated with OVA alone (40 μg/ml), c-di-AMP alone (5 μg/ml) or OVA + c-
di-AMP for 24 h. Cells were subsequently stained for activation (CD69) and maturation markers (CD86 
and MHC II) and further analyzed by flow cytometry. Frequencies of A) CD69, B) CD86 and C) MHC II 
expressing B cells were determined. Columns represent the mean ± SEM of one experiment (n=3). 
Shown is one representative out of two independent experiments. Asterisks denote significant values as 
calculated by Two-way ANOVA when comparing different treatment conditions;**** p < 0.0001. 
Furthermore, in vitro co-culture studies were performed to address whether TFH cells 
can directly induce plasma B cell differentiation upon c-di-AMP stimulation. To this end, 
TFH cells (CD4
+CXCR5+) and GC B cells (CD19+PNA+) sorted from cLNs and spleen 
obtained from WT and IL-17a/f-/- mice were co-cultured for 6 days either in the presence 
of OVA alone, c-di-AMP alone, or OVA + c-di-AMP; control cells were left untreated. In 
addition, the role of IL-17 in c-di-AMP-induced plasma B cell differentiation was 
addressed by supplementing IL-17a/f-/- cultures with recombinant IL-17A (rIL-17A). 
Plasma B cell differentiation can be detected by the downregulation of CD19 and the 
upregulation of CD138 by B cells under stimulating conditions. Immunization of WT 
mice with OVA co-administered with c-di-AMP resulted in increased IgG1 titers, thus 
IgG1 plasma B cells was also analyzed. Cell cultures containing only GC B cells with 
different treatment conditions showed no IgG1+ plasma B cell differentiation (Figure 
32A). Interestingly, a significant increase in the frequency of IgG1+ plasma B cells 
(CD19-CD138+) was observed in WT co-cultures of TFH cells and GC B cells 
supplemented with OVA in combination with c-di-AMP as compared to untreated control 
cells, and cells treated with OVA or c-di-AMP alone. Furthermore, no plasma B cell 
differentiation was observed in IL-17a/f-/- culture conditions when compared to its WT 
counterpart (Figure 32B). However, the supplementation of rIL-17A to the IL-17a/f-/-
conditions restored the differentiation of plasma B cells, thereby demonstrating the 
direct role of IL-17 for the observed c-di-AMP-induced plasma B cell differentiation. 
These data illustrate that c-di-AMP directly activates B cells and hence might mediate 
TFH cell activation, thereby indirectly supporting plasma B cell generation. The increased 
frequency of TFH cell observed in IL-17a/f
-/- mice does not seem to play a role in plasma 
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B cell differentiation. These data highlight the importance of the IL-17-dependent c-di-
AMP-mediated induction of IL-5 secretion as well as TFH cells for the observed 
stimulation of an OVA-specific humoral immune response.  
 
Figure 32: Restoration of plasma B cells differentiation by supplementation of IL-17a/f
-/-
 cultures 
with rIL-17A: GC B cells (CD19
+
PNA
+
)and TFH cells (CD4
+
CXCR5
+
) were sorted from cLNs and spleens 
obtained from WT and IL-17a/f
-/- 
mice and were left untreated or treated with OVA alone (40 μg/ml), c-di-
AMP alone (5 µg/ml) or OVA + c-di-AMP for 6 days. rIL-17A was added to IL-17a/f
-/-
 culture conditions as 
indicated. After 6 days, the cells were incubated with brefeldin A (5 μg/ml) and monensin (6 μg/ml) for 
additional 4 h, stained with antibodies specific markers of plasma B cell differentiation (CD138 and IgG1) 
and further analyzed by FACS. MFI of IgG1 plasma B cells in co-cultures with A) GC B cells alone and 
B) GC B cells together with TFH cells. Columns represent the mean ± SEM of one experiment (n=3). 
Shown is one representative out of two independent experiments. Asterisks denote significant values as 
calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/- 
GC B cells;**** p < 0.0001; * p < 0.05. 
Plus denote significant value as calculated by Two-way ANOVA when comparing WT mice immunized 
with OVA alone and OVA co-administered with c-di-AMP; ++++ p < 0.0001. 
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5.4.2. Influence of the microflora on c-di-AMP-induced IL-17-
mediated antigen-specific immune responses 
Recent studies have illustrated novel complex mechanisms by which the microbiota 
impacts immune cell development and differentiation, which ultimately might influence 
the outcome of vaccine efficacy [173]. Prior immunization experiments were performed 
under non-co-housed conditions. However, the microflora has been shown to positively 
influence Th17 development in the small intestine. Thus, in order to assess the 
contribution of microbiota on immunization-induced immune responses, WT mice 
(bought by Harlan) and IL-17a/f-/- mice (bred at the HZI animal facility) were co-housed 
for 4 weeks prior to immunization to obtain analogous flora in both mouse strains. 
To analyze the impact of the microflora on c-di-AMP-induced antigen-specific humoral 
immune responses, IgG titers in sera and IgA concentrations in the nasal and lung 
lavage samples of immunized mice were analyzed, comparing co-housed and non-co-
housed conditions. Immunization of WT and IL-17a/f-/- mice with OVA co-administered 
with c-di-AMP stimulated significantly enhanced IgG titers and IgA concentrations in co-
housed and non-co-housed conditions as compared to mice immunized receiving PBS 
or OVA alone. The comparison of non-co-housed WT and IL-17a/f-/- mice showed 
significantly enhanced IgG titers and IgA concentrations in WT mice (Figure 33A, B 
and C). Interestingly, upon co-housing increased IgG and IgG2c titers were detected in 
IL-17a/f-/- mice as compared to the co-housed WT group and non-cohoused IL-17a/f-/- 
groups (Figure 33A and B). No significant differences in IgG titers and its isotypes were 
observed in WT mice upon co-housing as compared to non-co-housed WT mice. No 
significant differences in IgG1 titers were detected in IL-17a/f-/- mice upon co-housing 
compared to non-co-housed IL-17a/f-/- mice (Figure 33B). Concerning IgA production, a 
trend towards reduced concentrations was observed in co-housed WT mice as 
compared to non-co-housed WT mice. No differences were observed in the IgA 
concentration in IL-17a/f-/- mice upon co-housing as compared to non-co-housed IL-
17a/f-/- mice (Figure 33C). Interestingly, upon co-housing reduced IgA concentrations 
were detected in IL-17a/f-/- mice as compared to the corresponding co-housed WT 
group (Figure 33C). These results indicate that the microbiome significantly influences 
the quality of c-di-AMP-induced systemic humoral responses, promoting a shift with 
increase in IgG2c (IgG2c/1 ratios 0.33 and 0.90 in WT and 0.21 and 2.87 in IL-17a/f-/- 
mice, non-co-housed and co-housed respectively). No significant influence of the 
microbiome was observed with respect to c-di-AMP-induced mucosal IgA responses. 
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Figure 33: Impact of microbiota on c-di-AMP-induced antigen-specific humoral responses: WT and 
IL-17a/f
-/-
 mice were co-housed for 4 weeks prior to immunization with PBS, OVA alone (10 μg/dose) or 
OVA co-administered with c-di-AMP (5 μg/dose) and compared to non-cohoused immunized mice. Serum 
samples of single animals were analyzed for the presence of antigen-specific IgG and its isotypes, and 
nasal and lung lavage samples were analyzed for the concentration of IgA by ELISA. Serum titers of 
antigen-specific A) IgG and B) IgG, IgG1 and IgG2c were determined. C) IgA concentrations in nasal and 
lung lavage samples were determined. Boxes represent the interquartile range, horizontal lines show the 
mean value and whiskers show the overall range of the data. Columns represent the mean ± SEM of one 
experiment (n=6). Shown is one representative out of two independent experiments. Asterisks denote 
significant values as calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/-
 mice; **** p < 
0.0001; ** p < 0.01; * p < 0.05; n.s. = not significant. 
To further analyze the impact of the microflora on c-di-AMP-induced antigen-specific 
cellular immune responses, splenocytes from individual animals were re-stimulated with 
OVA and the frequencies of IFNȖ-, IL-4- and IL-17-secreting CD4+ T cells were 
assessed comparing WT and IL-17a/f-/- mice held under co-housed and non-co-housed 
conditions. Immunization of WT and IL-17a/f-/- mice with OVA co-administered with c-di-
AMP stimulated significantly enhanced frequencies of IFNȖ- and IL-4-secreting CD4+ T 
cells under co-housed and non-co-housed conditions as compared to PBS and OVA 
alone (Figure 34A, B and C). Furthermore, a trend of increased frequencies of IFNȖ-
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secreting CD4+ T cells was observed in IL-17a/f-/- mice immunized with OVA co-
administered with c-di-AMP as compared to correspondingly treated WT mice (Figure 
34A). No significant differences in the frequency of IFNȖ-secreting CD4+ T cells were 
observed when comparing co-housed and non-cohoused conditions. On the other hand, 
a significantly reduced frequency of IL-4-secreting CD4+ T cells was observed in 
samples derived from IL-17a/f-/- mice immunized with OVA co-administered with c-di-
AMP as compared to its corresponding WT group (Figure 34B). The comparison of WT 
mice under co-housed and non-co-housed conditions showed significantly reduced IL-4 
secretion by CD4+ T cells under co-housed conditions. Similarly, a reduced frequency of 
IL-17-secreting CD4+ T cells was observed in co-housed WT mice as compared to non-
co-housed ones (Figure 34C). These data demonstrate that the microbiota significantly 
influence c-di-AMP-induced Th2 and Th17 cellular immune responses.  
 
Figure 34: Impact of microbiota on c-di-AMP-induced antigen-specific Th2 responses: WT and IL-
17a/f
-/-
 mice were i.n. immunized with PBS, OVA alone (10 μg/dose) or OVA co-administered with c-di-
AMP (5 μg/dose). Splenocytes were re-stimulated with OVA (40 μg/ml) overnight. The cells were 
incubated with brefeldin A (5 μg/ml) and monensin (6 μg/ml) for additional 4 h and were analyzed by flow 
cytometry. Frequencies of CD4
+
 T cells secreting A) IFNȖ, B) IL-4 and C) IL-17 were analyzed. Results 
are expressed as subtracted background of unstimulated samples from stimulated samples. Columns 
represent the mean ± SEM of one experiment (n=5). Asterisks denote significant values as calculated by 
Two-way ANOVA comparing WT and IL-17a/f
-/-
 mice; **** p < 0.0001; ** p < 0.01. Plus denote significant 
values as calculated by Two-way ANOVA when comparing WT mice immunized with OVA alone and with 
OVA co-administered with c-di-AMP; ++++ p < 0.0001; ++ p < 0.01; + p.< 0.05. 
In order to analyze the impact of the microflora on c-di-AMP-induced antigen-specific 
cellular mucosal immune responses, lung cells were re-stimulated with OVA and the 
frequencies of IFNȖ- and IL-17-secreting CD4+ T cells were assessed comparing WT 
and IL-17a/f-/- mice held under co-housed and non-co-housed conditions. Immunization 
of co-housed and non-co-housed WT and IL-17a/f-/- mice with OVA co-administered 
with c-di-AMP stimulated significantly enhanced frequencies of IFNȖ-secreting CD4+ T 
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cells as compared to animals receiving PBS or OVA alone (Figure 35A). IL-17a/f-/- mice 
immunized with OVA co-administered with c-di-AMP displayed a significantly increased 
frequency of IFNȖ-secreting CD4+ T cells as compared to the correspondingly treated 
WT mice within the co-housed as well as non-co-housed groups (Figure 35A). 
Furthermore, a significant reduction in the frequency of IFNȖ-secreting CD4+ T cells was 
observed comparing co-housed WT mice immunized with OVA co-administered with c-
di-AMP to WT non-cohoused mice. A significant increase in the frequency of IFNȖ-
secreting CD4+ T cells was also observed comparing co-housed IL-17a/f-/- mice to non-
co-housed IL-17a/f-/- mice immunized with OVA and c-di-AMP. With regard to IL-17-
secreting CD4+ T cells, increased frequencies were detected in WT mice immunized 
with OVA-co-administered with c-di-AMP as compared to WT mice immunized with 
OVA or PBS. The comparison of WT mice held under co-housed and non-co-housed 
conditions showed significantly reduced frequencies of IL-17-secretion CD4+ T cells 
under co-housed conditions (Figure 35B). As expected, no IL-17 secretion was 
observed in IL-17a/f-/- mice. These results indicate that the microflora also impacts Th1 
as well as Th17 responses at mucosal level.  
 
Figure 35: Impact of microbiota on c-di-AMP-induced antigen-specific Th1 and Th17 responses: 
WT and IL-17a/f
-/-
 mice were i.n. immunized with PBS, OVA alone (10 μg/dose) or OVA co-administered 
with c-di-AMP (5 μg/dose). Lung cells were re-stimulated with OVA (40 μg/ml) overnight. The cells were 
incubated with brefeldin A (5 μg/ml) and monensin (6 μg/ml) for additional 4 h and were analyzed by flow 
cytometry. Frequencies of CD4
+
 T cells secreting A) IFNȖ and B) IL-17 were determined. Results are 
expressed as subtracted background of unstimulated samples from stimulated samples. Columns 
represent the mean ± SEM of one experiment (n=5). Asterisks denote significant values as calculated by 
Two-way ANOVA when comparing WT and IL-17a/f
-/-
 mice; **** p < 0.0001; *** p < 0.001;* p < 0.05. Plus 
denote significant values as calculated by Two-way ANOVA when comparing WT mice immunized with 
OVA alone and with OVA co-administered with c-di-AMP; ++++ p < 0.0001; + p.< 0.05. 
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To further elucidate the impact of the microflora on IgG responses upon co-housing and 
immunization, the microbiota composition from the different mice strains were 
compared. For this, a 16s rRNA analysis of feces samples was performed. The overall 
microbial community was compared by applying R statistical programming and 
analyzed using PHYLOSEQ. Feces samples derived from non-co-housed untreated WT 
and IL-17a/f-/- mice showed a huge variability in the composition of the microbiota. 
Additionally, the microbial composition obtained from the same genotype clustered 
uniformly as observed in the non-metric multidimensional scaling (NMDS) plots 
(Figure36A). Furthermore, a lower relative abundance of segmented filamentous 
bacterium (Clostridiacaea SFB) microbial community was observed in IL-17a/f-/- mice 
when compared to untreated WT mice (Figure 36B). 
 
Figure 36: Microbial composition in WT and IL-17a/f
-/-
 mice: Composition of the microbiota in feces 
samples derived from WT and IL-17a/f
-/-
 mice were assessed using genomic bacterial 16s rRNA 
sequence. The plots represent A) NMDS and B) relative abundance of SFB bacterial community 
comparing WT and IL-17a/f
-/-
 mice. 
This finding is in accordance with recent reports stating that mice obtained from different 
commercial vendors have marked differences in the number of Th17 cells which 
correlates with the presence of members of the Cytopaga-Flavobacter-Bacteroides 
phylum namely SFB [174, 175]. Thus, to address whether the low abundance of SFB 
found in IL-17a/f-/- mice impacts the c-di-AMP-induced Th17-mediated antigen-specific 
humoral response, IL-17a/f-/- mice were colonized with feces obtained from mice mono-
colonized with SFB. WT controls were left untreated. 4 weeks after fecal transplant WT 
and IL-17a/f-/- mice were i.n. immunized with OVA alone or co-administered with c-di-
AMP, according to the prime boost protocol described above (5.4). Subsequently, 
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serum IgG titers and concentrations of IgA in nasal and lung lavage samples were 
analyzed by ELISA. As observed earlier, immunization of WT and IL-17a/f-/- mice with 
OVA co-administered with c-di-AMP stimulated significantly enhanced IgG titers and IgA 
concentrations as compared to PBS and OVA alone (Figure 37A, B and C). 
Interestingly, IL-17a/f-/- mice showed lower IgG and IgG1 titers as compared to WT mice 
immunized with OVA and c-di-AMP independently of the fecal transplant (Figure 37A 
and B). Similarly IL-17a/f-/- mice displayed significantly reduced IgA concentrations in 
nasal and lung lavage samples as compared to WT mice immunized with OVA and c-di-
AMP independently of the fecal transplant (Figure 37C). However, in the lung lavage 
samples IgA concentrations were slighlty increased in SFB colonized IL-17a/f-/- mice 
when compared to non-colonized IL-17a/f-/- mice.This finding suggests that SFB alone is 
not sufficient to influence c-di-AMP-induced Th17-mediated antigen-specific humoral 
response.  
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Figure 37: Impact of SFB on the outcome of c-di-AMP-induced antigen-specific humoral response: 
Oral fecal transplant using feces from SFB mice into IL-17a/f
-/-
 mice was performed 4 weeks prior to 
immunization with PBS, OVA alone (10 μg/dose) or OVA co-administered with c-di-AMP (5 μg/dose). 
Transplanted IL-17a/f
-/-
 mice were compared to non-cohoused WT and IL-17a/f
-/-
 mice. Sera and nasal 
and lung lavage samples of single animals were analyzed for IgG titers and IgA concentrations by ELISA. 
OVA-specific serum titers of A) IgG and B) IgG, IgG1 and IgG2c were determined. C) Concentration of 
OVA-specific IgA in nasal and lung lavage samples. Boxes represent the interquartile range, horizontal 
lines show the mean value and whiskers show the overall range of the data. Columns represent the 
mean ± SEM of one independent experiment (n=5). Asterisks denote significant values as calculated by 
Two-way ANOVA when comparing WT and IL-17a/f
-/-
 + SFB mice; **** p < 0.0001; *** p < 0.001; ** p < 
0.01; * p < 0.05. 
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5.4.3. Influenza vaccine elicits Th17 dependent local antigen-
specific IgA response 
To investigate the impact of c-di-AMP-induced IL-17 secretion on the generation of 
antigen-specific humoral responses in a disease-relevant influence vaccine model, mice 
were i.n. immunized with PBS, inactivated NIBRG-14 (a H5N1 vaccine antigen) alone or 
co-administered with c-di-AMP. Additionally, mice were co-housed prior to immunization 
to exclude the observed impact of the microflora on the antigen-specific immune 
response. In an influenza vaccine model, IgG and neutralizing antibody responses are 
known to mediate protective immunity [176]. The analysis of sera derived from WT and 
IL-17a/f-/- mice immunized with NIBRG-14 co-administered with c-di-AMP revealed 
enhanced NIBRG-14-specific IgG titers as compared to mice immunized with PBS or 
NIBRG-14 alone (Figure 38A). No significant differences in IgG titers including IgG1 and 
IgG2c titers were detected in IL-17a/f-/- mice as compared to WT mice immunized with 
NIBRG-14 co-administered with c-di-AMP (Figure 38A and B). Additionally, neutralizing 
antibody titers in the sera of immunized mice were determined by performing 
hemagglutination inhibition (HAI) and microneutralization (MN) assays, determining the 
amount and the functionality of the antibodies. Sera derived from WT and IL-17a/f-/- 
mice immunized with NIBRG-14 co-administered with c-di-AMP showed enhanced HAI 
titers and H5-specific neutralizing antibody titers as compared to PBS and NIBRG-14 
alone (Figure 38C and D). Significantly increased HAI titers and H5-specific neutralizing 
antibody titers were observed in IL-17a/f-/- mice immunized with NIBRG-14 co-
administered with c-di-AMP as compared to correspondingly treated WT mice (Figure 
38C and D). These data indicate that IL-17 secretion hampers the generation of 
neutralizing antibodies but not the overall IgG responses in this particular experimental 
model. 
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Figure 38: NIBRG-14-specific neutralizing antibody responses: WT and IL-17a/f
-/-
 mice were i.n. 
immunized with PBS or NIBRG-14 alone (0.5 μg/dose) or NIBRG-14 co-administered with c-di-AMP 
(5 μg/dose). Sera samples of single animals were analyzed for the presence of antigen-specific IgG titers 
by ELISA and for neutralizing antibody titers by HAI and MN assay. NIBRG-14-specific serum titers of 
A) IgG, B) IgG, IgG1 and IgG2c, and neutralizing antibody titers assessed by C) HAI and D) MN assay 
are shown. Boxes represent the interquartile range, horizontal lines show the mean value and whiskers 
show the overall range of the data. Columns represent the mean ± SEM of one experiment (n=6). Shown 
is one representative out of two independent experiments. Asterisks denote significant values as 
calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/-
 mice; *** p < 0.001; ** p < 0.01. 
Mucosal surfaces are persistently exposed to potentially harmful pathogens such as 
influenza. Therefore, they are protected by a first-line of defense that is mediated by 
sIgA amongst other factors [177-179]. Thus to investigate the impact of c-di-AMP-
induced IL-17 secretion on mucosal immunity in the influenza vaccine model, the 
concentration of IgA, as well as the sIgA titers, were analyzed in nasal washes and lung 
lavage samples. In both, WT and IL-17a/f-/- mice, immunization with NIBRG-14 co-
administered with c-di-AMP induced the secretion of NIBRG-14-specific IgA and 
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enhanced sIgA titers as compared to PBS and NIBRG-14 alone (Figure 39A and B). 
Interestingly, IL-17a/f-/- mice immunized with NIBRG-14 and c-di-AMP harbored a 
significantly reduced concentration of NIBRG-14-specific IgA and sIgA titers in nasal 
washes and lung lavage samples as compared to correspondingly immunized WT mice. 
This indicates that c-di-AMP-induced IL-17 secretion supports mucosal IgA responses. 
 
Figure 39: Mucosal IgA concentrations and sIgA titers upon immunization: WT and IL-17a/f
-/-
 mice 
were i.n. immunized with PBS or NIBRG-14 alone (0.5 μg/dose) or NIBRG-14 co-administered with c-di-
AMP (5 μg/dose). Nasal and lung lavage samples of single animals were analyzed for the level of 
antigen-specific IgA concentration in 1 µg of total IgA by ELISA. NIBRG-14-specific A) IgA concentrations 
and B) sIgA titers are shown. Boxes represent the interquartile range, horizontal lines show the mean 
value and whiskers show the overall range of the data. Columns represent the mean ± SEM of one 
experiment (n=6). Shown is one representative out of three independent experiments. Asterisks denote 
significant values as calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/-
 mice; **** p < 
0.0001; ** p < 0.01 
To further investigate the impact of c-di-AMP-induced IL-17 secretion on the generation 
of antigen-specific cellular responses in this disease-relevant influenza vaccine model, 
WT and IL-17a/f-/- mice were immunized i.n. with PBS, in-activated H5N1 NIBRG-14 
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alone or co-administered with c-di-AMP. Subsequently, the secretion of IL-17, IFNȖ and 
IL-4 by splenocytes was assessed by ELISPOT following re-stimulation with NIBRG-14. 
The number of IL-17-producing cells was significantly enhanced in samples derived 
from WT animals immunized with NIBRG-14 co-administered with c-di-AMP as 
compared to samples derived from WT animals immunized with PBS or NIBRG-14 
alone (Figure 40A). To confirm these results, splenic and lung lymphocytes were 
stimulated ex vivo with NIBRG-14 and analyzed by intracellular cytokine staining for 
CD4+ T cells secreting IL-17. WT mice immunized with NIBRG-14 co-administered with 
c-di-AMP revealed significantly enhanced frequencies of splenic and lung IL-17-
secreting CD4+ T cells as compared to mice immunized with PBS or NIBRG-14 alone 
(Figure 40B and C). As expected, immunization of IL-17a/f-/- mice with NIBRG-14 co-
administered with c-di-AMP did not induce any IL-17 secretion. 
 
Figure 40: c-di-AMP-induced IL-17 secretion by CD4
+
 T cells: WT and IL-17a/f
-/- 
mice were i.n. 
immunized with PBS, NIBRG-14 alone (0.5 μg/dose) or NIBRG-14 co-administered with c-di-AMP 
(5 μg/dose). Splenocytes and lung lymphocytes were re-stimulated with NIBRG-14 (0.5μg/ml) overnight. 
The cells were incubated with brefeldin A (5 μg/ml) and monensin (6 μg/ml) for additional 4 h and were 
analyzed for A) IL-17secreting cells by ELISPOT (splenocytes) and frequencies of B) splenic and C) lung-
derived IL-17-producing CD4
+
 T cells by FACS. Results are expressed as subtracted background of 
unstimulated samples from stimulated samples. Columns represent the mean ± SEM of one experiment 
(n=6). Shown is one representative out of two independent experiments. Asterisks denote significant 
values as calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/-
 mice;**** p < 0.0001; ** p < 
0.01. Plus denote significant values as calculated by Two-way ANOVA when comparing WT mice 
immunized with NIBRG-14 alone and with NIBRG-14 co-administered with c-di-AMP; ++++ p < 0.0001; 
++ p < 0.01. 
To understand the impact of c-di-AMP-induced IL-17 secretion on the NIBRG-14-
specific Th1 response, splenocytes derived from immunized WT and IL-17a/f-/- mice 
were re-stimulated with NIBRG-14 and the number ofIFNȖ producing splenic cells was 
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evaluated by ELISPOT. In both WT and IL-17a/f-/- mice the number of IFNȖ-secreting 
splenic cells was significantly enhanced in the groups immunized with NIBRG-14 co-
administered with c-di-AMP as compared to NIBRG-14 and PBS alone. Interestingly, IL-
17a/f-/- mice immunized with NIBRG-14 co-administered with c-di-AMP displayed a 
higher number of CD4+IFNȖ-secreting cells as compared to WT mice (Figure 41A). 
These findings are confirmed by FACS analysis of NIBRG-14 re-stimulated splenic and 
lung lymphocytes. In both organs, WT and IL-17a/f-/- mice immunized with NIBRG-14 
co-administered with c-di-AMP harbored enhanced frequencies of CD4+IFNȖ+ cells as 
compared to mice immunized with PBS or NIBRG-14 alone (Figure 41B and C). The 
comparison of WT and IL-17a/f-/- mice immunized with NIBRG-14 co-administered with 
c-di-AMP revealed elevated frequencies of CD4+IFNȖ-secreting cells in both organs 
derived from IL-17a/f-/- mice immunized with NIBRG-14 co-administered with c-di-AMP 
as compared to WT mice (Figure 41B and C). These data indicate that immunization 
with c-di-AMP induces Th1 responses that are more profound in the absence of IL-17 
signaling. 
 
Figure 41: Impact of c-di-AMP-induced IL-17 secretion on NIBRG-14-specific Th1 responses: WT 
and IL-17a/f
-/-
 mice were i.n. immunized with PBS, NIBRG-14 alone (0.5 μg/dose) or NIBRG-14 co-
administered with c-di-AMP (5 μg/dose). Splenocytes and lung lymphocytes were re-stimulated with 
NIBRG-14 (0.5μg/ml) overnight. The cells were incubated with brefeldin A (5 μg/ml) and monensin 
(6 μg/ml) for additional 4 h and were analyzed for A) IFNȖ-secreting cells by ELISPOT (splenocytes) and 
frequencies of B) splenic and C) lung-derived IFNȖ-producing CD4+ T cells by FACS. Results are 
expressed as subtracted background of unstimulated samples from stimulated samples. Columns 
represent the mean ± SEM ofone experiment (n=6). Shown is one representative out of two independent 
experiments. Asterisks denote significant values as calculated by Two-way ANOVA when comparing WT 
and IL-17a/f
-/-
 mice;**** p < 0.0001. Plus denote significant values as calculated by Two-way ANOVA 
when comparing WT mice immunized with NIBRG-14 alone and with NIBRG-14 co-administered with c-
di-AMP; ++++ p < 0.0001; +++ p < 0.001. 
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To understand the impact of c-di-AMP-induced IL-17 secretion on the NIBRG-14-
specific Th2 response, splenocytes derived from immunized WT and IL-17a/f-/- mice 
were re-stimulated with NIBRG-14 and the number of IL-4 producing splenic cells was 
evaluated by ELISPOT. In both, WT and IL-17a/f-/- mice, the number of IL-4-secreting 
splenic cells was significantly enhanced in the groups immunized with NIBRG-14 co-
administered with c-di-AMP as compared to NIBRG-14 and PBS alone. IL-17a/f-/- mice 
immunized with NIBRG-14 co-administered with c-di-AMP displayed a reduced number 
of CD4+ IL-4-secreting cells as compared to WT mice (Figure 42A). These findings were 
confirmed by FACS analysis of NIBRG-14 re-stimulated splenic and lung lymphocytes. 
In both organs, WT and IL-17a/f-/- mice immunized with NIBRG-14 co-administered with 
c-di-AMP harbored enhanced frequencies of CD4+ IL-4+ cells as compared to mice 
immunized with PBS or NIBRG-14 alone (Figure 42B and C). The comparison of WT 
and IL-17a/f-/- mice immunized with NIBRG-14 co-administered with c-di-AMP revealed 
reduced frequencies of CD4+ IL-4-secreting cells in both organs derived from IL-17a/f-/- 
mice immunized with NIBRG-14 co-administered with c-di-AMP as compared to WT 
mice (Figure 42B and C). These data demonstrate that c-di-AMP-induced IL-17 
secretion drives Th2 response stimulation. 
 
Figure 42: Impact of c-di-AMP-induced IL-17 secretion on NIBRG-14-specific Th2 responses: WT 
and IL-17a/f
-/-
 mice were i.n. immunized with PBS, NIBRG-14 alone (0.5 μg/dose) or NIBRG-14 co-
administered with c-di-AMP (5 μg/dose). Splenocytes and lung lymphocytes were re-stimulated with 
NIBRG-14 (0.5 μg/ml) overnight. The cells were incubated with brefeldin A (5 μg/ml) and monensin 
(6 μg/ml) for additional 4 h and were analyzed for A) IL-4 secreting cells by ELISPOT (splenocytes) and 
frequencies of B) splenic and C) lung-derived IL-4-producing CD4
+
 T cells by FACS. Columns represent 
the mean ± SEM of one experiment (n=6). Shown is one representative out of two independent 
experiments. Asterisks denote significant values as calculated by Two-way ANOVA when comparing WT 
and IL-17a/f
-/-
 mice; **** p < 0.0001;** p < 0.01. Plus denote significant values as calculated by Two-way 
ANOVA when comparing WT mice immunized with NIBRG-14 alone and with NIBRG-14 co-administered 
with c-di-AMP; ++++ p < 0.0001. 
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5.4.4. Mechanisms favoring c-di-AMP-induced mucosal IgA 
response in an influenza vaccine model  
The c-di-AMP-induced secretion of IL-17 seems to support antigen-specific IgA 
responses. Therefore, the factors favoring IgA secretion were subsequently evaluated 
upon immunization with NIBRG-14 and c-di-AMP. Two different mechanisms are 
described to play a central role for IgA-dependent mucosal immune responses: The 
activation of high-affinity IgA producing plasma B cells and modulation of the expression 
level of pIgR (polymeric Ig receptor) by epithelial cells responsible for sIgA transport 
[180, 181]. To investigate the impact of c-di-AMP-induced IL-17 secretion on plasma 
cell differentiation, the formation of germinal centers was assessed with respect to the 
interaction of GC B cells and TFH cells. In addition, the expression level of pIgR by lung 
epithelial cells upon immunization was determined. 
5.4.4.1. c-di-AMP-induced IL-17 secretion results in the co-localization 
of TFH cells and GC B cells in GCs thereby promoting plasma B 
cell differentiation 
GCs provide a microenvironment that promotes and regulates the interaction of B cells 
with TFH cells, which provide the cognate help required for the generation of high-
affinity, antibody-producing plasma B cells [44]. To investigate the role of c-di-AMP-
induced IL-17 secretion in the context of plasma B cell generation in an influenza 
vaccination model, the interaction of GC B cells with TFH cells was assessed. 
Histological analysis was performed 12 days post immunization (6 day post 1st boost) 
with PBS, NIBRG-14 alone or NIBRG-14 co-administered with c-di-AMP to determine 
the interaction of GC B cells with TFH cells in context to plasma B cell differentiation. WT 
mice immunized with PBS or NIBRG-14 alone showed disseminated TFH cells and GC 
B cells (Figure 43A and B upper panel). In contrast, WT mice immunized with NIBRG-
14 co-administered with c-di-AMP showed co-localization of GC B cells and TFH cells, 
hence favoring the environment for generation of plasma B cells (Figure 43C upper 
plots). In IL-17a/f-/- mice the GC B cells and TFH cells were disseminated under all 
treatment conditions (Figure 43C lower plots). The histological scoring revealed a 
significant increase in co-localization of GC B cells and TFH cells in WT mice immunized 
with NIBRG-14 co-administered with c-di-AMP as compared to mice immunized with 
PBS alone (Figure 43D). A significantly reduced co-localization of GC B cells and 
TFH cells was observed in IL-17a/f
-/- mice immunized with NIBRG-14 co-administered 
with c-di-AMP as compared to the corresponding WT group. These data indicate that 
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NIBRG-14 and c-di-AMP-induced IL-17 secretion is required for optimal GC responses 
with respect to the generation of plasma B cells. 
 
 
Figure 43: Co-localization of TFH cells and GC B cells mediated by c-di-AMP-induced IL-17 
secretion: WT (upper panel) and IL-17a/f
-/-
 (lower panel) mice were i.n. immunized with PBS or NIBRG-
14 alone (0.5 μg/dose) or NIBRG-14 co-administered with c-di-AMP (5 μg/dose). The animals were 
sacrificed on day 12 post immunization. Spleen tissues were stained for GC B cells (CD19
+
PNA
+
, green) 
and TFH cells (CD3
+
CXCR5
+
, red) and fluorescent imaging was performed to assess for the cell 
distribution. The analysis was performed at 20x magnification. Localization of GC B cells and TFH cells in 
mice immunized with A) PBS, B) NIBRG-14 and C) NIBRG-14 co-administered with c-di-AMP. D) 
Histology scoring of co-localization of GC B cells (PNA
+
) and TFH cells (CXCR5
+
) was determined. 
Columns represent the mean ± SEM of one independent experiment (n=9). Asterisks denote significant 
values as calculated by Two-way ANOVA comparing WT and IL-17a/f
-/- 
mice; * p < 0.05. Plus denote 
significant values as calculated by Two-way ANOVA when comparing WT mice immunized with PBS 
alone and with OVA co-administered with c-di-AMP; ++ p < 0.01. 
Results 
  
98 
 
To further confirm these in vivo observations in vitro co-culture studies were 
performed.To this end, sorted TFH cells (CD4
+CXCR5+) and GC B cells (CD19+PNA+) 
obtained from cLNs and spleens of naïve WT and IL-17a/f-/- mice were co-cultured for 6 
days in the presence of NIBRG-14 or c-di-AMP alone or in combination. Controls were 
left untreated. A significantly increased frequency of plasma B cells (CD19+CD138+) 
was detected in co-cultures supplemented with both NIBRG-14 and c-di-AMP as 
compared to NIBRG-14 alone. Furthermore,a significantly lower frequency of plasma B 
cells was observed in wells containing cells isolated from IL-17a/f-/- mice cultured with 
NIBRG-14 and c-di-AMP as compared to corresponding WT co-cultures (Figure 44A). 
The addition of rIL-17A to the IL-17a/f-/- co-cultures significantly increased the 
differentiation of plasma B cells to the level found in co-cultures containing cells isolated 
from WT mice. The analysis of plasma B cell subclasses showed that c-di-AMP-induced 
IL-17 secretion supports IgA subclass differentiation (Figure 44B).This indicates that IL-
17 plays a direct role for the differentiation of plasma B cells. 
 
Figure 44: c-di-AMP-induced plasma B cell differentiation: Sorted GC B cells and TFH cells derived 
from cLNs and spleens of WT and IL-17a/f
-/-
 mice were left untreated or treated with NIBRG-14 alone 
(1 μg/ml) or c-di-AMP alone (5 µg/ml) or in combination for 6 days. rIL-17A was added to IL-17a/f-/- culture 
conditions as indicated. The cells were incubated with brefeldin A (5 μg/ml) and monensin (6 μg/ml) for 
additional 4 h, subsequently stained with cell population specific markers and analyzed by flow cytometry. 
Frequencies of A) plasma B cells (CD19
-
CD138
+
) and B) IgA
+
 plasma B cells (CD19
-
CD138
+
IgA
+
) were 
determined. Columns represent the mean ± SEM of one independent experiment (n=3). Asterisks denote 
significant values as calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/- 
cultures; **** p < 
0.0001; ** p < 0.01; * p < 0.05. Plus denote significant value between different treatment groups of 
NIBRG-14 co-administered with c-di-AMP as calculated by Two-way ANOVA; ++++ p < 0.0001; +++ p < 
0.001 ++ p < 0.01. 
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IgA class switching is known to be impacted by T cell-derived cytokines including 
TGFȕ1, IL-4, IL-6 and IL-10 [182]. Thus, the analysis of the specific cytokine milieu 
induced upon immunization can provide insights into the immune processes initiated by 
c-di-AMP treatment leading to IgA+ plasma B cell generation. Therefore, to gain insights 
into the cytokines contributing to IgA class-switch, the c-di-AMP-induced cytokine 
environment was evaluated. To this end, splenic cells obtained from immunized mice 
were stimulated ex vivo with NIBRG-14 for 72 h and the supernatant was assessed to 
gain an in depth insight into the cytokine profile. Splenic cells obtained from WT and IL-
17a/f-/- mice immunized with NIBRG-14 co-administered with c-di-AMP displayed 
elevated levels of IFNȖ, IL-2, TNFα, IL-4, IL-6, IL-10, IL-17 and IL-22 as compared to 
PBS and NIBRG-14 alone (Figure 45A, B, C and D). Furthermore, a significantly 
reduced secretion of IL-4, IL-6 and IL-10, cytokines known to favor IgA class-switch, 
was observed in IL-17a/f-/- mice immunized with NIBRG-14 co-administered with c-di-
AMP as compared to WT mice (Figure 45B and D). Therefore, the obtained results 
suggest that the in vivo induction of c-di-AMP-induced IL-17 secretion might favor a 
cytokine environment that promotes IgA class-switch. 
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Figure 45: Immunization-induced serum cytokine pattern: Splenic cells obtained from WT and IL-
17a/f
-/-
 mice immunized with PBS, NIBRG-14 alone (0.5 μg/dose) or NIBRG-14 co-administered with c-di-
AMP (5 μg/dose) were re-stimulated ex vivo with NIBRG-14 (2 μg) for 72 h and the supernatant was 
collected and stored at -20°C. The cytokine profiles resulting from A) Th1 B) Th2 C) Th17 and D) Treg 
cytokine secretion were analyzed by CBA. Columns represent the mean ± SEM of one experiment (n=3). 
Asterisks denote significant values as calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/- 
mice; **** p < 0.0001; *** p < 0.001; ** p < 0.01. 
5.4.4.2. Impact of c-di-AMP-induced mucosal IL-17 secretion on pIgR 
expression by lung epithelium 
Besides the generation of plasma B cells, pIgR is known to play a central role in 
mucosal immunity by mediating the delivery of polymeric IgA to the apical surface of 
epithelial cells via transcytosis [183]. The pIgR is typically expressed by mucous and 
ciliated epithelial cells in the bronchi [184]. Therefore, to assess the role of pIgR for the 
c-di-AMP-induced IL-17-mediated IgA responses a kinetic experiment was performed. 
Results 
  
101 
 
Mice were i.n. immunized and subsequently boosted once 14 days after immunization 
with PBS, NIBRG-14 alone or NIBRG-14 co-administered with c-di-AMP. On day 1, day 
6 and day 11 post boost the level of pIgR expression was determined by performing 
RTPCR using RNA obtained from lung tissue. Although not statistically significant, there 
is a clear trend for slightly increased expression levels of pIgR in WT mice on day 15 
and day 20 after the immunization as compared to WT mice immunized with PBS alone. 
On the other hand, on day 25 a significant induction of pIgR expression in WT mice 
immunized with NIBRG-14 co-administered with c-di-AMP as compared to WT mice 
immunized with PBS or NIBRG-14 alone was observed. Furthermore, samples derived 
from IL-17a/f-/- mice immunized with NIBRG-14 co-administered with c-di-AMP showed 
a significantly reduced pIgR expression as compared to correspondingly immunized WT 
mice (Figure 46). These findings show that c-di-AMP-induced IL-17 secretion mediates 
the upregulation of pIgR expression on lung epithelial cells, thereby representing a 
possible mechanism for the observed enhanced sIgA secretion. 
 
Figure 46: Impact of c-di-AMP-induced IL-17 secretion on pIgR expression by lung epithelial cells: 
WT and IL-17a/f
-/-
 mice were i.n. immunized with PBS, NIBRG-14 alone (0.5 μg/dose) or NIBRG-14 co-
administered with c-di-AMP (5 μg/dose). Animals were sacrificedon day 15, day 20 and day 25 after 
immunization and pIgR expression was determined. Columns represent the mean ± SEM of one 
independent experiment (n=3). Asterisks denote significant values as calculated by Two-way ANOVA 
when comparing WT and IL-17a/f
-/- 
mice; **** p < 0.0001. 
pIgR expression is induced by a range of factors including the cytokine 
microenvironment [42]. Therefore, the local cytokine profile in the lung was analyzed in 
order to obtain a mechanistic insight into the induction of pIgR expression by epithelial 
Results 
  
102 
 
cells upon i.n. immunization with NIBRG-14 co-administered with c-di-AMP. Thus, the 
cytokine profile in lung lavage samples obtained at day 15, 20 and 25 post immunization 
was analyzed with respect to cytokines known to up-regulate pIgR expression, including 
IFNȖ, TNFα and IL-4. In addition, the concentration of IL-17A was assessed in order to 
confirm that the presence of IL-17A is responsible for the observed pIgR expression. On 
day 20 and 25 no cytokine secretion was detected. Whereas, on day 15 enhanced 
levels of IFNȖ and TNFα were observed in lung lavage samples derived from WT and 
IL-17a/f-/- mice immunized with NIBRG-14 co-administered with c-di-AMP as compared 
to WT and IL-17a/f-/- mice immunized with PBS or NIBRG-14 alone (Figure 47). 
Furthermore, a significantly reduced concentration of IFNȖ and TNFα was observed in 
IL-17a/f-/- mice immunized with NIBRG-14 and c-di-AMP as compared to WT mice 
immunized accordingly. Additionally, a significantly enhanced level of IL-17A was 
observed in WT mice immunized with NIBRG-14 and c-di-AMP as compared to WT 
mice immunized with PBS or NIBRG-14 alone. IL-4 was not detected in lung lavage 
samples. These data indicate that the enhanced pIgR expression by airway epithelial 
cells upon immunization with NIBRG-14 and c-di-AMP might be modulated by increased 
secretion of IFNȖ and TNFα dependent on IL-17 signaling. 
 
Figure 47: c-di-AMP-induced IFNγ and TNFα secretion in the airways: WT and IL-17a/f-/- mice were 
immunized with PBS, NIBRG-14 alone (0.5 μg/dose) or NIBRG-14 co-administered with c-di-AMP 
(5 µg/dose). Lung lavage samples were collected at day 15 after immunization and analyzed for the 
indicated cytokines by CBA. Columns represent the mean ± SEM of one experiment (n=3). Asterisks 
denote significant values as calculated by Two-way ANOVA when comparing WT and IL-17a/f
-/- 
BAL 
samples; **** p < 0.0001; ** p < 0.01; * p < 0.05. 
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5.5. Assessment of c-di-AMP-induced protective immune 
responses in an acute influenza challenge 
The presented data provide evidence that c-di-AMP-induced IL-17 secretion mediates 
strong antigen-specific cellular (Th2 and Th17) and humoral (IgA) responses upon i.n. 
administration. However, the protective efficacy of c-di-AMP-induced antigen-specific 
Th17 responses in the course of viral infections still remains elusive. Therefore, to 
explore the protective potential of c-di-AMP-induced Th17 responses WT and IL-17a/f-/- 
mice were immunized i.n. with PBS, NIBRG-14 alone or co-administered with c-di-AMP 
according to the prime boost schedule and subsequently challenged with a sub-lethal 
dose of 2.5x104 ffu H5N1 influenza virus. The body weight and health status of the 
animals were monitored daily. Animals immunized with PBS lost more than 20% of their 
starting weight at day 6 in WT mice and day 7 in IL-17a/f-/- mice after infection and were 
thus sacrificed (Figure 48). WT mice immunized with NIBRG-14 alone displayed ~8% of 
weight reduction at day 4 post infection and started to recover their weight at day 5 post 
infection. In contrast, IL-17a/f-/- mice immunized with NIBRG-14 alone displayed 
negligible (~2%) weight loss at day 4 post infection as compared to corresponding WT 
mice. WT mice vaccinated with NIBRG-14 co-administered with c-di-AMP exhibited a 
strong resistance to influenza challenge with less than 5% of weight reduction at day 2 
post infection, and showed a rapid recovery of their starting weight at day 3 post 
infection. No significant difference in the weight reduction was observed when 
comparing WT and IL-17a/f-/- mice immunized with NIBRG-14 co-administered with c-di-
AMP (Figure 48B). 
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Figure 48: Weight development of immunized mice after i.n. H5N1 virus challenge: WT and IL-17a/f
-
/-
 mice were i.n. immunized with PBS, NIBRG-14 alone (0.5 μg/dose) or NIBRG-14 co-administered with 
c-di-AMP (5 μg/dose). Subsequently, immunized mice were i.n. challenged with a sub-lethal dose of 
2.5x10
4 
ffu of the H5N1 virus strain. Animals were sacrificed when they showed weight loss > 20% of their 
starting weight. A) Starting weight and B) weight loss at day 2, 3 and 5 post infection. Columns represent 
the mean ± SEM of one independent experiment (n=6). Plus denote significant value comparing WT mice 
immunized with NIBRG-14 alone and with NIBRG-14 co-administered with c-di-AMP as calculated by 
Two-way ANOVA; ++++ p < 0.0001; n.s. = not significant.  
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6. Discussion and Outlook 
The crucial role of IL-17-secreting cells in combating bacterial and fungal mucosal 
infections has been well described. In this line, it was shown that IL-17 regulates anti-
fungal immunity against C. albicans by upregulating proinflammatory cytokines like IL-6, 
as well as by recruiting neutrophils at thesite of infection [185, 186]. Recent studies 
have further described the role of Th17 cells in promoting pIgR-mediated delivery of 
sIgA into the airway lumen and intestines [187, 188]. This is likely to support defense 
against respiratory and gastro-enteric pathogens, and contribute to intestinal 
homeostasis. The versatile functions of Th17 cells including the initiation of humoral 
immunity by regulating GC formation in response to acute viral myocarditis and 
augmenting other T helper subsets in response to infections (e.g. M. tuberculosis) 
additionally highlight the potential of Th17 cells as targets for mucosal vaccination 
strategies [189, 190]. However, the exploitation of their potential as targets for 
prophylactic and therapeutic applications requires an in-depth understanding of the 
mechanisms underlying Th17 differentiation as well as their role in inducing antigen-
specific immune responses. Therefore, this thesis aimed at elucidating the impact of 
Th17 responses for the outcome of vaccination strategies.  
The c-di-AMP, a bacterial secondary messenger, has been reported as a potent 
systemic and mucosal vaccine adjuvant [97]. It is able to promote the elicitation of Th17 
responses; however, its specific impact on Th17-differentiation and vaccine-induced 
antigen-specific Th17 responses still needs to be elucidated. Thus, c-di-AMP was 
applied as a tool to understand the cellular mechanisms inducing antigen-specific Th17 
responses upon i.n. immunization. The specific impact of IL-17-secreting cells for viral 
control and vaccine-induced protective immune responses were assessed using IL-
17a/f-/- mice. These approaches represent an important step towards understanding 
Th17-mediated immune responses, their regulation and their subsequent exploitation 
for the development of innovative immunization strategies.  
Aiming at revealing the mechanisms underlying Th17 differentiation, in vitro treatment of 
WT-derived BMDCs with c-di-AMP resulted in a strong maturation with an enhanced 
surface expression of MHC I and CD86. This up-regulation of MHC I and CD86 are 
consistent with previous studies identifying BMDCs and macrophages as the target cell 
populations activated upon in vitro treatment with c-di-AMP [96, 112]. However, the 
additional observation of an increased surface expression of IL-17RA and TNFα is not 
completely in line with its described STING-dependent activation of theTBK3-IRF3 
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pathway resulting in type 1 IFN production in vitro [110, 191, 192]. These findings hint 
towards an alternative c-di-AMP-activated signaling pathway downstream of STING via 
NF-ĸB signaling subsequently resulting in TNFα production. This hypothesis is 
supported by previous studies in IFNAR-/- mice demonstrating that type 1 IFNs are 
dispensable for CDN-induced antigen-specific generation of IgG and IgA, in which a 
non-canonical STING-dependent TNF activation pathway has been proposed [193]. The 
side-by-side comparison of BMDCs derived from WT and IL-17a/f-/- mice upon 
stimulation with c-di-AMP in vitro revealed an impaired surface expression of MHC I and 
CD86 by IL-17a/f-/- BMDCs as compared to those derived from WT mice. This suggests 
a reduction in their ability to evoke effector immune responses. The findings also show 
that IL-17 seems to be required for c-di-AMP-induced BMDC maturation, which in turn 
facilitates the stimulation of an adaptive immune response.  
WT-derived CD4+ T cells co-cultured with c-di-AMP-primed IL-17a/f-/--derived BMDCs 
exhibited impaired expression of IL-17 as well as RORȖt as compared to WT-derived 
CD4+ T cells co-cultured with WT-derived BMDCs. As expected, these results confirm 
the inability of IL-17a/f-/- BMDCs to drive Th17 differentiation. In vitro stimulation of naïve 
CD4+ T cells with exogenous addition of IL-6, TGF-ȕ, IL-1ȕ and IL-23 were shown to 
contribute to Th17 differentiation [194-196]. Therefore, to thoroughly understand the 
mechanism underlying the observed defective Th17 differentiation, the effects of 
different cytokines secreted following in vitro treatment of BMDCs with c-di-AMP were 
considered. The analysis of supernatants derived from c-di-AMP treated WT BMDCs 
revealed increased levels of IL-6 as compared to IL-17a/f-/- BMDCs. IL-6 is a pleiotropic 
cytokine secreted by DCs, macrophages and CD4+ T cells [165]. Besides its importance 
for Th17 differentiation IL-6 also inhibits the TGF-ȕ-induced Treg differentiation [197]. 
Thus, c-di-AMP-induced IL-6 secretion might inhibit the functionality of Treg cells thus 
enabling the induction of Th17 response in WT settings. In IL-17a/f-/- mice, the reduced 
IL-6 response might result in a higher functionality of Treg cells, thus suppressing Th17 
induction. This hypothesis is supported by a study showing that in vivo immunization of 
IL-6-/- (gp130-/-) mice with myelin oligodendrocyte glycoprotein (MOG35-55) in complete 
Freund's adjuvant (CFA) resulted in enhancedTreg response [198]. While IL-23 was not 
detectable in the supernatant of c-di-AMP-treated BMDCs, the flow cytometry analysis 
of IL-12/IL-23p40-expressing BMDCs upon in vitro stimulation with c-di-AMP revealed 
an enhanced expression of IL-12/IL-23p40 by BMDCs derived from WT mice as 
compared to those derived from IL-17a/f-/- mice. Several reports showed that Th17 cells 
can be generated in vitro using either IL-23 alone or co-stimulation with TGF-ȕ and IL-6 
[194, 195, 199]. In addition, stimulation of naïve T cells with IL-23 was shown to induce 
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the generation and expansion of pathogenic Th17 cells [168]. However, in vitro 
experiments in the presence of antibodies blocking IL-6 and/or IL-23 signaling revealed 
that IL-6 but not IL-23 is required for the observed c-di-AMP-induced Th17 
differentiation. This is supported by previous studies showing the differentiation of naïve 
CD4+ T cells into Th17 cells upon co-culture with LPS-stimulated DCs in vitro in the 
presence of IL-23 blocking antibodies, as long as IL-6 and TGFȕ are present [194, 200]. 
Since TGFȕ levels were not affected by c-di-AMP stimulation, the obtained results 
strongly support that c-di-AMP-induced IL-6 secretion by BMDCs induces Th17 
differentiation while IL-23 is dispensable for this commitment. However, an IL-23-
dependent homeostasis of Th17 cells cannot be excluded, since IL-23 has been 
reported to maintain the Th17 phenotype in vitro [201]. To address this role of IL-23, in 
vitro co-culture experiments applying the stepwise blocking or addition of IL-6 and or IL-
23 could provide crucial insights.  
In order to explore the role of c-di-AMP-induced Th17 responses in evoking antigen-
specific immunity, immunization experiments using OVA as model antigen co-
administered with c-di-AMP as adjuvant were conducted comparing the immune 
responses in WT and IL-17a/f-/- mice. Previous studies performed in WT mice showed 
that co-administration of c-di-AMP as a mucosal vaccine adjuvant results in improved 
antigen-specific cellular and humoral responses [97]. The present study revealed that c-
di-AMP-induced IL-17 secretion supports antigen-specific Th2 immunity, as detected by 
an enhanced IL-4 secretion. IL-17a/f-/- mice showed an impaired Th2 response upon 
vaccination, as indicated by a reduced IL-4 secretion compared to what observed in WT 
mice. Th1 responses were found to be enhanced in IL-17a/f-/- mice as compared to WT 
mice, as demonstrated by a higher IFNȖ secretion. While there is no direct evidence 
linking IL-17 secretion and Th2 responses, the repressive effect of IL-17 on Th1 
responses has been reported in mice treated in vivo with anti-IL-17, which showed an 
increased number of IFNȖ-producing cells in response to a C.albicans infection as 
compared to untreated controls [202]. IL-17A has further been shown to inhibit Th1 cell 
development by suppressing Th1 associated gene expression, such as T-bet, 
osteopontin and IL-12ȕ2, in a colitis model [203]. In addition to Th cells, mice lacking IL-
17a/f revealed an increased cytotoxic capacity as compared to WT mice. Combined 
with the observed enhanced Th1 response in IL-17a/f-/- mice, this finding is consistent 
with the described importance of Th1 cells for the generation of CTL-mediated 
immunity. Mice immunized with DCs pulsed with a Th1 polarizing antigen, displayed a 
higher magnitude of IFNȖ-producing CTLs. This effect was abrogated upon depletion of 
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CD4 cells [204, 205]. IL-17a/f-/- mice immunized with OVA co-administered with c-di-
AMP further exhibited an impaired OVA-specific humoral immune response with regard 
to the secretion of IgA, IgG and IgG1. This is in line with a study describing that the 
adoptive transfer of Th17 cells derived from 2D2 MOG35-55-specific TCR transgenic mice 
into WT mice resulted in a significantly enhanced MOG-specific IgG1 response as 
compared to mice that did not receive Th17 cells [206]. Another study described that 
adoptive transfer of DO11.10 CD4+ Th17 cells and subsequent exposure to OVA 
aerosols resulted in enhanced IgA levels in the broncho-alveolar lavage fluid (BAL) of 
Th17 recipient BALB/c mice [187]. These data indicate that c-di-AMP-induced IL-17 
supports the humoral immune response both at the systemic (IgG1) as well as the 
mucosal (IgA) level.  
The production of IgA is a hallmark of adaptive mucosal immunity and its ability to 
prevent colonization of pathogens at the mucosal surfaces contributes to the prevention 
of infections [73, 207, 208]. Several factors such as cytokines including IL-4, IL-5 and 
IL-6 derived from interacting B and T cells are described to modulate mucosal humoral 
responses [209]. In this regard, Th2 cell-derived IL-5 has been shown to increase the 
IgA production of LPS-activated murine B cells in vivo [210]. Thus, the reduced IL-5 
secretion observed in ex vivo stimulated splenic cells obtained from immunized IL-17a/f-
/- mice as compared to WT mice might explain the reduced IgA levels detected in the 
absence of IL-17. The analysis of in vivo intraperitoneal administered rIL-5 and rIL-17 
alone or in-combination (1 day prior to immunization and boosting) confirmed the 
requirement of IL-5 for the induction of IgA secretion. Thus, the obtained data suggest 
that c-di-AMP-induced Th17 responses favor antigen-specific Th2 responses, thereby 
contributing to antigen-specific humoral immune responses. 
Experiments comparing the immune response of co-housed and non-co-housed mice 
showed a significant increase in OVA-specific IgG and IgG2c titers in IL-17a/f-/- mice 
upon co-housing with WT mice as compared to non-co-housed IL-17a/f-/- mice. These 
findings are in line with recent publications highlighting the strong influence of the 
microbiota on the immune system and vaccine efficacy [173, 211]. Colonization of 
germ-free mice with microbiota obtained from WT mice contributes to the generation of 
Th17 cell immune responses [212]. In addition, germ-free mice displayed a reduced 
trivalent inactivated influenza vaccine-specific IgG response as compared to WT mice 7 
days post vaccination, thereby highlighting the role of microbiota for vaccine 
efficacy [213]. Thus, the generated data indicate that the microbiota strongly influences 
c-di-AMP-induced systemic humoral immune responses. In contrast, OVA-specific IgA 
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titers were not impacted by changes in the microbiota upon co-housing. This suggests 
that the observed IgA response is solely dependent on the c-di-AMP-induced Th17 
response. The comparison of 16s rRNA isolated from feces of naïve WT and IL-17a/f-/- 
mice showed a huge variability in the composition of the microbiota which was 
paralleled by a low relative abundance of the SFB microbial community in IL-17a/f-/- 
mice. SFB has been reported to promote the accumulation of Th17 cells in the small 
intestine, thereby driving the production of IgA [214]. This represents a possible 
mechanism accounting for the observed reduction of antigen-specific IgA response in 
IL-17a/f-/- mice as compared to WT mice. Thus, the observed altered systemic humoral 
response due to co-housing and simultaneous differences in the SFB microbial 
community support a direct correlation of microbiota and humoral responses in the 
presented experimental setting. This hypothesis is supported by a previous publication 
showing that secondary colonization of germ-free mice that were already mono-
associated with SFB with Morganella morganii resulted in increased GC reaction, 
thereby favoring antibody production [215, 216]. In addition, upon colonization of germ-
free mice with SFB, 95% of all IL-17 producing cells in the lamina propria lymphocytes 
of the small intestine were identified as Th17 cells (CD4+TCRαȕ+ lymphocytes) [217, 
218]. This report supports the finding of a higher abundance of SFB microbial 
community in correlation with the c-di-AMP-induced expansion of CD3+CD4+ cells as 
the main IL-17 secreting population in WT mice. Interestingly, colonization of IL-17a/f-/- 
mice with feces obtained from mice monocolonized with SFB showed no significant 
difference in IgG immune responses upon immunization. In contrast, in lung lavage 
samples IgA concentrations were slightly increased in IL-17a/f-/- mice monocolonized 
with SFB when compared to non-colonized IL-17a/f-/- mice. Thus, it is likely that SFB 
alone is not responsible for the altered humoral immunization-induced immune 
response. Other factors such as the complex interplay of other microbial communities 
can be responsible for the altered c-di-AMP induced systemic humoral response in IL-
17a/f-/- mice upon co-housing. 
The role of c-di-AMP-induced IL-17 responses in mediating adaptive immunity and the 
generation of protective immune responses was further assessed in an influenza 
vaccination model. IL-17a/f-/- mice immunized with the inactivated NIBRG-14 strain co-
administered with c-di-AMP exhibited enhanced neutralizing antibody responses as 
compared to WT mice. However, no significant differences in the IgG titers were 
observed in the two mouse strains. This finding is in contrast to a study showing that 
mice immunized with HA-DNA displayed high IgG1 levels which were associated with 
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enhanced titers of neutralizing antibodies that positively correlate to vaccine-induced 
protective immunity against sublethal challenge with 3 minimum lethal doses (MLD50) of 
HK/Syd which consists of A/Sydney/5/97 (H3N2) strain and A/Puerto Rico/8/34 (H1N1) 
strain. In the same study, IgG2c titers were correlated with protection and viral 
clearance after a lethal influenza challenge [219]. Individuals vaccinated with LAIV and 
TIV vaccines displayed increased anti-influenza neutralizing antibody responses with an 
increased salivary homotypic IgG concentration but displayed no IgA response [220]. 
This in line with findings where IL-17a/f-/- mice exhibited enhanced titers of NIBRG14-
specific neutralizing antibodies but reduced IgA responses. Furthermore, reduced 
NIBRG-14-specific IgA and sIgA titers were observed in IL-17a/f-/- mice when compared 
to WT mice. These findings are in line with a report stating that mice vaccinated with the 
Th17-inducing adjuvant Cationic Adjuvant Formulation no.1 promoted substantial IgA 
levels but not IgG in the lungs. This effect was abrogated upon depletion of IL-
17A [221]. The importance of IgA is further supported by studies showing its potential to 
prevent influenza infection better than IgG [222]. The induction of mucosal immunity in 
terms of sIgA production acts as an important first line of defense against pathogens 
such as influenza [223]. Although, IgG is the major systemic antibody class, more than 
80% of human and mouse plasma cells located at the gastrointestinal and respiratory 
tracts produce IgA with incorporated J chain, thus being committed to sIgA 
generation [224]. These data suggest that c-di-AMP-induced Th17-mediated NIBRG-14-
specific IgA might be an essential defense mechanism needed for protection against 
influenza infection upon immunization using a c-di-AMP-adjuvanted vaccine.  
Following the ex vivo re-stimulation of splenic cells isolated from WT mice immunized 
with NIBRG-14 and c-di-AMP, elevated concentrations of IL-4, IL-6 and IL-10 were 
detected in supernatant fluids. This cytokine environment has been reported to promote 
an IgA class-switch [182]. This is supported by the finding that the stimulation of LPS-
activated B cells with TGFȕ1, IL-4 and IL-6 supports the secretion of IgA [225]. 
Therefore, the obtained results hint that the induction of Th17 responses by c-di-AMP 
in vivo triggers IgA class-switching possibly by impacting the micro environment.  
The histological analysis of splenic TFH cells and GC B cells 12 day post immunization 
showed their co-localization in follicles upon immunization with NIBRG-14 and c-di-AMP 
in WT but not IL-17a/f-/- mice. This is consistent with recently published studies showing 
that IL-17RA-IL-17 signaling regulates the localization of TFH cells in GC light zone. In 
the presence of IL-17, TFH cells upregulate the expression of regulator of G-protein 
signaling (Rgs16), thereby promoting GC development and high-affinity antibody 
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production [226]. The observed importance of c-di-AMP-induced IL-17 for the 
differentiation of plasma cells is further supported by the finding that the co-culture of 
TFH cells and GC B cells derived from WT mice, but not IL-17a/f
-/- mice, supplemented 
with c-di-AMP resulted in the differentiation of GC B cells to plasma B cells. The need of 
IL-17 for this effect was confirmed by IL-17A supplementation, which resulted in a 
restored plasma B cell differentiation of cells derived from IL-17a/f-/- mice. The cytokine 
profile analysis of the supernatant derived from the IL-17A-supplemented co-culture of 
cells derived from IL-17a/f-/- mice revealed enhanced concentrations of IL-4 and IL-21 
as compared to non-supplemented conditions. Besides other factors, IL-4 and IL-21 are 
known to be essential for the proliferation and survival of B cells in GCs [227, 228]. This 
suggests that IL-17-induced IL-21 and IL-4 secretion promotes the observed plasma B 
cell differentiation. Furthermore, a considerable degree of plasticity between TFH cells 
and Th17 cells favored by the microenvironment of the Peyer’s patches has been 
reported [229]. In this regard, it was reported that the conversion of Th17 cells into TFH 
cells is needed for the generation of antigen-specific IgA responses in the gut 
mucosa [230]. In order to assess the extent of this plasticity upon treatment with c-di-
AMP, experiments conducted in IL-17 fate-reporter mice should be included in future 
studies. IL-17 fate reporter (Il17aCreR26ReYFP) mice enable to identify and visualize fate 
mapping of Th17cells in vivo. The fluorescent reporter would permanently label Il17Cre 
cells, thus allowing identification of cells that switched on the IL-17 program.This could 
provide crucial information regarding whether c-di-AMP-induced Th17 cells deviate 
towards a TFH cell-like phenotype, thereby contributing to the observed NIBRG-14-
specific IgA response. 
The absence of IL-17 signaling further resulted in significantly lower pIgR expression 
levels on lung epithelial cells upon immunization with NIBRG-14 co-administered with c-
di-AMP as compared to WT mice. This indicates a role of c-di-AMP-induced IL-17 in the 
induction of pIgR expression. The pIgR is an integral component of the airway and 
intestinal mucosal immunity that mediates the delivery of polymeric IgA and IgM to the 
apical surface of epithelial cells via transcytosis [73, 231]. It has been reported that 
adoptive transfer of polarized DO11.10 CD4+ Th17 cells mediates the influx of CD19+ B 
cells into the lungs resulting in elevated IgA levels in the BAL [187]. Furthermore, the 
i.n. administration of IL-17 promoted pIgR-mediated delivery of sIgA into the airway 
lumen, thus contributing to airway immunity [157, 232]. In addition, lower levels of pIgR 
and IgA have been reported in the fecal content of IL-17R-/- mice as compared to WT 
mice, resulting in severe colitis upon treatment with dextran sodium sulfate [158]. These 
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data support the crucial role of IL-17 for an efficient mucosal immunity mediated via 
pIgR. The analysis of the lung lavage cytokine profile showed an elevated concentration 
of IFNȖ, TNFα and IL-17 in WT but not IL-17a/f-/- mice after immunization with NIBRG-
14 co-administered with c-di-AMP. The expression level of pIgR is known to be 
regulated by a range of factors including IFNȖ, TNFα and IL-4 [233]. Therefore, the 
obtained results strongly support the assumption that the c-di-AMP-induced IL-17 
secretion mediates upregulation of pIgR expression on lung epithelial cells, supposedly 
via the activation of IFNȖ and TNFα, thereby representing a potential mechanism 
contributing to the observed enhanced sIgA secretion. 
The role of IL-17A during influenza virus infections remains controversial, since it has 
been reported as playing both pathogenic and protective roles [234-237]. Similar to 
these reports, higher weight loss and viral loads were observed in lungs of naïve WT 
mice as compared to naïve IL-17a/f-/- mice 5 days post infection with the H5N1 influenza 
strain. While WT mice eventually succumbed to infection, IL-17a/f-/- mice recovered their 
weight. In addition, an increase in the frequency of neutrophils and NK cell populations 
was observed in the lungs of infected WT mice. Th17 cells are known to have profound 
effects on neutrophil recruitment and activation through the release of IL-6, G-CSF, KC, 
MIP-2 by tissue epithelial and endothelial cells, thus contributing to increased 
inflammation during influenza infection [238]. Apart from their role in viral clearance, NK 
cells are also described to contribute to exacerbated pathology during influenza virus 
infection, as shown by NK cell depletion studies [239]. These findings suggest a direct 
correlation between the IL-17-neutrophil-NK cell network and immunopathology during 
influenza infection, resulting in the death of infected mice. However, further studies such 
as in vitro infection experiments and in vivo depletion studies need to be performed to 
support this hypothesis. 
Upon challenge of immunized mice with a sub-lethal dose of the H5N1 influenza strain, 
no significant differences in weight loss post challenge were observed comparing WT 
and IL-17a/f-/- mice immunized with NIBRG-14 co-administered with c-di-AMP. Hence, 
c-di-AMP-induced NIBRG-14-specific responses seem to mediate protective immunity 
against influenza virus independently of the IL-17-mediated response. This finding 
contradicts previously described challenge studies using mucosal adjuvants such as 
CRX-601, a TLR4 agonist, and CT. In these experiments an exacerbated, Th17-
dependent, morbidity of vaccinated mice was observed. This effect was shown to be 
dependent on an enhanced Th17-dependent neutrophil recruitment to the lung [160, 
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240]. However, c-di-AMP-primed NIBRG-14-specific Th17 cells seem not to be 
detrimental in the presented H5N1 influenza infection model. 
The results presented here disclose specific key mechanisms responsible for c-di-AMP-
induced Th17 differentiation as well as Th17-mediated antigen-specific immune 
responses. However, in order to get comprehensive insights into c-di-AMP-induced 
mechanisms impacting IL-17-secreting cells, several aspects still need to be addressed. 
One of these aspects includes the identification of factors responsible for a defective 
Th17 differentiation driven by IL-17a/f-/--derived BMDCs. In this context, an enhanced 
Th1 response was observed in immunized IL-17a/f-/- mice as compared to WT mice. 
Thus, a shift towards the secretion of Th1 driving cytokines by IL-17a/f-/--derived BMDCs 
might be the reason for the defective Th17 differentiation of co-cultured WT-derived 
CD4+ T cells. In order to confirm this hypothesis, in vitro studies using antibodies that 
block Th1 polarizing cytokine signaling, e.g. IL-12 and IL-2 could be performed. 
Furthermore, the assessment of signaling pathways contributing to the migration of c-di-
AMP-stimulated plasma B cells from the lymph nodes to the lung as effector site should 
be addressed, since defective migration might contribute to hamper immune responses. 
The migration capacity can be addressed by performing migration assays using trans-
well systems in the presence of different chemokines, such as CXCL12 and CXCL13. 
These chemokines are described to induce the migration of plasma cells expressing 
mucosal homing receptors such as CXCR10, CXCR9 or CXCR4 [241]. IL-17 has further 
been shown to contribute to CXCL12 – CXCR4 signaling, which has been demonstrated 
to be essential for the appropriate maturation of B cell follicles in P. aeruginosa-induced 
BALT formation [242]. Additionally, C.albicans-specific Th17 cells isolated from humans 
have been shown to express CXCL13, thus promoting B cell chemotaxis [243]. The 
suggested trans-well experiments would thus provide crucial information regarding the 
contribution of IL-17 induced chemokines which are responsible for the migration of 
plasma B cells from the lymph nodes to the lungs in the stimulation of local IgA 
responses. Another aspect that will need to be addressed is the stimulation of antigen-
specific memory responses. Advanced multi-color flow cytometry panels can be used 
for the analysis of different memory cell populations and their effector functions to 
elucidate the effect of c-di-AMP-induced IL-17 responses on memory cell 
subpopulations. The resulting data could provide insights into the role of IL-17 signaling 
for the long-term maintenance of protective immune response. In addition, an adoptive 
transfer of c-di-AMP-induced Th17 cells into IL-17a/f-/- mice prior to viral challenge 
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represent a valid approach to address the importance of this Th17 subset for viral 
clearance upon challenge with the H5N1 influenza strain. 
In conclusion, the results presented in this thesis reveal essential mechanisms 
mediated by c-di-AMP-induced Th17 cells and their importance for the generation of 
antigen-specific immunity. The findings draw attention to the need for a more thorough 
characterization of Th17-mediated immune responses. In contrast to what has been 
shown so far, the findings demonstrate that c-di-AMP-induced Th17 cells are not 
detrimental but facilitate effective immune responses that mediate protection against the 
sub-lethal H5N1 challenge. Therefore, the results depicted in this thesis highlight the 
potential of using Th17 inducing adjuvants such as c-di-AMP for the development of 
safe mucosal vaccines with the ability to promote effective local immunity against 
infectious agents.  
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7. Summary 
Respiratory infections caused by influenza virus represent a major health problem 
worldwide causing annual epidemics leading to 250,000 to 500,000 deaths yearly. 
Vaccination has proven to be an effective tool in controlling and eradicating many viral 
infections but due to inadequate protection elicited by current vaccines foster the search 
for improved or new immune interventions. In this regard, highly accepted needle-free 
vaccination strategies are urgently needed. Among them, mucosal vaccines appeal as a 
very promising approach. Current use of subunit vaccines and purified antigens are 
often very poorly immunogenic when delivered by mucosal route. Therefore 
implementation of adjuvants represents a key approach to improve immunogenicity 
thereby improving vaccine efficacy. One of the striking features of mucosal vaccines is 
the induction of IL-17 responses since IL-17 secreting cells predominantly reside at the 
mucosal surfaces. Therefore, IL-17 secreting cells represent interesting targets for 
mucosal vaccination strategies. The role of IL-17 secreting cells in the fight against 
mucosa associated bacterial and fungal infections have been emphasized. However, 
their role in combating viral infections and their significance for mucosal vaccine design 
remains elusive. Bis-(3’,5’)-cyclic dimeric adenosine monophosphate (c-di-AMP), a 
potent IL-17 inducer, was investigated for its potential to induce IL-17-mediated antigen-
specific immune responses. The c-di-AMP treated BMDCs derived from IL-17a/f-/- mice 
displayed reduced expression of activation markers MHC I and CD86, thereby 
suggesting a reduction in their ability to evoke effector immune response. Furthermore, 
in vitro blocking experiments suggested that IL-6 but not IL-23 secreted by c-di-AMP-
primed BMDCs seems to be the crucial mediator for c-di-AMP-induced Th17 
differentiation. The i.n. immunization with OVA or NIBRG-14 adjuvanted with c-di-AMP 
resulted in impaired Th2 responses and IgA concentrations, but enhanced Th1 
response in mice lacking IL-17. In addition, in an influenza infection model the 
histological evaluation revealed that c-di-AMP induced IL-17 is required for the co-
localization of TFH cells and GC B cells, thus favoring the generation of plasma B cells. 
Further in vitro co-culture studies of TFH cells and GC B cells obtained from mice lacking 
IL-17 showed abrogated plasma cell differentiation, which could be restored by 
supplementation of rIL-17A. In addition, elevated concentrations of IL-4, IL-6 and IL-10 
detected following re-stimulation of splenic cells obtained from immunized WT mice, 
indicating a cytokine environment promoting IgA class-switch. In this regard, the 
absence of IL-17 signaling resulted in a significantly lower pIgR expression level on lung 
epithelial cells in mice immunized with the inactivated H5N1 NIBRG-14 strain co-
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administered with c-di-AMP. This indicates a role of c-di-AMP induced IL-17 for the 
induction of pIgR and thus the delivery of polymeric IgA to the apical surface of 
epithelial cells. Furthermore, the analysis of the cytokine milieu in lung lavage samples 
derived from immunized WT mice showed an elevated concentration of IFNȖ and TNFα, 
which are required for regulating pIgR expression. Taken together this data 
demonstrates that c-di-AMP-induced Th17-mediated mucosal immunity is regulated via 
two different mechanisms (i) increased production of high-affinity plasma B cells and 
(ii) enhanced expression of pIgR by lung epithelial cells which in turn favors sIgA export. 
Interestingly, upon influenza virus challenge with the H5N1 strain, mice immunized with 
NIBRG-14 and c-di-AMP displayed strong resistance to infection with no significant 
differences between WT and IL-17a/f-/- mice. Differences in the microbiota impacted c-
di-AMP-induced IL-17 mediated antigen-specific Th1 and IgG responses, but showed 
no significant influence on the IgA responses. The findings presented in this thesis 
reveal mechanisms underlying c-di-AMP mediated Th17 cell differentiation as well as 
the impact of c-di-AMP triggered IL-17 responses on the generation of antigen-specific 
mucosal immune responses (Figure 49). A better understanding of the mechanisms 
involved in the induction of vaccine-induced IL-17 responses and their contribution 
towards the generation of antigen-specific immunity will substantially facilitate the 
rational design of novel mucosal vaccines against infectious diseases. 
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Figure 49: Schematic overview illustrating the potential mechanism of c-di-AMP-induced Th17-
mediated responses contributing to the generation of antigen-specific mucosal IgA response post 
vaccination
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